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Summary 
 
Hypoglycaemia and fear of hypoglycaemia is considered one of the greatest barriers to 
patients optimising their metabolic control in Type 1 Diabetes (T1D).  Recurrent 
hypoglycaemia (RH) leads to diminished symptomatic and hormonal (blunted counter-
regulatory) responses to further hypoglycaemia, which collectively form a clinical syndrome 
referred to as  Impaired Awareness of Hypoglycaemia (IAH), a condition that affects one in 
four of all patients with T1D.   IAH markedly increases an individual’s risk of severe 
hypoglycaemia (defined as the need for active external assistance for recovery), which has a 
recognised morbidity and mortality. 
Despite improvements in insulin formulations and delivery devices, rates of severe 
hypoglycaemia have remained static in the last two decades, therefore there remains an 
urgent clinical need for novel, alternative strategies to prevent severe hypoglycaemia and 
restore hypoglycaemia awareness.   
This thesis contains studies that represent a first attempt to translate basic research in cells 
and animal models into novel therapies for impaired awareness of hypoglycaemia in human 
subjects with Type 1 diabetes. The first study was based on the pre-clinical finding that 
hypothalamic ATP-sensitive K + (KATP) channels are integral to the detection of 
hypoglycaemia as well as instrumental to mounting a counter-regulatory response to 
hypoglycaemia.  In a randomised, double-blind hyperinsulinaemic hypoglycaemia clamp 
study, I compared the effect of an oral KATP channel activator, Diazoxide, on 
counterregulatory responses to hypoglycaemia in a cohort of subject with type 1 diabetes and 
impaired hypoglycaemia awareness. I was able to show that diazoxide magnified the counter-
regulatory response (particularly adrenaline) in patients with long standing T1D. In addition, 
a subgroup analysis revealed that participants with E23K polymorphism in the KATP channel 
24 
 
had a blunted response to oral diazoxide. This study confirmed for the first time in humans 
that KATP channels also played an important role in modulating counterregulatory responses 
to hypoglycaemia and demonstrated the potential utility of KATP channel activators to 
improve counterregulatory responses to hypoglycemia in subjects with T1D.   
The second approach focused on the paradoxical role in Type 1 diabetes of dysregulated 
glucagon secretion during fasting and in the post-prandial states, contributing to 
hyperinsulinaemia, hypoglycaemia and increased glycaemic variability (GV).  I postulated 
that suppression of glucose-induced glucagon secretion in Type 1 diabetes would reduce 
hyperinsulinaemia, reduce GV and subsequent exposure to hypoglycemia. This in turn, 
through hypoglycaemia avoidance, would over time lead to improved hypoglycaemia 
awareness. To test this, we performed a double-blind, 12 week randomized cross over trial, 
comparing Saxagliptin, a dipeptidyl peptidase 4 inhibitor (DPP4-I) that had been shown to 
known for its glucagon suppressive action, with placebo in a small cohort of subjects with 
Type 1 diabetes. However, we found that 12-weeks Saxagliptin therapy failed to have any 
significant impact on glucose variability indexes in Type 1 diabetes or exposure to 
hypoglycaemia. Subsequently, I found no differences between Saxagliptin or vehicle on CRR 
to hypoglycaemia.  These findings therefore do not support the use of DPP4-inhibitors as a 
means of improving hypoglycaemia awareness in T1D.   
For the second part of this thesis, we sought to explore the wider impact of recurrent 
hypoglycaemia on the hypothalamo-pituitary adrenal (HPA) axis.  This study arose from the 
understanding that hypoglycaemia represents a profound stimulation to the HPA axis, with a 
rise in peripheral glucocorticoid.  Repeated HPA axis stimulation leads to (i) suppression of 
HPA axis activation in response to recurrent exposure to that stressor  - this would have the 
additional effect of reducing the CRR response to hypoglycaemia, (ii) suppress diurnal 
variation in cortisol circadian rhythm – associated with increased cardiovascular risk as well 
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as chronic alteration in mood and cognitive state. To examine this I studied T1D subjects 
with increased glucose variability (GV) (as an index of hypoglycaemia exposure) and 
measured circadian variation in salivary cortisol levels.  In this study, I report that increased 
GV is associated with a blunted diurnal cortisol diurnal slope, associated with a significant 
increase in the area under the curve.   
As a follow on study to this, I examined the HPA axis in greater detail by conducting a 
Corticotrophin releasing hormone (CRH) test, to determine the physiological level of the 
dysregulation seen in those with T1D and recurrent hypoglycaemia.  I found no significant 
difference to the CRH response between those with recurrent and those with infrequent 
hypoglycaemia.   
In conclusion, this thesis has explored two potential therapeutic strategies, based on current 
understanding of those mechanisms that underlie the development of impaired 
hypoglycaemia awareness in Type 1 diabetes and reported that a strategy based on KATP 
channel activators, but not DPP4i, may have therapeutic potential. This would need to be 
explored in longer term intervention studies. In addition, I have shown that increased GV and 
hypoglycaemia exposure is associated with blunting of normal cortisol circadian patterns. 
Future studies will aim to assess the impact of this on long-term cardiovascular function and 
atherosclerosis in Type 1 diabetes.  
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Introduction 
CHAPTER 1  
 
Iatrogenic hypoglycaemia was first recognised shortly after the introduction of insulin in 
1922 (Banting, Best et al. 1922) but was highlighted as a major issue in the clinical 
management of Type 1 Diabetes (T1D) following the publication of the Diabetes Control and 
Complications Trial in 1993 (group 1993). This trial was designed to compare intensive 
insulin therapy (IIT) using multiple daily injections (MDI) or continuous subcutaneous 
insulin infusion (CSII), with the aim of achieving near-normal glucose control, against 
conventional insulin therapy (one or two daily injections) in 1,441 volunteers with T1D 
recruited from 29 medical centres in the United States and Canada between 1983 and 1989, 
and followed up until 1993. The results were hugely impressive, demonstrating significant 
benefits of IIT in terms of both incidence and progression of major microvascular end-points, 
neuropathy, retinopathy and albuminuria (DCCT group 1993). However, it was also noted 
that severe hypoglycaemia (requiring active third party assistance to aid recovery) was 
increased by over three-fold in those on IIT, with many subjects reporting multiple episodes 
of severe hypoglycaemia (DCCT group 1997).  Moreover, it was soon recognised that 
recurrent hypoglycaemia (RH) leads to a down-regulation of both the magnitude and 
threshold for activation of counterregulatory hormonal and symptomatic responses during 
subsequent hypoglycaemia; a clinical phenomenon referred to as impaired awareness of 
hypoglycaemia (IAH) (McCrimmon &Sherwin). IAH affects approximately 25-30% of all 
individuals with T1D increasing to almost 50% among those with longer duration diabetes 
(>20years) (Elliott 2011), and markedly increases the risk of severe hypoglycaemia (SH) by 
nearly six fold (Geddes, Schopman et al. 2008).  Based on these findings, Cryer, in his 1994 
Banting Lecture to the American diabetes Association, would refer to hypoglycaemia as  “the 
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limiting factor to the management of [Type 1 diabetes]” (Cryer 2002)..Thus an effective 
strategy to reduce individual and societal burden of the microvascular complications of T1D 
could only be achieved at the expense of recurring episodes of severe hypoglycaemia.  
The publication of the DCCT served as a major stimulus to basic and clinical research in 
hypoglycaemia. In the ensuing decades we have learnt more about the mechanisms by which 
hypoglycaemia is detected and how these mechanisms fail over time in T1D leading to the 
development of IAH. Newer insulin formulations, insulin delivery devices and delivery 
strategies have been introduced in order to reduce hypoglycaemia risk, and yet despite this 
the frequency of severe hypoglycaemia remains relatively unchanged in most western health 
care systems. This means there is a need for novel therapies and strategies that may help to 
prevent severe hypoglycaemia in T1D, while allowing individuals to maintain near-normal 
glucose control over the life-time of their disease.  
In this thesis, I will explore the potential merits of two different oral agents as adjuncts to 
insulin therapy that might serve to prevent severe hypoglycaemia and/or restore awareness of 
hypoglycaemia.  The first is a non-selective KATP channel opener (diazoxide) and the second 
will be a dipeptidyl peptidase 4 inhibitor (DPPIVi) (saxagliptin).  The first approach was 
chosen following several publications that revealed the importance of the ATP sensitive 
potassium channel (KATP) in the detection and generation of counterregulatory responses to 
hypoglycaemia (Evans, McCrimmon et al. 2004, McCrimmon, Evans et al. 2005).  The 
second drug was chosen because of its dual action to suppress glucose-stimulated glucagon 
secretion and to reduce the overall dose of exogenous insulin replacement. Taken together, 
this would be anticipated to reduce glucose fluctuations, and as a consequence, exposure to 
hypoglycaemia, indirectly leading to improve the counter-regulatory responses to further 
hypoglycaemia.  
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The second part of the thesis, will explore the impact of recurrent hypoglycaemia (RH) 
and/or glucose variability (GV) on the hypothalamo-pituitary adrenal axis (HPA) - the system 
which largely controls the body’s response to stressful stimuli, in order to gain a wider 
appreciation of possible maladaptive processes on this system and then speculate the impact 
on wider systems controlled by the HPA axis.    
So to begin, I will give an overview of hypoglycaemia, with a discussion around the 
challenges of defining hypoglycaemia, the enormity of the problem in those with T1D, the 
normal defence mechanisms against hypoglycaemia (or the counterregulatory (CRR) defence 
mechanism), and possible mechanisms of failure of this system.  One of the main reasons for 
failure of this system is the recurrent nature of hypoglycaemia and I will then follow the 
discussion with the potential impact on other systems as a result of recurrent hypoglycaemia 
(RH).   
Definition of hypoglycaemia 
 
One of the earliest definitions of hypoglycaemia was an episode of low glucose meeting the 
criteria of Whipple’s triad that is of; symptoms consistent with hypoglycaemia, low plasma 
glucose, and a relief of symptoms when the plasma glucose concentration was 
raised(Whipple and Frantz 1935).   Subsequently, there has been debate as to how to define 
the exact glucose value at which hypoglycaemia occurs.  Most clinicians use the cut-off 
plasma glucose between 3.5 and 3.9 mmol/L.(Frier 2009).  Diabetes UK recommend that 
individuals should not allow their blood glucose to drop below 4.0mmol/L, but this clearly 
does not define hypoglycaemia(O'Neill 1997).  The American Diabetes Association (ADA) 
have defined their set threshold at <3.9mmol/L(Workgroup on Hypoglycemia 2005) which 
has also been endorsed by the Food and Drug Administration (FDA) agency.   They deemed 
it important that their definition should include all episodes of an abnormal plasma glucose 
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that could potentially harm the individual and therefore included other categories, such as 
relative and probable hypoglycaemia.  The ADA have therefore suggested that 3.9 should be 
an “alert value”. There is however increasing consensus to make the biochemical criteria less 
than 3.5mmol/L, as it includes the advice given to children (ISPAD 2009). These biochemical 
definitions, also highlight the importance of differentiating between lower values for target 
ranges and values designated to represent true hypoglycaemia.  
Table 1; Summary of criteria to enable definition of hypoglycaemia 
Cut off (mmol/L) Organisation 
Less than 4.0 Diabetes UK 
<3.9 ADA/FDA (American 
Diabetes Association/Food 
and Drugs Administration)  
<3.5 ISPAD (International 
Society For Paediatric and 
Adolescent Diabetes  
Also, a further complication in coming to a definition of hypoglycaemia, lies in differences in 
reporting.  Finger pricking measures whole blood glucose whereas the meters are calibrated 
to plasma glucose values. Plasma glucose is on average 10% higher than whole blood glucose 
concentrations and therefore, there can be a considerable error range on most home blood 
glucose monitoring systems(Cengiz and Tamborlane 2009). (Current standard (ISO) is 
BG>4.2mmol/L to be within 15% of reference range, and BG<4.2mmol/L not to differ from 
reference range by more than 0.83mmol/L).   
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The ADA criteria however are all based on plasma glucose, and therefore is often an 
overestimate of the true value. Most recently however a joint working group(Seaquist, 
Anderson et al. 2013) between the ADA and the Endocrine society defined hypoglycaemia as 
“all episodes of an abnormally low plasma glucose concentration that expose the individual 
to potential harm”.  The absence of an exact figure in this definition was the realisation that 
glycaemic thresholds are dynamic and change with prior glucose exposure. However for the 
purposes of patients and caregivers, a pragmatic value of <3.9 mmol/L was given, chosen 
because it is the glycaemic threshold for activation of counterregulatory responses (CRR) in 
non-diabetic individuals and the upper limit of plasma glucose at which there is a subsequent 
reduction of CRR during further episodes of hypoglycaemia. However most patients with 
T1D do not have a glucagon response (McCrimmon and Sherwin 2010) and therefore using a 
threshold suitable for non-diabetics has been seen as having a questionable relevance in this 
context.    
In summary, there still exists much debate regarding the cut off point for defining 
hypoglycaemia. Variable definitions used by different authorities, make comparison of 
research studies particularly challenging.  Although a fixed value maybe somewhat artificial, 
as in real life situations, the ambient glucose environment and glucose control determine 
variable thresholds for symptom generation leading to recognition and reporting of 
hypoglycaemia by an individual, it may be necessary for pragmatic and educational reasons.   
In order to get some consensus of hypoglycaemia reporting, a workgroup was set up in 2005, 
and the suggested definitions described below are generally well accepted by trialists and aids 
in current reporting.(Workgroup on Hypoglycemia 2005)   
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a. Severe hypoglycaemia (SH)  
A neuroglycopenic event, which requires third party assistance in administering 
carbohydrate, glucagon, or other resuscitative actions, in aiding recovery.  Provided 
there is quick restoration of neurological status following resuscitative measures, a 
plasma glucose is not crucial.  However this definition spans episodes where 
carbohydrates are offered by a third party and then ingested by the patient, and so is 
partially dependant on the patient (this may be the case in both young and elderly 
patients), and also episodes which involve significant neuroglycopenia and collapse 
requiring parental administration.  Theoretically, administration of glucagon to 
prevent severe hypoglycaemia could also be included in this category.  Therefore 
inclusion of these other scenarios, could potentially overestimate the prevalence of 
SH.    
b. Documented symptomatic hypoglycaemia  (Mild) 
Typical symptoms of hypoglycaemia + a plasma glucose <= 3.9mmol/L 
c. Asymptomatic hypoglycaemia (Mild) 
No symptoms of hypoglycaemia + a plasma glucose <=3.9mmol/L.  This could be 
when the patient tests their plasma glucose co-incidentally before a meal or an insulin 
dose, and finds it lower than expected.  The other situation this may arise, is if 
someone apart from the patient recognises the signs of hypoglycaemia, even though 
the patient has no subjective awareness. Traditionally, b and c are usually clumped 
into the mild hypoglycaemia category in clinical research studies. 
d. Probable symptomatic hypoglycaemia 
Patients experience typical symptoms of hypoglycaemia which were rectified by 
administration of appropriate carbohydrates with no documented blood glucose. It is 
recognised, that if self-testing is neither available or possible,  the most pragmatic 
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approach recognises that if symptoms are reversed by appropriate treatment, then 
corroborative evidence with blood sugar testing is not an absolute requirement to 
identify hypoglycaemia.   
e. Relative/pseudo hypoglycaemia  
Especially important in those with poor glycaemic control, who have typical 
symptoms of hypoglycaemia at a blood glucose of >3.9mmol/L  
 
The above discussion therefore shows the varying problems with defining hypoglycaemia, 
and may account for the widely quoted ranges of the frequency of hypoglycaemia in different 
cohorts of patients.   
Frequency 
 
Mild hypoglycaemia 
 
On average, those with T1D experience 2 episodes of mild symptomatic hypoglycaemia per 
week (Pramming, Thorsteinsson et al. 1991, Frier 2009) .  However the true frequency of 
hypoglycaemia is hard to determine unless it is done prospectively in those having mild 
symptomatic hypoglycaemia. Even then, a study in 66 T1D subjects(Pramming, 
Thorsteinsson et al. 1990)  in the outpatient setting showed that true biochemical 
hypoglycaemia (BH) was only present in 29% of symptomatic hypoglycaemia and only 16% 
of true BH was accompanied with symptoms. Often if an episode is deemed to be mild, the 
patient may even forget to mention it to their physician, and therefore this may also account 
for substantial under-reporting.   This was reported in a qualitative study whereby relatives of 
those with IAH, commented on poor recollection of hypoglycaemia from their relative during 
consultations. (Lawton, Rankin et al. 2014).    Estimates of asymptomatic hypoglycaemia are 
also dependant on the intensity of self-monitoring of blood glucose (SMBG).     
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Continuous glucose monitoring (CGM) has proved to be a useful tool in this setting and 
particularly important in identifying hypoglycaemia in those who have lost their warning of 
hypoglycaemia, or indeed those who have frequent nocturnal hypoglycaemia. As an example, 
a study in a group of well controlled T1D using CGM showed an average of 2.1 episodes 
over a 24 hour period.(Kubiak, Hermanns et al. 2004), and even those with intact awareness 
did not have symptoms during 62% of biochemical hypoglycaemia (BH).  Studies have 
shown that CGM, in those with Impaired Awareness of Hypoglycaemia (IAH) can pick up 
40-60% of all hypoglycaemic episodes, which would otherwise go unrecognised even in 
those who do SMBG regularly(Geddes, Schopman et al. 2008).   However there is debate as 
to the accuracy of CGM at lower blood glucose levels or when the rate of change of blood 
glucose is rapid.   Continuous glucose monitoring systems which measure interstitial glucose 
is calibrated to finger prick (whole blood) which is often calibrated to plasma glucose, and 
therefore there can be a lag behind plasma glucose particularly during periods of quick flux. 
Interstitial glucose has been shown to overestimate blood glucose at all levels of 
hypoglycaemia (p<0.001), with each 1 mmol/L drop in blood glucose associated with a 0.32 
mmol/L difference (Choudhary, Lonnen et al. 2011).  A recent study comparing CGM 
(Guardian Real-Time) with  laboratory references showed an overall mean absolute relative 
difference (MARD) of 16.7%, with 94.6% lying in the Clarke error grid zone (A+B), 
however there was a failure to accurately detect half of all true hypoglycaemic events 
(sensitivity 37.5%) with a MARD of 38.8% in the hypoglycaemic range(Zijlstra, Heise et al. 
2013).  
Therefore there are still deficiencies in current technological methods to detect mild 
hypoglycaemia. Self-reporting is  problematic because of poor correlation with symptoms 
and blood glucose (even in those with intact awareness). Under-reporting particularly of 
mild symptomatic and asymptomatic hypoglycaemia accounts for 88% of all hypoglycaemic 
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events(Brod, Christensen et al. 2011) .  CGM devices may overcome some of these problems 
but deficiencies in sensitivity in the hypoglycaemic range may also fail to provide a true 
measurement of the burden of mild hypoglycaemia(Zijlstra, Heise et al. 2013).  
Severe hypoglycaemia 
 
Yearly incidence rates of severe hypoglycaemia (SH) in those with T1D, of up to 42% have 
been reported in observational studies conducted in both UK and Europe. (ter Braak, 
Appelman et al. 2000, Pedersen-Bjergaard, Pramming et al. 2004, Gimenez, Lopez et al. 
2012).  The UK Hypoglycaemic Study Group in those with T1D showed an incidence of 
severe hypoglycaemia of 1.1 and 3.2 episodes per patient year in those with disease duration 
of less than 5 years greater than 15 years respectively.    
However, the definition of severe hypoglycaemia in some of these studies included those who 
“needed assistance”.  This definition may therefore include those who were given glucagon in 
the context of mild hypoglycaemia to avoid a more severe episode (uncommon) but also the 
very young and elderly population due to other reasons.   As a result, it has been proposed 
that it may be more accurate to define severe hypoglycaemia as that which involves a seizure 
or loss of consciousness (LOC). (Weinstock, Xing et al. 2013).   In the US, T1D exchange 
clinic registry data (26,000 participants from paediatric and adult endocrinology practices) 
(Weinstock, Xing et al. 2013) whereby this definition of either LOC or seizure was 
employed, 18.6% and 11.8% had SH (if duration of diabetes >40 years and <40 years 
respectively.  These figures are fewer than previously reported probably reflecting the 
narrower criteria used in the T1D Exchange clinic network.   
Interestingly frequency of SH in RCTs (Little, Chadwick et al. 2012) remains far lower than 
seen in routine clinical practice (Weinstock, Xing et al. 2013) indicating either that the 
implementation of strategies employed in these RCTs have not translated as yet to routine 
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clinical care or that the frequent monitoring and repeated contact with a health care 
professional during RCTs has a very positive influence on the patient and improves diabetes 
outcomes compared to routine clinical care. 
From the above discussion, it follows that hypoglycaemia is almost inevitable in those with 
T1D, however there are numerous risk factors for multiple episodes of hypoglycaemia and 
these are summarised below.   
Risk factors 
 
Often one of the first steps in reducing the burden of hypoglycaemia on a patient is through 
identification of scenarios that confer risk, with a discussion around avoidance or 
preventative strategies.   However, on other occasions, the cause is often multi-factorial, or no 
definite cause can be identified.   There are multiple  factors that increase the likelihood of 
developing hypoglycaemia and these are summarised below.   
Table 2; Listing of modifiable and non-modifiable risk factors for further hypoglycaemia, with likely mechanisms. 
   
Modifiable risk factors Mechanism References 
Antecedent hypoglycaemia 
(AH) 
 
Increased catecholamine and 
opioid production during 
AH leading to suppression 
of CRR subsequently 
(Heller and Cryer 1991) 
(Caprio, Gerety et al. 1991) 
History of previous severe 
hypoglycaemia 
Blunting of counter-
regulatory responses. 
SH in the previous 6 months 
was the strongest predictor 
of further SH in the JDRF-
CGM RCT.  
(DCCT Hypo Study, 1997) 
(Donnelly, Morris et al. 
2005) 
(Fiallo-Scharer, Cheng et al. 
2011 
Impaired awareness of 
hypoglycaemia (IAH) 
IAH RR  6.2 (4.6-8.4) 
p<0.0001 
(Pedersen-Bjergaard, 
Pramming et al. 2004) 
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Completely Unaware RR 20 
(13-31) p<0.0001 
Low insulin requirements 
(<0.43u/kg) irrespective of 
BMI were associated with 
higher rates of SH 
Higher insulin sensitivity (Weinstock, Xing et al. 
2013) 
Glycaemic variability (GV)  
 
Increased GV associated 
with hypoglycaemia  
(Janssen, Snoek et al. 2000) 
Tight glycaemic control 
 
HbA1c has been shown to 
have a U shaped relationship 
with frequency of SH, with 
the lowest frequency at 53-
58 mmol/mol  
(Weinstock, Xing et al. 
2013) 
Exercise Inability to reduce 
circulating insulin increases 
risk.   
Decreases the CRR to 
subsequent hypoglycaemia. 
(Galassetti, Mann et al. 
2001) 
(Galassetti, Mann et al. 
2001) 
(Milman, Leu et al. 2012) 
Alcohol Endogenous hepatic glucose 
production is reduced.  
Reduces peripheral 
autonomic responses 
Impairs cognitive function 
but only in fasted patients 
(Vindedzis, Marsh et al. 
2013) 
Smoking Could be indirect effect due 
to differences in lifestyle.   
(Pedersen-Bjergaard, 
Pramming et al. 2004) 
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Peripheral neuropathy Mechanism not clear 
Symptomatic; OR 2.2 (1.5-
3.3) p<0.0001 
Those with and without PN 
(p=0.002) 
(Pedersen-Bjergaard, 
Pramming et al. 2004) 
(ter Braak, Appelman et al. 
2000) 
Renal failure Reduction in insulin 
clearance. Degradation of 
insulin in peripheral tissues 
is decreased. Suboptimal 
nutrition may mean poor 
glycogen stores. Reduction 
in renal gluconeogenesis 
(Moen, Zhan et al. 2009) 
Non-modifiable risk factors   
No residual C peptide  Indicator of more complete 
loss of endogenous insulin 
and associated with greater 
loss of glucagon responses 
DCCT (1993) 
Duration of diabetes Appears to be the strongest 
determinant of frequency of 
SH 
DCCT Hypo study (1997) 
(Weinstock, Xing et al. 
2013) 
Female sex 
 
Catecholamine levels are 
suppressed during moderate 
hypoglycaemia. Peripheral 
insulin sensitivity appears 
lower in women, but women 
have enhanced hepatic 
sensitivity. It is thought to 
be mediated by oestrogen  
(Amiel et al, 1993,  
(Sandoval, Ertl et al. 2003) 
 
Older age Despite an intact counter-
regulatory response, a small 
study showed reduced 
symptomatic awareness, 
may be due to reduced end 
organ response to counter-
regulatory hormones. 
 
(Brierley, Broughton et al. 
1995) 
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Sleep Reduced sympatho-adrenal 
responses during sleep, 
which also results in lower 
likelihood of being 
awakened during 
hypoglycaemia. 
May be part of a general 
reduction in overall 
sympathetic activity seen in 
non-REM sleep. 
Asymptomatic nocturnal 
hypo may suppress response 
to further hypo 
 
(Banarer et al, 2003) 
 
(Jones et al, 1998) 
Lower education levels 
(p=0.03)  
Lower household incomes 
(p<0.001) 
Observational data (Weinstock, Xing et al. 
2013) 
 
Having considered possible risk factors of hypoglycaemia, I will move on to the 
physiological compensatory mechanisms that occur in response to a reduction in blood sugar 
in a non-diabetic individual prior to a discussion on how the system fails in those with 
recurrent hypoglycaemia and Type 1 Diabetes.     
The normal counter-regulatory response in hypoglycaemia  
 
A continuous supply of glucose to the brain, is maintained by a set of complex peripheral, 
central and behavioural defence systems to enable optimal performance (Cryer and Gerich 
1985) delivered through a sturdy counter-regulatory system. The key components of the 
counter-regulatory system were first identified in the early 1980s and will be discussed below 
(Drost, Gruneklee et al. 1980)  and is pictorially displayed in Figure 1.  
39 
 
 
Figure 1; The normal counter-regulatory system in the non-diabetic human.   
The main glucose sensors are found in the brain with signals transmitted via the autonomic nervous system to the main 
effector organs, which ultimately release glucose and decrease glucose utilisation, restoring euglycaemia. ANS Autonomic 
Nervous System.   Adapted from (Martin-Timon and Del Canizo-Gomez 2015).    
Firstly, the hormonal systems in place, in the non-diabetic are listed below,  
1. Suppression of endogenous insulin secretion. Decrease of insulin produced by the 
beta cells of the pancreas.  In healthy humans, this occurs whilst plasma glucose is 
still in the physiological range at approximately 4.4mmol/L.  (Fanelli, Pampanelli et 
al. 1994)  This decrease in insulin and co-secreted GABA are thought to lift tonic 
inhibition of the α cell which results in an increased secretion of glucagon (Xu, 
Kumar et al. 2006).  Together with the low levels of portal insulin, this stimulates 
hepatic glycogenolysis and gluconeogenesis with a resulting increase in hepatic 
glucose production.   
2. Secretion of the α cell product – glucagon.  Glucagon is a 29 amino acid peptide, 
cleaved by pro-hormone convertase-2 from the pro-glucagon molecule in pancreatic 
islet alpha cells. Secretion of glucagon occurs as the blood glucose drops and the 
threshold for release is around an arterialized blood glucose of 3.8mmol/L (Fanelli, 
Pampanelli et al. 1994). This was found to be play a primary role in counter-
regulation (Gerich, Langlois et al. 1973, Rizza, Cryer et al. 1979), as early studies 
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using catecholamine deficient patients with spinal cord transections and those who 
had a previous adrenalectomy were found to be still capable of restoring euglycaemia 
during induced hypoglycaemia.  Activation of the glucagon receptor stimulates a (Gs) 
protein which increases production of cAMP through activation of adenylate cyclase.   
Glucagon is directly secreted into the portal vein and acts directly on the G-protein 
coupled receptors in the liver to enhance glucose production. (Ramnanan, Edgerton et 
al. 2011). The majority of this effect is through hepatic glycogenolysis.  However in 
combination with adrenaline, which enhances delivery of gluconeogenic precursors, 
and when substrate availability increases, (during meals) glucagon also stimulates 
hepatic gluconeogenesis.(Gustavson, Chu et al. 2003).  Glucagon also inhibits 
glycolysis and glycogen synthesis.   Glucagon can also stimulate lipolysis through 
activation of cAMP and lipases.  In Kir6.2 -/- deficient mice which lacked both 
functional KATP channels and VMH glucose excitatory (GE) (neurons which increase 
their output as glucose levels increase)neurons, glucagon response was severely 
impaired, suggesting that there is also a central control of glucagon release(Miki, Liss 
et al. 2001). In recent studies, a central control of glucagon has been shown to 
originate from the autonomic nervous system through the para and sympathetic 
nervous systems and also via adrenal secretion of adrenaline(Porte, Woods et al. 
1975). The contribution of each of these systems appears to be related to the severity 
of the hypoglycaemia.  Glucagon secretion also appears to be sustained in isolated 
islets suggesting other factors involved in its release(Stagner, Samols et al. 1980). 
There are still contradictory findings as to whether glucose has a direct or indirect 
effect on the α cells(Gilon 2014).  Other factors that have been suggested to regulate 
glucagon secretion include nutrients, insulin, zinc, GABA, glutamate, somatostatin, 
ghrelin, and glucagon itself. (Gromada, Franklin et al. 2007). 
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3. Autonomic responses during acute hypoglycaemia( see figure 1); There is a rise in 
adrenaline (epinephrine) in the circulation and noradrenaline at the nerve terminals 
produced by the adrenal medulla(Sprague and Arbelaez 2011).   
Adrenaline acts on alpha and beta adrenergic receptors at multiple end organs, and is 
effectual in maintaining a sustained increase in glucose, by increasing glycogenolysis 
and gluconeogenesis in the liver(Cryer, Davis et al. 2003).  It also acts on the pancreas 
to reduce insulin and increase glucagon secretion.  Peripherally, it reduces glucose 
uptake and utilisation and increases glycolysis in the muscle, and increases lipolysis 
in the adipose tissue.  (Cryer 2002) Neurogenic symptoms occur as a result of the 
activation of the autonomic nervous system.  Presence of these symptoms in patients’ 
who have had an adrenalectomy, shows these symptoms are generated through 
sympathetic neuronal activation rather than through adrenaline release from the 
adrenal medulla whilst the noradrenaline responses and the haemodynamic responses 
are mainly due to adreno-medullary release.(DeRosa and Cryer 2004) 
Increased adrenaline also accounts for the increased cardiac work load, and promotes 
ECG changes such as QT lengthening, which can provoke arrhythmias particularly in 
a patients with coronary artery disease(Frier, Schernthaner et al. 2011).  
4. Growth hormone; Secretion of growth hormone (GH) usually occurs at a glucose 
threshold of 3.7mmol/L.  However studies which rendered subjects selectively growth 
hormone deficient during hypoglycaemia, showed no difference in glucose 
appearance and disappearance compared to control subjects(Rizza, Cryer et al. 1979), 
therefore it is postulated that GH does not have any role in the immediate recovery 
but may be more important in more prolonged hypoglycaemia.   
5. Glucocorticoid; similarly cortisol is found to also have a role during more prolonged 
hypoglycaemia, with a glucose threshold for release at approximately 3.2mmol/L. 
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Studies have suggested that this lower threshold for HPA activation is not true, but 
due to a delay in activation of ACTH which may require a longer set period of 
hypoglycaemia  (Schwartz, Clutter et al. 1987).  Both GH and cortisol stimulate 
lipolysis in adipose tissue, ketogenesis and gluconeogenesis in the liver.   When GH 
and cortisol were both blocked, it has been shown that glucose recovery was much 
slower despite increases in adrenaline.(De Feo, Perriello et al. 1989) 
6. Symptom profile; alongside the above, autonomic symptoms arising from the 
sympathetic neural response alert the individual of progressive hypoglycaemia.  These 
symptoms are key to recognition of hypoglycaemia.   These symptoms have been 
shown to be broadly divided into a three factor model (autonomic, neuroglycopenic 
and non-specific) (Deary, Hepburn et al. 1993).  Neuroendocrine responses are 
responsible for generation of the autonomic component, whereas neuroglycopenic 
symptoms are thought to be as a result of brain cortical glucopenia(Hepburn 1993).  
Mitrakou et al showed that the glycaemic thresholds for the autonomic symptoms 
(3.2mmol/L) were higher than that for neuroglycopenic symptoms (2.8mmol/L) 
(Mitrakou, Ryan et al. 1991). Symptoms can be highly variable in patients and 
depends on a number of factors such as the exposure to hypoglycaemia in the 
preceding 48 hours, rate of glucose decline, the person’s current level of activity, 
duration of diabetes and prevailing glycaemic control.  Therefore, a patient who has 
poor glycaemic control may have symptoms even when the blood sugar is much 
above 4.0mmol/L (Boyle, Schwartz et al. 1988) termed by the ADA as relative 
hypoglycaemia and vice versa, with a patient with strict glycaemic control only 
having symptoms at a very low glucose level(Boyle, Kempers et al. 1995).   However, 
if they do have symptoms, patients tend to have similar patterns, albeit atypical.   
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7. Cognitive function  
 
Generally in a non-diabetic individual, cognition is impaired when plasma glucose 
drops below 2.9mmol/L.  The most impaired domains of cognition tend to be 
information processing, attention, memory and reaction times(McCrimmon, Ryan et 
al. 2012).  It is often the most complex processes that are affected by acute 
hypoglycaemia, and therefore it has been emphasised that it is crucial to use a battery 
of psychometric tests to detect a subtle cognitive defect(Heller and Macdonald 1996).  
Those however who experience RH, appear to have cognitive preservation, even 
when the blood sugars are extremely low, and this has been seen to be part of the 
adaptive processes of hypoglycaemia. (Fanelli, Pampanelli et al. 1994)   
 
Therefore, through these above hormonal and symptomatic responses, blood glucose is kept 
in a very tight physiological range, ensuring optimal delivery of glucose to vital organs, 
particularly the brain. The following discussion describes when these mechanisms start to fail 
in T1D, as the islet cells are destroyed and glucagon release becomes dysregulated.   
Counter-regulatory responses in those with T1D 
 
Major defects in the generation of counter-regulatory response contribute to the high 
frequency of hypoglycaemia seen in those with T1D.   
Starting at 1-8 months after diagnosis(Siafarikas, Johnston et al. 2012) and certainly within 5 
years, almost all individuals fail to generate an adequate glucagon response to hypoglycaemia 
and is a key feature of impaired hypoglycaemia counter-regulation. (McCrimmon 2008)  The 
portal insulin: glucagon ratio is primary in controlling hepatic glucose production. An 
inadequate glucagon response is associated with marked delay in glucose recovery as a result 
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of reduced glycogenolysis and gluconeogenesis. (Gerich, Langlois et al. 1973). Several intra 
and extra pancreatic defects have been identified which may explain this.   
a. Intra -islet factors 
i. Failure of local regulation on the α-cell signalling by insulin, zinc 
and/or GABA(Fukuda, Tanaka et al. 1988). This is suggested because 
there is a loss of this stimulus specific (i.e. hypoglycaemia) glucagon 
secretion which closely follows the decrease in C-peptide levels 
(Fukuda, Tanaka et al. 1988). 
ii. Elevated somatostatin within the islets has also been shown to suppress 
the glucagon response to hypoglycaemia.  This was illustrated in 
rodent models when glucagon responses could be restored when there 
was pharmacological antagonism of the somatostatin receptor. (Yue, 
Burdett et al. 2012) 
iii. There is now evidence suggesting there is a local intra-islet 
sympathetic neuropathy. (Mundinger, Mei et al. 2003) 
b. Extra-islet factors 
i. The VMH has been recently been shown to modulate the interaction 
between insulin and glucagon.(Paranjape, Chan et al. 2010).  Recurrent 
hypoglycaemia has shown to significantly suppress the VMH 
stimulation of the- α cells. (Borg, Borg et al. 1999) 
2. Reduced autonomic stimulation-  
a. Attenuated adrenaline release; within 10 years of diagnosis, the majority of 
those with T1D have a reduced autonomic response (Fanelli, Pampanelli et al. 
1997). The reduction in adrenaline during subsequent hypoglycaemia, is as a 
result of a resetting of the glycaemic threshold for activation at a lower level, 
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and this may be due to both the duration of diabetes as well as exposure to 
hypoglycaemia, rather than a reduced secretory capacity.  It has been shown 
that a single episode of antecedent hypoglycaemia is sufficient to attenuate the 
CRR to further hypoglycaemia (Heller and Cryer 1991, Davis, Mellman et al. 
1992).   The magnitude of attenuation appears to be linked to the depth, 
duration and frequency of the hypoglycaemia stimulus.  This reduction is 
thought to be as a result of reduced sympathetic drive to the adrenals rather 
than a defective secretory capacity of the adrenals.  There is also a reduced 
magnitude of adrenaline release with age irrespective of diabetes, with a study 
showing that children with/without(Amiel, Simonson et al. 1987) T1D have 
almost twice as much adrenaline as adults.  The elderly in addition have been 
shown to have a reduced sensitivity to catecholamines (Pende, Musso et al. 
1991).   
One of the original studies looking at the mechanisms of this phenomenon showed that 
intravenous administration of adrenergic blockers could prevent development of counter-
regulatory failure the subsequent day during hypoglycaemia, suggesting it is the generation of 
the adrenergic response during hypoglycaemia that potentiates the defective counter-
regulation.(Ramanathan and Cryer 2011).  
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Table 3; Summary of main studies showing the effect of duration of antecedent hypoglycaemia on subsequent counter-
regulatory responses.  
Stimulus Effect  
1 hypo-30mins (2.8mmol/L) 
on day 1 
No reduction in CRR on day 2 (Heller and Cryer 1991) 
2 hypos-30mins 
(2.8mmol/L) mane and 
(3.0mmol/L) afternoon on 
day 1 
Significant reduction in CRR on 
day 2 
(Heller and Cryer 1991) 
3 hypos- Less than 30mins – 
(<2.8mmol/L) on day 1, 2, 3 
No blunting of CRR on day 4  (Peters, Rohloff et al. 
1995) 
Two hypos on day 1/or one 
hypo on day 1 and one hypo 
on day 3 and day 8 
If 2 hypos on day 1; Blunting of 
adrenaline/sweating on day 3 
and 8  
No blunting of noradrenaline or 
symptoms on day 8 
(George, Harris et al. 
1995) 
Three (2 hour) hypos over 
30 hours- protocol 1 /two (2 
hour) hypos over 8 hours-
protocol 2 
 
Blunting of CRR on day 5 only 
in protocol 1.   
(Moheet, Kumar et al. 
2014) 
 
3. Reduction in symptoms; this adrenergic response is closely linked with the 
symptomatic response to hypoglycaemia as both are driven by autonomic activation, 
and therefore when a reduced autonomic response is present, there is usually a 
reduced awareness of hypoglycaemia with the resultant increase in the risk of severe 
hypoglycaemia(White, Skor et al. 1983).  
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4. Defects in cortisol and growth hormone may additionally be responsible for causing 
longer duration hypoglycaemia with longer recovery times, with reduced cortisol 
causing a reduction in hepatic glucose production.  Acute hypoglycaemia (AH) 
activates various pathways involved in the regulation of the neuroendocrine stress 
response.  It is well established that prolonged hypoglycaemia activates the 
hypothalamic pituitary adrenocortical axis (HPA).  However, a reduction in cortisol 
secretion is seen with RH, and has also been shown to contribute to a poor CRR 
(Davis, Shavers et al. 1996).  Glucocorticoid deficiency with its resultant increase in 
whole body insulin sensitivity, has been shown in small case series to be associated 
with recurrent severe hypoglycaemia(Hardy, Burge et al. 1994). 
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Figure 2; The mechanisms behind the diminished counter-regulation and hypoglycaemia unawareness  
Taken from (Cryer 2002).  
 
 
 
As a result of the reduced glucagon, adrenaline and cortisol responses (defective glucose 
counter regulation) and the reduced symptom profile (hypoglycaemia awareness) see figure 
above, there is much morbidity in these patients with a 25 fold increase in the incidence of 
severe hypoglycaemia. Following is a review of the mechanisms proposed to date of the 
aetiology of defective counter regulation.   
 
Mechanisms of counter-regulatory failure 
 
Recurrent hypoglycaemia has been shown in multiple studies to be primarily responsible for 
the impairment of the counter-regulatory responses to further hypoglycaemia in both healthy 
individuals (Heller and Cryer 1991) and in those with T1D (Dagogo-Jack, Craft et al. 1993) 
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(see table 3). Recurrent hypoglycaemia appears to cause a reduction in the magnitude and 
threshold for stimulation of CRR responses. Several mechanisms as well as several brain 
regions are thought to be involved in the development to impaired CRR..   
For instance, in a study involving rodent models using cFos activation as a label of cellular 
activity, it was shown that following RH, there is a diminishing response not only in the 
hypothalamus but also in other areas of the brain such as the paraventricular hypothalamus 
(PVH), dorsal medial hypothalamus (DMH), lateral hypothalamus area (LHA), 
paraventricular nucleus of the thalamus (PVT), nucleus tractus solitaris (NTS) and area 
postrema.   This attenuation seems to be dependent on both extent and duration of the 
hypoglycaemia.(Paranjape and Briski 2005). This study and others demonstrate that many 
brain regions may directly, or indirectly be involved in the detection of hypoglycaemia. 
Others have explored the way the brain senses and responds to low glucose.  The brain 
contains populations of specialised neurons that respond directly to a change in the glucose 
level to which they are exposed with a change in membrane potential and firing rate. These 
glucose response (GR) neurons are divided into glucose-excited (GE) neurons that are 
activated when glucose levels rise and glucose inhibited (GI) neurons that are activated when 
glucose levels fall. In rodent models, the ability of GR neurons (both GE and GI neurons) to 
sense hypoglycaemia is dysregulated following recurrent hypoglycaemia.  GE neurons 
exhibit a decreased response to low glucose as demonstrated by a lower threshold (0.1 instead 
of 0.5mM) before GE neurons are inhibited(de Vries, Arseneau et al. 2003).  Similarly, GI 
neurons are also less able to sense decreased glucose after RH(Song and Routh 2006).   
The mechanism for the change in glucose responsivity of GR neurons following RH is 
unknown but may reflect a change in the metabolism of glucose within the cell. Several 
investigators have suggested a key role for glucokinase as a regulator of neuronal 
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glucosensing (Dunn-Meynell, Routh et al. 2002).  Inhibition of glucokinase has been shown 
to reduce activity in glucose excited (GE) neurons and increase glucose inhibited (GI) 
neuronal activity (Dunn-Meynell, Routh et al. 2002).   This pattern of GE/GI change has been 
shown to increase the counter-regulatory responses(Routh 2002).  Conversely, up regulation 
of glucokinase mRNA has been linked with the development of defective CRR, through 
potentially increasing the metabolism of glucose and therefore generation of ATP. This 
would lead to a lowering of the glucose level where glucose responsive (GR) neurons are 
activated (Kang, Dunn-Meynell et al. 2006).   
Nitric oxide (NO) has also been shown to play a part in glucose sensing particularly in the GI 
neurons.  AMP-activated protein kinase (AMPK) activation during periods of low glucose in 
GI Neurons leads to phosphorylation of the neuronal nitric oxide synthetase (nNOS) and 
production of NO which through binding to soluble guanylyl cyclase (sGC), increases cGMP 
levels.  Adequate cGMP levels is essential for AMPK activation, chloride channel activation 
and consequently results in increased GI neuronal activation (Murphy, Fakira et al. 2009)  
However in models of RH (insulin injected for 3 consecutive days) the increase in NOS is 
severely blunted (Fioramonti, Marsollier et al. 2010) and this can theoretically affect GI 
neuronal activity and decrease the counter-regulatory response.  It is also known that insulin 
induced hypoglycaemia down regulates mitochondrial free radical scavenger systems and 
increases reactive oxygen species (ROS) (Singh, Jain et al. 2004).   The combination of 
increased NOS production in the presence of ROS, has been shown to increase S-
nitrosylation of key proteins such as nNOS, which in turn decreases their activity, and 
subsequently may adversely affect GI neuronal glucose sensing(Jaffrey, Erdjument-Bromage 
et al. 2001).   
Alternatively or in parallel, RH may impair the release of neurotransmitters from key GR 
neurons resulting in suppression of the neural networks involved in the detection of 
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hypoglycaemia and initiation of a CRR response. Gamma-aminobutyric acid (GABA) is the 
main inhibitory neurotransmitter in the brain. Recurrent hypoglycaemia has been shown to 
result in a significant increase in GABA levels (3 times higher) in a key brain glucose sensing 
region, the ventromedial hypothalamus (VMH)  associated with an increase in GAD65 (a 
protein that is associated with GABA turnover), resulting in a higher inhibitory tone (Chan, 
Cheng et al. 2008)..  Increased GABA inhibitory tone would be predicted to lead to decreased 
action potential (AP) frequency in glucose sensing neurons, with suppression of the CRR 
during subsequent hypoglycaemia(Chan, Cheng et al. 2008). 
Another modulator of the CRR system is the hypothalamo-pituitary-adrenal (HPA) axis. It 
has been suggested that modulation of the CRR, is through preferential activation of one of 
its receptors.  VMH microinjection of CRH, ACTH and corticosterone,which acts primarily 
through CRHr1 amplifies the counter regulatory response (McCrimmon, Song et al. 2006).  
In contrast, urocortin-3, a member of the CRH family of neuropeptides, shows a suppressive 
action on the counterregulatory response through activation of the CRFr2 (CRF receptor 2) 
(McCrimmon, Song et al. 2006).   
 
Recently, key ion channels within the brain have been identified in modulation of the CRR, 
notably the KATP channels as well as the glucose transporters.  Studies with rodent models 
(Kir 6.2-) lacking both KATP channels and VMH GE neurons show a blunted glucagon 
response and significant defective counter-regulation, suggesting an important role of GE 
neurons (which contain KATP channels) in counter-regulation(Miki, Liss et al. 2001).  
Moreover agents that modulate the KATP channels such as sulphonyureas (a KATP channel 
closer) (Evans, McCrimmon et al. 2004) and diazoxide (KATP channel opener) (McCrimmon, 
Evans et al. 2005), have been shown to modulate the CRR in rodent models.  For example, 
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oral diazoxide has been shown to augment the counterregulatory responses during acute 
hypoglycaemia in rodent models.   One potential explanation for this, suggests that when 
diazoxide opens the channel in the GE neurons, there is inactivation of the neurons.  This 
consequently lifts the tonic inhibition placed on the GI neurons (usually from the activated 
GE neuron), which then stimulates the counter-regulatory response. However, as KATP 
channels are found throughout the brain, including other non-glucose sensing neurons, its 
promiscuity can cause many unwanted side effects.    
An increase in the transport of glucose (Koranyi, Bourey et al. 1991)and alternative fuels into 
the glucose sensing neurons has been shown in animals models exposed to RH.  However, 
recent PET studies have shown that after intravenous injection of (1-(11) C glucose), there was 
no change in glucose transport between those with T1D who had antecedent hypoglycaemia 
and those who were exposed to chronic hyperglycaemia.(Fanelli, Dence et al. 1998) In 
contrast other imaging studies have shown reduced glucose uptake and activity in the 
hypothalamus(Cranston, Reed et al. 2001), the prefrontal cortex(Bingham, Dunn et al. 2005), 
the amygdala and the orbitofrontal cortex(Dunn, Cranston et al. 2007) but with greater 
synaptic activity particularly in the dorsal midline thalamus (DMT) (Arbelaez, Powers et al. 
2008) in those with T1D and IAH 
Extra metabolic substrates may also be obtained from local sources such as brain glycogen. 
Rodent models(Herzog, Chan et al. 2008) have shown that although there is an increase 
(super compensation) immediately after restoration of euglycaemia,   levels are restored to 
normal within a few hours ( a time when there is still defective counter-regulation), so 
glycogen super compensation is unlikely to be primarily responsible for the defective 
counter-regulation.   This was confirmed in a recent study using in vivo (13)C nuclear 
magnetic resonance spectroscopy in association with radiolabelled glucose showed an overall 
lower glycogen content in patients with(T1D) with IAH than in controls.(Oz, Tesfaye et al. 
53 
 
2011)  Lactate, a metabolite that can be taken up into neurons via monocarboxylate 
transporters however has been shown to be increased by 5 fold during a hypoglycaemic 
clamp. (De Feyter, Mason et al. 2013).  This adaptation may mean that the metabolic needs 
are met, such that subsequent hypoglycaemia does not elicit an appropriate response with 
suppression of both CRR and decreased symptom response.  
Peripheral components of the sympathoadrenal system (SAS) have also recently appeared to 
be affected as demonstrated in a recent rodent model.  Animals exposed to RH showed a 
subsequent intact response to acetylcholine, with a much blunted adrenaline response 
suggested that this was a stimulus specific defect.  This was thought to be as a result of a 
reduced efficacy of splanchnic nerve stimulation on the adrenal medullary chromaffin cells 
(Orban, Routh et al. 2014). Opioid generation during hypoglycaemia has been proposed in 
the generation of this defective CRR. A study showed that when opioid receptors were 
blocked with Naloxone, the sympatho-adrenal responses to hypoglycaemia was preserved.  
(Caprio, Gerety et al. 1991) 
Although presence of autonomic neuropathy (AN) can contribute to the diminished symptom 
complex in IAH, it is not thought that presence of AN can solely contribute to IAH.  This is 
confirmed when studies show that complete exclusion of hypoglycaemia over a period of 
time, can restore symptoms associated with hypoglycaemia even in the presence of AH.  
Also, there appears to be no relationship between autonomic dysfunction and hypoglycaemic 
symptoms(Berlin, Grimaldi et al. 1987).     
In summary, counter-regulatory failure has been studied through examination of various 
cellular models. Mechanisms proposed have included increases in GABA, upregulation of 
glucokinase mRNA, blunting of the NOS, increases in ROS, as well as an increase in the 
metabolism of glucose and/or alternate fuels.  In addition, various modulators of the CRR 
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have also been studied and include the CRH family of neuropeptides, and the opioids. Animal 
models have suggested changes in the glucose uptake in the brain, but this is yet to be 
replicated in humans.  Alternate fuels such as lactate have shown to be a valuable source of 
energy when glucose is deficient, maintaining the cell’s metabolic needs and appears to be a 
leading hypothesis for adaptation in this context.  
Thresholds 
 
Not only is the magnitude of the counter-regulatory responses (CRR) significantly 
diminished but the glucose thresholds at which the various components of this response are 
initiated are also altered in those experiencing recurrent hypoglycaemia.  Therapies therefore 
need to focus not only on increasing the magnitude of CRR, but should also strive to improve 
thresholds in order for patients to be given adequate time and warning, before experiencing a 
severe hypoglycaemic episode.    
Generally in a non-diabetic individual thresholds are fairly static and counter-regulatory 
hormones are activated at a plasma glucose threshold of ≈3.6-3.8 mmol/L, autonomic 
symptoms appear at ≈ 3.2 mmol/L, with neuroglycopenic symptoms at approximately 
2.8mmol/L  and cognitive function deteriorates at about 2.8 mmol/L(Mitrakou, Ryan et al. 
1991).  This hierarchy of responses ensures that blood glucose is kept at a very tight range in 
a non-diabetic individual. Also, this hierarchy gives the patient ample time before cognitive 
function is affected.   
 
 
 
55 
 
Figure 3; Glucose thresholds for activation of CRR hormone release, autonomic and neuroglycopenic symptoms and 
cognitive deterioration in the non-diabetic human. 
 (Frier 1999) 
 
Several methods have been used to calculate thresholds. The most reliable of which is the 
hyperinsulinemic hypoglycaemic clamp technique.   
Methods used have been;  
a. Plasma glucose at which mean responses were significantly different from the mean 
respective values in a time-matched euglycaemic study 
b. Plasma glucose at which the mean response exceeds the 95% CI for that parameter at 
the corresponding time during the euglycaemic arm.  (Schwartz, Clutter et al. 1987, 
Mitrakou, Ryan et al. 1991) 
c. Plasma glucose at which mean response exceeds a predetermined increment from the 
mean values calculated during the euglycaemic phase of the trial.  (Adrenaline- 
75pg/ml; noradrenaline-50pg/ml; growth hormone-7mg/ml; and cortisol 7mcg/dL).  
The adrenaline increment represents a clinically meaningful rise.    The other 
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increments were based on average responses of these hormones during an insulin 
tolerance test of pituitary adrenal axis function.  This method did not require a 
euglycaemic arm(Amiel, Sherwin et al. 1988).   
d. Plasma glucose at which mean response is greater than 2 SD or a doubling of the 
euglycaemic values.  
However these thresholds are far more dynamic in an individual with diabetes and can be 
influenced by a number of factors such as prevailing glucose levels and level of metabolic 
control. It has been shown that even a short period of intensive insulin therapy (3-6 months) 
in newly diagnosed patients with T1D,  results in a consistent increase of  the glucose 
threshold (2.6mmol/L) for  adrenaline release with markedly lower adrenaline concentrations 
ultimately leading to a diminished symptom complex(Hoffman, Arslanian et al. 1994).   It 
was also noted that the thresholds for the other counter-regulatory hormones were also 
increased.  (Amiel, Sherwin et al. 1988). The converse is true in those with poorly controlled 
diabetes (lower glucose threshold) compared to non-diabetic subjects. (Boyle, Schwartz et al. 
1988).  The thresholds however are not dependent on the rate of fall,  with rates up to 9 fold 
difference in plasma glucose level not affecting glucose thresholds for CRR hormone 
release(Amiel, Simonson et al. 1987).   
Impact of defective counter regulation 
Impaired Awareness of Hypoglycaemia 
 
It is imperative that an individual has adequate symptoms to alert them of impeding 
hypoglycaemia, to allow them to self-treat and prevent severe hypoglycaemia.  It has been 
shown that both autonomic and neuroglycopenic symptoms contribute equally to the 
symptomology alerting an individual to impeding hypoglycaemia (Cox, Gonder-Frederick et 
al. 1993).   However, RH has been shown to increase the glucose thresholds at which 
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symptoms and counter-regulatory response are generated(Heller and Cryer 1991, Dagogo-
Jack, Craft et al. 1993, Davis, Mann et al. 2000) The combination of a defective counter-
regulatory response and a diminished symptom complex during hypoglycaemia has been 
termed Impaired Awareness of Hypoglycaemia (IAH). In patients with IAH, it is thought that 
there is a significant delay for autonomic activation, and hence relatively little sensory 
feedback to alert the patient of falling blood sugars.  This then quickly leads to 
neuroglycopenia (confusion, drowsiness, odd behaviour, speech difficulty, and inco-
ordination).   IAH is associated with a six fold increase in severe hypoglycaemia and is a 
cause of major morbidity (Gold, MacLeod et al. 1994).   
Several hypothesis are currently being tested as to why patients develop IAH.  One of the 
popular viewpoints is illustrated below (Figure 4).  Hypoglycaemia is a significant stress to 
the cell and leads to energy depletion.  This normally would lead to sympathetic activation, 
and in severe cases lead to cell death.   However with RH, the cell adapts by using alternate 
fuels and alters its glucose metabolism such that during subsequent hypoglycaemia, there is 
less energy depletion.  This can be seen as an adaptive process with less cell death, but is also 
maladaptive with a significant diminishing of the sympathetic response with reduced 
symptom generation (hypoglycaemia unawareness) and a reduced adrenomedullary response 
and ultimately an increased risk of severe hypoglycaemia.  
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Figure 4.  Proposed model for development of hypoglycaemia associated autonomic dysfunction (HAAF) 
Adapted from (Martin-Timon and Del Canizo-Gomez 2015).  Acute hypoglycaemia can be seen as a stressor with 
appropriate physiological responses (Counterregulatory responses), however severe hypoglycaemia can lead to cell death, 
but with recurrent hypoglycaemia, there is less metabolic stress with reduced responses, which may be protective with less 
cell death.  
There is still much debate about how to define IAH, with the proposed methods listed below; 
a. A diminished ability to detect the onset of acute hypoglycaemia. 
b. Gold score ≥ 4 or Clark score ≥4 
c. Failure to develop symptoms during experimental induction of hypoglycaemia.  
d. Failure to mount an adequate CRR hormonal response to hypoglycaemia.  (>2SD 
from mean basal levels) 
Use of questionnaires have enabled researchers to determine the extent of the problem in 
patients with T1D.  In the UK Hypoglycaemia Study, the incidence of IAH was 7% in those 
with short duration T1D, and 35% in those with duration of disease over 15 years(Choudhary, 
Geddes et al. 2010)A recent cross sectional study in 445 patients with T1D showed that a 
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longer duration of diabetes was associated with lower intensity of autonomic symptoms and 
higher prevalence of impaired awareness (with 3% for duration 2-9 years to 28% for duration 
>=30 years).   
Effect on cognitive ability 
 
Effects during acute hypoglycaemia (in those with RH) 
 
It appears that those who have IAH perform better on cognitive tests during hypoglycaemia 
than those who have normal awareness. In this group, it has also been found that those with 
IAH, have a quicker recovery time of cognitive ability once euglycaemia is 
restored.(Zammitt, Warren et al. 2008, Stalder, Evans et al. 2010)  This suggests that IAH can 
be viewed as both an adaptive and maladaptive condition.  
Long term effects of recurrent hypoglycaemia on cognitive function 
 
The DCCT and its 18 year follow up study have shown recently, that when cognitive tests 
were done regularly, that those with SH showed no deterioration of these neurocognitive tests 
as opposed to those without SH. (Diabetes, Complications Trial/Epidemiology of Diabetes et 
al. 2007) However using newer imaging techniques, it appears that greater volumes of the 
brain are recruited to maintain the cognitive function during hypoglycaemia.(Bolo, Musen et 
al. 2011), however this maybe at the risk of poor brain efficiency.  
However,, a recent review showed that those with T1D had impaired cognition with an effect 
size of 0.3-0.8 SD units compared to non-diabetic controls.(McCrimmon, Ryan et al. 2012)  
The main cognitive domains that were affected were of information processing speed, mental 
flexibility and psychomotor functioning. It was concluded that the main risk factor for 
developing these complications was the presence of microvascular complications rather than 
occurrence of SH or poor glycaemic control. (Brands, Biessels et al. 2005)  Numerous studies 
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have consistently found that T1D results in a decrease in hippocampal cell proliferation and 
survival (Balu and Lucki 2009), which may also be related to HPA axis dysregulation(Revsin 
and de Kloet 2009).   
One of the factors which may provoke cognitive decline, is the experience of severe 
hypoglycaemia (SH)  before the age of 5, which resulted in problems with spatial intelligence 
and delayed recall later on in life(Perantie, Lim et al. 2008).  However a study in older adults 
(60.4 +-4.6 years) showed that those who had SH were more susceptible to cognitive decline 
particularly in information processing speed, which suggested that in the older adult, the 
brain is more vulnerable to the effects of hypoglycaemia. (Duinkerken, Brands et al. 2011) 
Therefore it appears that hypoglycaemia per se, does not cause any long term cognitive 
decline and rather it is presence of microvascular complications that may confer a greater risk 
in development of cognitive problems.  However the very young and elderly tend to be more 
vulnerable in sustaining chronic injury.  The potential impact on cognition, may also account 
for a reduced adherence to suggested changes to medications in patients with long duration 
diabetes.(Smith, Choudhary et al. 2009, Marketou, Kalyva et al. 2014).  
Effect on the Hypothalamo-pituitary axis (HPA) 
 
Hypoglycaemia can be considered to be a stressor and activates the paraventricular nucleus of 
the hypothalamus, which then secretes corticotropin releasing hormone (CRH).  This 
molecule is carried through the hypophyseal portal circulation to the anterior pituitary gland, 
which consequently secretes adrenocorticotropin hormone (ACTH).  ACTH carried through 
the peripheral circulation stimulates the adrenal gland to make and release cortisol in the zona 
fasciculata.    
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Recurrent hypoglycaemia on the other hand is thought to lead to a reduction in cortisol 
response similar to the counter-regulatory hormones, but to a lesser extent (Mokan, Mitrakou 
et al. 1994).  Antecedent glucocorticoids have been shown to reduce the magnitude of 
catecholamine release during next day hypoglycaemia (Davis, Shavers et al. 1996) Similarly 
pre-treatment with multiple treatments with CRH but not ACTH or cortisol was found to 
suppress the next day hypoglycaemic CRR(Flanagan, Keshavarz et al. 2003).  This effect is 
thought to be mediated by the CRH receptors with CRH-R2 mediated effects leading to 
suppression and CRH-R1 amplifying the CRR to hypoglycaemia(Bale and Vale 2004).  
Interestingly, glucocorticoids either endogenous or exogenous can lead to an increase in the 
CRH R2; R1 ratio.  This rise in endogenous glucocorticoids (as determined by the depth and 
duration of hypoglycaemia) during AH may explain why there is a reduction in 
catecholamine release during a subsequent hypoglycaemia (Davis, Mann et al. 2000). 
There is currently very little in the literature on the effects of recurrent hypoglycaemia on the 
diurnal variation of the HPA axis in humans and therefore the literature on the impact of 
other recurrent stressors on the HPA system may be illuminating.  Certainly exposure to a 
chronic stressor is known to increase the vulnerability to poor health outcomes. (Cohen, 
Frank et al. 1998)  
Thus recurrent hypoglycaemia (RH) has widespread deleterious impact on several systems, 
with diminishing sympathoadrenal activation and symptom generation and possible altered 
cognition (particularly in the extremes of life-very young and very old).  RH may also 
through recurrent activation of the stress systems-HPA axis lead to more widespread 
maladaptive changes through alteration of the diurnal patterns of cortisol release and is the 
focus of STUDIES 3 and 4.   
62 
 
CHAPTER 2 
Therapeutic strategies employed to improve Impaired Awareness 
Hypoglycaemia  
 
Problems with current Insulin preparations 
 
Despite newer insulin analogues and new insulin delivery devices, the overall rates of severe 
hypoglycaemia in epidemiological studies have remained unchanged over the last 20 years 
(Bulsara, Holman et al. 2004).   Although more recently, Bulsara et al, reported that in the 
Western Australia children’s database (age range 1-18 years), rates of severe hypoglycaemia 
had fallen over the last decade with the nadir in 2006 (17.3 to 5.8 events per 100 patient 
years)(O'Connell, Cooper et al. 2011).  
Despite the improvement in the pharmacodynamic properties of newer insulins, exogenous 
insulin still requires to be delivered subcutaneously rather than directly into the portal vein.  
In normal physiology 100% of endogenous insulin (released every  4-5mins throughout the 
day) flows from the pancreas to the  liver(Geho 2014). This insulin, during fasting, directly 
inhibits hepatic glucose release by inhibiting gluconeogenesis, glycogenolysis and also 
indirectly through the suppression of -cells, glucagon release. The latter occurs because 
blood flow in the islet is such that -cells are exposed to high intra-islet levels of insulin and 
other factors released by the -cell which are tonically inhibited by insulin. However, post-
prandial endogenous insulin stimulates glucose storage by the liver. The remaining insulin 
released by the liver, also acts on the two other insulin sensitive tissues (adipose and skeletal 
muscle) and stimulates glucose uptake.  Up to 80% of endogenously secreted insulin is 
degraded on its first pass through the liver (Triplitt and Chiquette 2006). This means that in 
non-diabetic individuals there is a significant portal-peripheral insulin gradient with a 2-3-
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fold higher insulin concentration in the portal vein as compared to that seen in the systemic 
circulation. 
In type 1 diabetes this physiological state can only be achieved if there is a high systemic 
level of insulin to ensure portal insulin levels are adequate for suppression of -cell glucagon 
secretion.  This results in systemic hyper-insulinaemia which may have adverse 
cardiovascular consequences and has recently been implicated in the development of insulin 
resistance (Okamoto, Anhe et al. 2011).  Moreover, a depot of exogenous insulin is 
‘unregulated’, i.e. not influenced by the many alternate signals that modify pancreatic -cell 
insulin secretion. This is most obvious during hypoglycaemia where a failure of insulin to 
‘switch-off’ contributes both to the progressing hypoglycaemia and to a specific defect in the 
ability of subjects with type 1 diabetes to secrete glucagon in response to low glucose 
(Ringholm, Pedersen-Bjergaard et al. 2012).  
Moreover, if there are insufficient levels of portal insulin, such that there is a reduced ability 
of the liver to store ingested carbohydrates as glycogen, this can further predispose patients to 
potential problems.   Consequently peripheral tissues have to dispose most of the 
carbohydrates and therefore require even more insulin to regulate post-prandial 
hyperglycaemia.  Secondly, the inadequacy of liver glycogen storage predisposes the patient 
to more severe hypoglycaemia.     
Furthermore, studies have shown a cohort of patients who are reluctant to change their 
medication regimen despite recurrent hypoglycaemia.  A PET study has shown that there is a 
pattern of decreased activation of stress pathways during hypoglycaemia in subjects with 
T1D and IAH with a preferential preservation of pathways which are involved with 
motivation and reward (Dunn, Cranston et al. 2007), which may be as a result of repeated 
exposure to opioids (β endorphins).  This may influence patients’ perception of 
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hypoglycaemia with possible pleasurable and addictive phenomena associated with recurrent 
hypoglycaemia or conversely that a sense of “threat” to well-being is not perceived.  
In summary, the non-physiological delivery of exogenous insulin, the almost inevitable 
burden of hypoglycaemia and the problems associated with recurrent hypoglycaemia such as 
IAH and the addictive phenomena all suggest that there needs to be further study in either 
improving the mode of delivery of insulin or adding in adjunct therapies to counter the above 
problems.  
Current treatment strategies 
 
As is now well established, recurrent hypoglycaemia leads to a suppression of the symptom 
and hormonal complex.  Meticulous avoidance of biochemical hypoglycaemia for 2 weeks 
(Fanelli, Epifano et al. 1993) has been shown to improve the autonomic symptoms (with 
complete restoration occurring after 3 months) and results in an alteration of glycaemic 
thresholds for adrenaline release, symptoms and cognitive function. However studies which 
have concentrated on meticulous avoidance of hypoglycaemia have been highly labour 
intensive, requiring considerable input from the study team (Fanelli, Epifano et al. 1993, 
Cranston, Lomas et al. 1994), a model which would be difficult to replicate in real life 
clinical settings. Several alternative strategies such as taking snacks in between meals and at 
bedtime(Cranston, Lomas et al. 1994) and raising blood sugar targets(Fritsche, Stefan et al. 
2001) have been employed in an attempt to achieve complete avoidance of BH but are often 
associated with worsening glycaemic control.    
Studies have shown that improvement of the deficient glucagon and adrenaline responses 
does not necessarily mean improvement of the symptom generation, implying there are 
different mechanisms underlying symptoms and the generation of the neuroendocrine 
responses.(Dagogo-Jack, Rattarasarn et al. 1994)  
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A number of non-drug strategies have been trialled to enable patients to try and reduce the 
incidence of recurrent hypoglycaemia and IAH with varying effects.  
Non-drug strategies for reducing hypoglycaemia 
Education  
 
Detection of hypoglycaemia 
 
As the magnitude of catecholamine release diminishes with time and with recurrent exposure 
to hypoglycaemia, the symptom complex diminishes(Graveling and Frier 2010).  Typical 
autonomic symptoms and even neuroglycopenic symptoms may not occur and patients are 
then increasingly reliant on atypical symptoms (strange sensation around mouth, “funny 
feeling” etc.), and in the worst case scenario, patients have no awareness of hypoglycaemia 
and rely on those around them to prompt them.    Patients and their families need to be taught 
about recognizing the symptoms of hypoglycaemia and to be familiar with appropriate 
treatment with an emphasis on not delaying treatment.  Blood Glucose Awareness Training 
(BGAT) programs has also been shown to be an effective way for both patients and partners 
to pick up subtle cues of evolving hypoglycaemia and then to respond promptly to prevent 
more SH. It was initially designed as 8 weekly group sessions, and showed both improvement 
in awareness and reduction in SH at 6 and 12 months(Cox, Gonder-Frederick et al. 1995, 
Fritsche, Stefan et al. 2001).   
Education programmes 
When therapies are used to intensify treatment, one would expect rates of hypoglycaemia to 
increase but education programmes running alongside such therapy have been shown to 
attenuate this risk.(Samann, Muhlhauser et al. 2005) In contrast to the increase in severe 
hypoglycaemia seen in the intensive arm of the DCCT cohort, the UK DAFNE(Dose 
adjustment for Normal Eating) have shown that the improvement in glucose control can be 
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achieved with a decrease(1.7 ± 8.5to 0.6± 3.7 episodes per person per year) in severe 
hypoglycaemia.   The DAFNE cohort (40% IAH at entry) showed that 43% of patients with 
hypoglycaemia unawareness, were able to improve recognition, after 1 year of 
training.(Hopkins, Lawrence et al. 2012)  Due to this resistance to change behaviour in 
certain groups, DAFNE-HART was designed to employ motivational interviewing and 
cognitive behavioural techniques in those who had attended the DAFNE insulin educational 
program, but still had persistent IAH.  This program showed after 12 months following 
intervention, that rates of SH fell from 3 to 0 (P<0.0001) per person per year and moderate 
hypoglycaemia fell from 14 to 0 (p<0.001) per person per 6 weeks. Perceptions around 
hyperglycaemia also improved(de Zoysa, Rogers et al. 2014) 
The recent HypoCOMPASS trial (Leelarathna, Little et al. 2013)  which utilised a 2 by 2 
factorial design was designed to compare the impact of real time –continuous glucose 
monitoring (RT-CGM) and continuous subcutaneous insulin infusion (CSII) vs Multiple 
Daily Injections (MDI) on hypoglycaemic awareness. The educational tool was given to all 
participants prior to entry onto the trial,  it taught patients to recognise the subtle symptoms 
associated with hypoglycaemia, never to delay the treatment and to recognise periods of 
increased risk, particularly at night. At the end of the 24 week trial, there was similar 
glycaemic outcomes with both conventional MDI and SMBG regimens compared with 
CSII/RT. It has been proposed that the frequent contact with the research team may have 
explained any lack of difference, with possible contamination between the 4 groups.  
Patients often get into set routines in order to combat hypoglycaemia, with some accepting 
hypoglycaemia as part and parcel of their condition and therefore failing to recognise 
avoidable precipitating factors or delaying treatment, with the experience of recurrent 
hypoglycaemia then leading to significant morbidity particularly with the development of 
IAH. Therefore education programs seek to re-train an individual in not only quick 
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identification of subtle cues of hypoglycaemia but also to identify preventable precipitants, 
and then to engage in quick, effective treatment.  Furthermore, the activation of cerebral 
networks involved with reward associated with hypoglycaemia, may further impinge the 
ability of certain individuals to change behaviour.  
Technology 
 
Continuous Glucose Monitoring (CGM) Systems 
 
The US Food and Drug Administration (FDA) advocate using CGM in the following 
situations: detecting trends of glucose values, an adjunct to self-monitoring of blood glucose 
(SMBG), aiding in the detection of hyperglycaemia or hypoglycaemia, minimising glucose 
excursions and facilitating both acute and long term therapy adjustments.   
CGM operates by measuring the glucose levels in the interstitium. An applicator is used to 
insert the 21-26 gauge devices into the interstitium.   The Medtronic systems have a 
disposable sensor that generates a current as a result of the ambient glucose and provide 
measurements every 5 minutes.  This signal is sent to the transmitter.  The sensor values are 
paired with calibration blood glucose readings in a retrospective manner, to ensure accuracy.  
The latest versions have a mean absolute relative difference (MARD) of <15% suggesting 
reasonable accuracy.   
RT-CGM is able to display the blood glucose, but more importantly the direction and the rate 
of change and therefore gives the wearer more information than a single reading in order to 
proactively avoid hypoglycaemia. CGM has the advantage of a semi-continuous flow of 
glucose readings, which may enable insulin dose decisions. 
The use of CGM has shown to improve HbA1c without increasing the incidence of 
hypoglycaemia (Deiss, Bolinder et al. 2006, Juvenile Diabetes Research Foundation 
68 
 
Continuous Glucose Monitoring Study, Tamborlane et al. 2008, Beck, Hirsch et al. 2009) 
with greatest effect in those with a higher HbA1c and with increased usage of sensor(Pickup, 
Freeman et al. 2011).  However, in contrast, two studies (Pepper, Steinsapir et al. 2012, 
Duran-Valdez, Burge et al. 2014) investigated the utilisation of blinded CGM/professional 
monitoring systems.   Firstly, it was shown that the magnitude of correlation between average 
interstitial glucose as determined by the CGM and A1c was too low (R2 <20%) with limited 
ability to improve HbA1c.  These studies shows that the blinded CGM may have limitations 
for improving A1c target, but may be more appropriate for identifying periods of nocturnal 
hypoglycaemia and  other periods of  glucose fluctuation (a measure that is not identified by 
HbA1c).   
The JDRF-CGM study did not however, show a reduction in hypoglycaemia.  Reasons for 
this included that patients were found to sleep through 74% of alarms(Buckingham, Block et 
al. 2005) and because of sensor inaccuracies (Leelarathna, Nodale et al. 2013).   However, the 
JDRF-CGM study showed that CGM readings with 30% or more of the readings in the 
hypoglycaemic range were associated with an 8 fold increase in SH the following day, 
however because SH was a relatively uncommon event, this was shown to have a poor 
positive predictive value (PPV) (<5%).(Fiallo-Scharer, Cheng et al. 2011).  Two possibilities 
were given for this poor PPV: Firstly, that of the patient altering behaviour after the 
hypoglycaemic episode.  Secondly, the measurement error from CGM.  The median error has 
been quoted during hypoglycaemia to range between 0.7 to 1.3mmol/L, which means there 
can be both over and underestimation with CGM devices. (Wilson, Beck et al. 2007, 2008)  
In the univariate analysis of this study, further risk factors for SH were ascertained;  higher 
scores on the Hypoglycaemia Fear Survey (p=0.02), those with higher percentage of CGM 
values below 3.9mmol/L and those with a higher GV measured with coefficient of variation 
(p=0.08).  However all these factors could be as a result of previous SH.  In the multivariate 
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analysis, only SH and female sex were found to be independent predictors of SH.  A further 
study looking at rates of SH over 6 months before and after CGM, showed rates of SH 
reduced from 21.8 to 7.1 events per 100 patient years with on average patient wear of 
6.8days/week. (Bode, Beck et al. 2009)   
However, a paediatric prospective study (Ly, Hewitt et al. 2011) recently showed that 
wearing RT-CGM with the use of low glucose suspend alarms set at 6mmol/L for a 4 week 
period was able to significantly improve the adrenaline response at 2.8mmol/L during a 
hyperinsulinemic hypoglycaemic clamp.  (1,093±221 vs 572±162pmol/L p=0.048). The 
recent ASPIRE trial has shown that using the automated suspension when BG reaches 
3.9mmol/L,  the duration (19% reduction) and severity of hypoglycaemia was significantly 
less (p=0.006) without significant rebound hyperglycaemia(Garg, Brazg et al. 2012) however 
a further analysis showed that the ability to mitigate this hypoglycaemia was dependant on 
the order of the studies, with more significant reduction in hypoglycaemia if the feature was 
used first.(Garg, Brazg et al. 2014)   A recent further study evaluating the effectiveness of 
alarms in those using CGM showed that irrespective of alarms, those wearing CGM had 
significantly lower time spent outside the glucose targets compared to SMBG.  This effect 
was greater when CGM was associated with CSII therapy. Presence of the alarms however 
did not deter patients from wearing the system(New, Ajjan et al. 2015).  However there is a 
reported 30% false alarm rate (Kamath, Mahalingam et al. 2010), which if perceived by the 
patient, can affect the response rates. It may therefore be pertinent to include alarm coping 
strategies during education(Shivers, Mackowiak et al. 2013).  
The major disadvantages of CGM technology is the time lag (which may be a couple of 
minutes), which may cause confusion regarding treatment decisions, particularly, when there 
is a discrepancy between CGM and peripheral SMBG readings.  Moreover, the constant 
provision of information may in certain patients be off putting and be considered as a 
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permanent reminder of their illness. As each sensor needs to be replaced every 5-7 days, there 
is also a cost implication of long term use of CGM.  In summary, real time CGM appears to 
have benefits in improving glycaemic control without worsening hypoglycaemia, with 
blinded CGM only being useful for identifying periods of high risk.  Further advantages have 
been seen when they are used with the low glucose suspend feature in a closed loop system, 
and also with alarms, although alarm fatigue can pose a problem.  However the major 
disadvantage is that of sensor inaccuracies particularly during hypoglycaemia, although this 
is improving with the newer generation CGM devices.   
Continuous Subcutaneous Insulin Infusion (CSII)  
 
A meta-analysis comparing CSII with MDI (Pickup and Sutton 2008)showed that there was a 
0.3-0.6% improvement in HbA1c and a 4 fold reduction in severe hypoglycaemia, in those 
with the highest baseline HbA1c levels and highest rates of SH, with the group on MDI 
benefiting the most after conversion to CSII.  A further review of 26 observational studies 
confirmed that CSII significantly decreases rates of severe hypoglycaemia. (Cummins, Royle 
et al. 2010)  The SWITCH study(Battelino, Conget et al. 2012) looking at the addition of 
CGM to CSII with its crossover design eliminating the most frequently encountered 
confounders of diabetes related education, showed a significant reduction in HbA1c 
(difference - 0.41% (95% CI - 0.28%, - 0.53%; p < 0.001) with a reduction in time spent with 
glucose levels less than 63mg/dL (3.5mmol/L) (19 vs. 31 min/day, respectively; p = 0.009).   
A prospective study in people with IAH, showed that transitioning patients onto CSII from 
multiple daily injections not only halved the frequency of hypoglycaemia but also reduced 
rates of SH from 1.25 to 0.05 events per year. (Gimenez, Lara et al. 2010) 
The meta-analysis of RCTs by Yeh et al comparing MDI with CSII and the monitoring 
strategies (SMBG vs RT-CGM) failed to show any change in SH and although HbA1c was 
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improved with CSII, it was heavily influenced by one study (due to higher baseline HbA1c) 
(DeVries, Snoek et al. 2002, Dupre, Behme et al. 2004) with the effect on HbA1c nullifying 
when this study was removed.  
More recently, the HypoCOMPASS study(Leelarathna, Little et al. 2013) compared the 
efficacy of optimised MDI versus CSII with and without sensors in a 2 by 2 factorial study 
design in patients with long standing T1D, who had all received the HypoCOMPASS 
educational tool prior to randomization.  Despite an improvement in the concentration and 
threshold for secretion of plasma metanephrine during hypoglycaemia, the investigators 
failed to show an advantage of one treatment modality over the other.  This was a landmark 
study, since prior to it, most of the studies compared CSII with MDI, where NPH was the 
comparator basal insulin, which has known problems of nocturnal hypoglycaemia.  A further 
study (REPOSE-Relative Effectiveness of Pumps over MDI and Structured Education for 
Type 1 Diabetes) which is currently running, will also aim to understand the benefit of CSII 
over MDI on glycaemic control and hypoglycaemia when all subjects are receiving structured 
training in insulin therapy (DAFNE).(White, Waugh et al. 2014)   
Although initial studies suggested that CSII over MDI had greater advantages of reducing SH 
and improving HbA1c, this was not found in a large meta-analysis by Yeh et al, with the 
HypoCOMPASS trial also not showing any superiority in either modality.  However we 
await the reporting of the REPOSE trial before drawing any further conclusions.  
Closed loop  
 
The Sensor-Augmented Pump therapy for A1C reduction (STAR-3) trial showed that when 
combining CGM with CSII, there was a significant reduction in HbA1c (8.3 to 7.5%) 
compared to MDI with no CGM (8.3 to 8.1%). However it did not lead to a significant 
reduction in rates of SH (13.1 pump vs 13.48 injections persons per 100 person years).  A 
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further study showed that if either MDI or CSII had access to CGM, then they were better 
able to manage extremes of glucose excursions. (Garg, Zisser et al. 2006)  
More recently,  Ly et al showed in the first randomized controlled trial that use of an sensor 
augmented insulin pump with the suspend feature (cf standard insulin pump therapy),  in a 
group where all participants had IAH (mean Gold score of 6.4), resulted in a significant 
reduction in both severe (defined as seizure or coma) and moderate (defined as needing 
assistance) (175 to 35 episodes in the Low glucose suspend group) hypoglycaemia, as well as 
a reduction in sensor readings (using a blinded CGM) of lower than 60mg/dL and 70mg/dL 
(3.3 and 3.9mmol/L)(Ly, Nicholas et al. 2013).  However in contrast to earlier studies, this 
study when using the low glucose suspend feature, did not show an improvement in 
adrenaline responses (to hypoglycaemia during a hyperinsulinemic hypoglycaemic clamp, 
(220pg/mL vs 148 pg/mL p=0.26) however there was an improvement in the Hypoglycaemia 
Unawareness Score (as determined by the Clark method) from 5.9 (95%CI 4.5-6.8)  to 4.7 
(95% CI 4.0-5.1) in the low glucose suspension group (p<0.001), once again comparable to 
earlier studies showing a dissociation between adrenaline responses and symptom scores(Ly, 
Nicholas et al. 2013).   
In fact a large Cochrane collaboration review (22 studies with 2883 patients)(Langendam, 
Luijf et al. 2012) showed that the best outcomes were in those with poor glycaemic control 
who started using sensor augmented pump therapy, as opposed to MDI and SMBG, with 
HbA1c level falling by 0.7%, 95% confidence interval (CI) -0.8% to -0.5%, 2 RCTs, 562 
patients, I2=84%). Those using CGM had a higher incidence of hypoglycaemia, however the 
confidence intervals was wide and included unity (95% CI 0.38 to 27.82).  This analysis was 
confined to one study, with insufficient detail to analyse frequency of hypoglycaemia, 
however, the follow-up was short (6 months), and therefore conclusions cannot be drawn 
from this (with GRADE of evidence- very low)  
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Closed loop studies have shown variable results, but appear to be most beneficial in those 
with poor glycaemic control, and when the low glucose suspend feature is utilised.  This 
technology is improving as sensor accuracy and algorithms are improving.   
Transplantation 
 
CGM has shown that those who have received transplantation either whole or islet cell 
significantly have reduced the time they spend in hypoglycaemia. This would be as a result of 
absence or reduction of exogenous insulin needed, a regulated insulin secretion pattern from 
the transplant and a partial restoration of both the glucagon and the sympatho-adrenal 
responses as a result of reduction in frequency of overall hypoglycaemia.  (Paty, Senior et al. 
2006).  Recent records show that one year islet cell survival in the UK is 87%.  Overall 
glycaemic control was improved from 66±16 and frequency of SH was reduced from 
23/patients per year to 0.56/patients per year.  A recent ADA abstract (Hering et al, 2014) 
reported on the Clinical Islet Transplantation Consortium, which was a prospective, open 
label single arm study, whereby allogenic human pancreatic islet product was infused 
intraportally.  All patients had reduced awareness of hypoglycaemia and at least one episode 
of SH.  The median daily dose at 1 year post transplantation was 0 (0-0.43u/kg), with 94% 
having a functional graft.  The median Clarke score reduced from a baseline 6 to 0 (p<0.001) 
with a reduction in SH and indices of glucose variability (p<0.001) 
This currently is a strategy reserved for those with recurrent severe hypoglycaemia.  This has 
become a relatively safe procedure, particularly since careful heparanisation (eliminating the 
previously feared complication of portal vein thrombosis) and the use of steroid free 
immunosuppression (based on sirolimus and tacrolimus) (Shapiro, Lakey et al. 2000).   
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In summary, patients with hypoglycaemia should have individualised therapy utilising the 
above models.  A recent evidence informed clinical practice recommendation for those with 
problematic hypoglycaemia suggests hypoglycaemic specific education programs, with 
progression to technology, and then sensor augmented insulin pumps with transplantation 
reserved for those who are still having problems. (Choudhary, Rickels et al. 2015).   
Drug strategies for reducing hypoglycaemia  
 
Although the search for more physiological strategies for insulin replacement may address 
some of the problems, potential adjunct therapeutic options have also been presented in the 
literature to date, to either preserve or improve the counter-regulatory responses to 
hypoglycaemia by inducing a recovery of glucagon, modulating neurotransmitters and 
sensing mechanisms or through the use of dietary supplementations.    
Approaches to address α cell defects 
 
Role for amino acids 
Within 5 years of disease duration, most patients with T1D have a blunted glucagon response 
to hypoglycaemia. Defects in the portal insulin to glucagon ratio, which is key in regulating 
hepatic glucose production, can lead to significant delays in glucose recovery following 
hypoglycaemia. Glucagon is probably the most important counter regulatory hormone and so 
restoration of this response would be beneficial in reducing severe hypoglycaemia risk.  
Amino acids stimulate glucagon release from pancreatic α cells (Kuhara, Ikeda et al. 1991), 
however their ability to restore this response in type 1 diabetes is inconsistent, particularly 
when given intravenously (Caprio, Tamborlane et al. 1993, M'Bemba, Cynober et al. 2003, 
Porcellati, Pampanelli et al. 2007).  In contrast, oral administration of amino acids enhanced 
glucagon responses (p=0.016) during hyper-insulinaemia hypoglycaemia in T1D subjects and 
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preserved some aspects of cognitive function (Rossetti, Porcellati et al. 2008). However, oral 
amino acids also stimulated glucagon release during euglycaemia and hence would be 
anticipated to have deleterious effects on overall glucose control.     
Approaches to address central defects 
 
Role of GABA 
-aminobutyric acid (GABA) is the major inhibitory neurotransmitter, and is known to 
regulate multiple physiological compensatory processes.  Rodent models have shown GABA 
levels to decrease during systemic hypoglycaemia (Beverly, De Vries et al. 2001). 
Pharmacological reduction of hypothalamic GABA has been shown to enhance the 
neuroendocrine responses to hypoglycaemia in rodent models.   
Modafinil  is an agent used in narcolepsy and reduces GABA activity probably through K+ 
channels (Gulanski, De Feyter et al. 2013). Although the full mechanism of modafinil is still 
unknown, it may work by increasing dopamine in the brain by reducing the re-uptake of 
dopamine in the nerves.  In a study of human subjects, modafinil resulted in a moderate 
increase in adrenergic symptoms and heart rate, but had no effect on the counter-regulatory 
responses to hypoglycaemia (Smith, Pernet et al. 2004). Nevertheless this effect could still be 
beneficial in improving subjective awareness of hypoglycaemia in those with IAH despite 
limited recovery of other counter-regulatory responses.  
Role for Beta agonists 
 
Noradrenaline, a monoamine neurotransmitter is released into the ventromedial hypothalamus 
(VMH), a key brain region involved in hypoglycaemia sensing and appears to regulate VMH 
function during hypoglycaemia.(Beverly, De Vries et al. 2001).  Noradrenaline has been 
reported to stimulate glutamatergic neurotransmission and is thought to mediate its effect via 
the β2 adrenergic receptors (B2AR). (Lee, Choi et al. 2007). Recent rodent studies have 
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shown that local VMH delivery of B2AR agonists increase both adrenaline and glucagon 
responses to hypoglycaemia. (Szepietowska, Zhu et al. 2011)   
 
A recent study looking at the different methods of reducing the risk of nocturnal 
hypoglycaemia (Raju, Arbelaez et al. 2006),  showed that night time administration of oral 
terbutaline (5mg), an oral β2 agonist reduced the percentage of blood glucose values below 
3.9mmol/l from 27% to 1% of the measured values however it did increase morning blood 
glucose values (37% higher) and increased heart rate and blood lactate levels.  Dose defining 
studies may need to be done to study this potential treatment further in order to keep the side 
effects minimal.  Use of β2 agonists may therefore stimulate central release of key counter-
regulatory hormones to aid quicker glucose recovery.   
 
Role of Selective Serotonin Reuptake Inhibitors (SSRI) 
 
Serotonergic neurons have a key role in the regulation of neuroendocrine function via both 
sympathoadrenal and hypothalamo-pituitary adrenal pathways.  Although, SSRIs have been 
associated with hypoglycaemia, the hypothesis that blocking serotonin uptake might actually 
increase sympathetic outflow was tested in a 6 week trial of high dose fluoxetine (60-80mg) 
in non-depressed T1D individuals. Fluoxetine was reported to significantly increase both 
adrenaline (90% increase) and noradrenaline responses as well as increased endogenous 
glucose production (EGP) and lipolysis (all p<0.05), (Briscoe, Ertl et al. 2008).  However, 
Fluoxetine did not produce an increase in hypoglycaemia symptom scores, suggesting that 
the serotonergic pathways are not important to symptom generation, perhaps limiting their 
application clinically.   
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Role for theophylline 
 
Theophylline, the adenosine-receptor antagonist is known to reduce cerebral blood flow, and 
can stimulate the release of catecholamines.  Acute intravenous theophylline has been found 
to lower the glucose threshold (higher glucose level) for symptoms and adrenaline release 
during insulin induced hypoglycaemia in those with T1D and IAH (de Galan, Tack et al. 
2002) .  However when oral theophylline was given over a 2 week period, despite an increase 
in symptomatic awareness, there was no change in the magnitude of adrenaline 
release(Slomski 2013).   
Manipulation of sensing mechanisms 
 
Role of Fructose 
 
Glucokinase (GK) plays an important rate limiting step in the phosphorylation of glucose to 
glucose 6 phosphate, (Efrat, Tal et al. 1994) which determines magnitude of insulin release 
and plays a role in brain glucose sensing during hypoglycaemia. Fructose 6 phosphate (F6P) 
inhibits glucokinase and fructose can be phosphorylated into F6P in the glucose sensing 
neurons.  Based on this, Gabriely et al were able to demonstrate in T1D subjects that fructose 
delivered systemically produced a significant potentiation of the adrenalin response to 
hypoglycaemia with both an upward shift in its glycaemic threshold as well as increased 
magnitude of release. Fructose also augmented endogenous glucose production (EGP), which 
aided in improved recovery from hypoglycaemia. (Gabriely and Shamoon 2005)   
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Role for dietary supplementation 
 
Medium chain fatty acids 
 
The brain primarily relies on glucose for its main energy source, however, it does have the 
ability to use alternate fuels.  Use of medium chain triglycerides (MCT), which can be rapidly 
metabolised into medium chain fatty acids, have been shown to ameliorate cognitive decline 
during hypoglycaemia.   These can be used directly (as they can readily cross the BBB) and 
indirectly (via generation of ketones) to provide an effective alternate fuel source during 
glucose deprivation.  Page et al, found that when MCT (three doses-20g, then 10g twice) 
were given at 25 minute intervals during induction of hypoglycaemia in patients with 
intensively treated T1D, there was a significant increase in free fatty acids and β-
hydroxybutyrate.  The MCT administration prevented the decline in cognitive performance 
(tests of immediate verbal memory (p=0.009), delayed verbal memory (p<0.001) and verbal 
memory recognition (p=0.008) during hypoglycaemia compared to placebo.   However, 
reassuringly, MCT did not adversely affect the counter-regulatory response (Page, 
Williamson et al. 2009).  Therefore it appears that MCT are preferentially used in cortical 
areas involved in cognition, without affecting the subcortical areas – such as ventromedial 
hypothalamus- which are involved with the generation of the CRR (Evans, Matyka et al. 
1998).     
Uncooked corn starch 
 
Nocturnal hypoglycaemia is a significant problem to those with T1D accounting for >50% of 
all cases of severe hypoglycaemia. The night time period is the longest inter-prandial interval 
humans experience and in addition it is also a period of increased sensitivity to insulin and is 
associated with a reduction in counter-regulatory responses to hypoglycaemia.  
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Understanding the rate of blood glucose appearance following the ingestion of certain foods 
could help reduce nocturnal hypoglycaemia in T1D.  
 
Many with T1D often take a bedtime snack to prevent nocturnal hypoglycaemia.  However 
this only has an effect over the first half of the night. (Peak effect 2 hours).  Uncooked corn 
starch, a slowly released carbohydrate, has a low glucose peak with a later peak (+ 4 hours) 
but can stabilise blood glucose levels for up to 7 hours.  When given to those with T1D at 
night, blood glucose was found to be consistently 1.9mmol/L higher at 3 am compared to 
placebo (p<0.01) with also a significantly higher morning blood glucose (+1.1 mmol/L) 
(Axelsen, Wesslau et al. 1999). However, another study showed that when carbohydrate 
content was matched in the control arm, uncooked corn starch did not reduce frequency of 
nocturnal hypoglycaemia, although rate of decline in blood glucose overnight was slower 
(Ververs, Rouwe et al. 1993).  
 
Caffeine 
 
Caffeine appears to have good acute effects in improving neuroendocrine responses. 
However, chronic use can be linked with an increase in highly symptomatic episodes but with 
possible benefits of reduction of nocturnal hypoglycaemia. Caffeine has also been found to 
have beneficial effects on the cardiovascular system, with improved heart rate variability 
when given to patients with long standing T1D. (Richardson, Rozkovec et al. 2004)     It is 
known that after a period of abstinence, acute caffeine ingestion can decrease cerebral blood 
flow(Debrah, Sherwin et al. 1996) and increase brain glucose utilization (Mathew 1986) and 
can also cause release of adrenaline(Nehlig, Daval et al. 1992). Caffeine ingestion 250mg 
(Debrah, Sherwin et al. 1996) or 400mg (Cox, Irvine et al. 1987) immediately prior to 
induced hypoglycaemia was associated with greater symptomatic awareness, and increased 
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levels of adrenaline.   However a randomised placebo-controlled double-blind study (Watson, 
Jenkins et al. 2000) with 200mg caffeine (approx. 2 cups of drip brewed coffee)  for 3 
months, actually resulted in an increase in the number of symptomatic hypoglycaemia 
episodes (1.3 vs 0.9 episodes/week, p<0.03), although subjects experienced more intense 
warning symptoms (29 vs 26 total symptom score; p<0.05 ) during a subsequent 
hypoglycaemia clamp study.  More recently, a double-blinded study(Reno, Daphna-Iken et 
al. 2013) reported that caffeine was associated with a significant reduction in duration of 
nocturnal hypoglycaemia (mean 49 vs 132 mins; p=0.035) assessed using continuous glucose 
monitoring. 
Modulation of the renal haemodynamic 
 
A recent single arm open label proof of concept trial(Perkins, Cherney et al. 2014) looked at  
empagliflozin (a sodium glucose co-transport 2 inhibitor) 25mg daily (for 8 weeks) in 
patients with T1D. Patients were advised to reduce bolus and basal doses by 30% as a safety 
measure.  Despite a decrease in insulin dose (which was primarily basal) from 54.7±20.4 to 
45.8± 18.8 units/day (p<0.0001), mean A1C decreased from 8±0.9% (64±10mmol/mol) to 
7.6±0.9% (60±10mmo/mol) (p<0.0001).  Symptomatic hypoglycaemia (<3.0mmol/L) also 
reduced from 0.12 to 0.04 events per patient per day (p=0.0004).  All hypoglycaemic 
episodes (<3.9mmol/L) were also reduced from 0.30 to 0.18 events per patient per day 
(p=0.0001) however the short duration of this trial limits further conclusions. In a recent dose 
finding exploratory study of 2 weeks duration, dapagliflozin showed a dose related reduction 
in glycaemic variability (greatest effect with 10mg- mean amplitude of glycaemic excursion 
(MAGE)), ((-3.77mmol/L (95% CI -6.09 to -1.45), however, the 95% CI did overlap with 
that of the placebo))(Henry, Rosenstock et al. 2015) suggesting that it may also be beneficial 
in reducing hypoglycaemia (although this was not specifically examined in the trial). 
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Modulating KATP channels in glucose sensing circuitry 
 
It is now recognized that specialized glucose-sensing neurons in the brain play a key role in 
the detection and response to acute hypoglycaemia and that recurrent hypoglycaemia impairs 
the ability of these neurons to detect hypoglycaemia, contributing to the development of IHA. 
As in the beta-cell, SUR-1 selective KATP channels are a key component of this sensing 
mechanism and this suggest a potential role for KATP channel openers in the treatment of 
hypoglycaemia unawareness. Rodent studies have shown that diazoxide (6mg/kg) delivered 
directly to the hypothalamus or systemically amplifies the peak adrenaline response to 
hypoglycaemia, and therefore could potentially play a role in improving the protective 
counter-regulatory responses to hypoglycaemia.(McCrimmon, Evans et al. 2005).  STUDY 1 
of this thesis will examine whether we can use oral Diazoxide in a cohort of patients with 
longstanding T1D to magnify the counter-regulatory responses.    
Incretins 
 
So far the major focus on the use of incretins in T1D, has been as a result of GLP-1, being 
shown to reduce beta cell apoptosis, and also stimulate beta cell proliferation and improve 
survival in pre-clinical studies, therefore providing a potential adjunct therapy in early T1D.  
Furthermore, GLP-1 has also been shown to be a powerful suppressor of glucagon 
(Creutzfeldt, Kleine et al. 1996, Dupre, Behme et al. 2004), which may be particularly useful 
later on in the disease progression, as there appears to be a paradoxical increase in both 
fasting and post-prandial glucagon in T1D, which may contribute to a significant glucose 
load and excursions commonly seen in this patient group. GLP-1 infusion has thus shown a 
45% improvement in post prandial glucose irrespective of C-peptide (Kielgast, Holst et al. 
2011).  There is evidence that reducing glucose variability can also reduce burden of 
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hypoglycaemia, however there is currently no evidence examining this concept, and will be 
examined in STUDY 2 of this thesis.  
In summary, adjunct therapy in patients with Type 1 have been disappointing.  Therapies 
such as use of amino acids and beta2 agonists may have improved outcomes during 
hypoglycaemia but have worsened overall glucose control.  Agents that reduce GABA and 
theophylline have been shown to improve symptoms during hypoglycaemia but have not 
consistently improved the magnitude of counter-regulatory responses whereas agents such as 
the SSRIs, beta2 agonists and fructose have improved the adrenaline responses during clamp 
studies but this has not translated to a greater symptom profile.  This dissociation between 
CRR hormone release and symptoms have been noted in a number of studies, suggesting 
generation of these components is through different mechanisms.  It is also possible that 
because of the relatively small sample sizes in all the studies, that only large effect sizes 
would have been detected. 
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CHAPTER 3  
STUDY 1 Use of KATP channel openers in Acute Hypoglycaemia 
 
Background 
 
One potential target for therapeutic intervention in people with T1D and IAH is the ATP-
sensitive potassium (K ATP ) channel.  This ligand gated ion channel is an octamer composed of 
4 inward-rectifier potassium ion channels and 4 sulphonylurea receptor subunits (subtypes 
include SUR-1, SUR 2-A and SUR 2-B) and plays a critical role in transducing changes in 
cellular energy status into changes in action potential firing.  Glucose sensing hypothalamic 
neurons thought to be central to the development of the suppressed hormonal counter-
regulatory responses to hypoglycaemia (McCrimmon and Sherwin 2010), express SUR-1 
containing K ATP  channels (Ashford, Boden et al. 1990, Dunn-Meynell, Routh et al. 1997, 
Kang, Routh et al. 2004).  Following is a brief summary of where and how glucose is sensed, 
and how modulation of the KATP channel could be used in the improvement of the counter-
regulatory responses in T1D.   
Where is glucose sensed? 
 
Plasma glucose concentrations are tightly regulated and normally maintained between 3.0 and 
5.6mM, with an even tighter control present in the brain 0.5-2.5mM (Silver and Erecinska 
1994). This is maintained through a complex network of glucose sensors and integrative 
networks.   
Glucose sensors (GS) were first reported by Matschinsky (Matschinsky 1990) in the 
pancreatic beta cell.  GS are responsible for detecting glucose concentrations in the 
extracellular fluid. (ECF).   GS are defined as those that alter their action potential frequency 
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in response to changes in interstitial glucose levels. These neurons are unique, in that glucose 
is used both as a fuel, as well as identified as a signal that can regulate its activity.   They are 
present in the gut, endocrine pancreatic cells, hepatic portal  mesenteric veins and parts of the 
central nervous system (particularly in areas of the brain where the blood brain barrier is 
leaky or absent), with greatest representation in areas involved with regulation of 
neuroendocrine function, metabolism of nutrients and energy homeostasis.  They are 
therefore represented  primarily in the hypothalamus and the hindbrain (area postrema (AP), 
the nucleus of the solitary tract and the dorsal motor nucleus of the vagus) (Watts and 
Donovan 2010))  and ultimately are responsible for preventing wide glucose fluctuations, and 
therefore maintaining glucose homeostasis (McCrimmon 2008).     
The hypothalamus has a number of areas which have been identified as key to glucosensing 
(GS) such as the arcuate nucleus, ventromedial hypothalamus (VMH), lateral hypothalamic 
area (LHA) and the dorsal medial hypothalamus (DMH)). (See figure 5)  These regions 
appear to vary in the homeostatic and behaviours they regulate. For instance, the LHA has 
also been shown to be important in the feeding behaviour, and is a region that can co-ordinate 
metabolic and arousal state regulation through orexin (Ohno and Sakurai 2008). Therefore, it 
seems likely the different glucose sensing machinery may act to link glucose homeostasis to 
other bodily functions such as feeding behaviour and arousal.  
Animal models can be invaluable in studying the molecular mechanisms involved in many of 
the processes involved in counter-regulation from glucose sensing to generation of defective 
counter-regulation.  The counterregulatory responses have been studied in both human and 
animal models.  For example, reduced hormonal counter-regulation following antecedent 
hypoglycaemia has been demonstrated in individuals with T1D, as well as in the rat (Powell, 
Sherwin et al. 1993) and mouse (Jacobson, Ansari et al. 2006) indicating a response to 
hypoglycaemic stress that is highly conserved.   
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A series of rodent experiments have illuminated the role of the VMH in the CRR to 
hypoglycaemia.  Electrical stimulation of the VMH in a rodent model, mimics the CRR and 
activates the sympathoadrenal system(Stoddard, Bergdall et al. 1986), with local glucopenia 
induced by 2-deoxyglucose (a non metabolizable form of glucose) within the VMH having a 
similar effect (Borg, Sherwin et al. 1995).   Both chemical destruction of the VMH with 
ibotenic acid and ample local perfusion with glucose obliterates the CRR to acute 
hypoglycaemia by 75% (Borg, During et al. 1994, Borg, Sherwin et al. 1997).  
The VMH has therefore, been shown to be the main structure involved in brain glucose 
sensing in the hypothalamus and has a key role in the counter-regulatory responses. (Borg, 
During et al. 1994, Borg, Sherwin et al. 1995).  It is a key region for interpreting peripheral 
signals of nutrient status. The VMH has been shown to have 2 distinct populations of neurons 
which respond to changes in blood glucose.  These post-synaptic neurons can be classified 
into those which respond to increases in glucose (Glucose excited- GE) or those which 
respond to decreasing glucose levels (Glucose Inhibited-GI). Both are very sensitive to drops 
in extracellular brain glucose below 2.5mM, with minimal input when glucose rises above 
this level.  There appears to be a synchronised activation of GI neurons and suppression of 
GE neurons as brain glucose drops from 2.5 to 0.1mM, which appears to initiate the neural 
network responsible for activating the sympatho-adrenal responses associated with 
hypoglycaemia(McCrimmon and Sherwin 2010).   
The GE neurons have been identified in the ARC and the VMN. (Song, Levin et al. 2001, 
Song and Routh 2005).  Most, but not all of the GE neurons share many features with the 
pancreatic beta cell in that, they appear to use the pancreatic form of glucokinase to sense 
glucose, and also contain the SUR1 isoform of the  ATP sensitive potassium channel (KATP) 
as well as GLUT-2 (Schuit, Huypens et al. 2001).   Glucokinase (GK) appears to have a key 
regulatory role in the sensing machinery of the GE neurons, demonstrated by the impairment 
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of glucose sensing when GK is downregulated (Kang, Dunn-Meynell et al. 2006). Tanacytes, 
specialized neurons that line the 3rd ventricle, have also been shown to have GK (as well as 
GLUT-2, KATP). Sanders et al discovered that selective inhibition of GK through alloxan 
delivery to the 3rd ventricle, taken up by the GLUT-2 in tanacytes, there was an increase in 
the CRR, suggesting that tanacytes are also crucial in facilitating the CRR response.(Sanders, 
Dunn-Meynell et al. 2004)  
Early evidence that KATP channels play a role in glucose sensing in the physiological range, 
comes from the fact that concentration-response relationship between the action potential of 
VMH GE neurons and the KATP channel currents has a linear relationship for glucose 
concentration between 0.1 and 1.5mM glucose, and thereafter the slope of the curve 
decreases and plateaus up to 5mM glucose (Wang, Liu et al. 2004).  It is thought to be the de- 
activation or opening of KATP channels in the GE neurons and subsequent activation of GI 
neurons which increase the sympathoadrenal responses to hypoglycaemia. (Kang, Routh et al. 
2004, McCrimmon, Evans et al. 2005, Routh 2010) 
GI neurons are predominantly involved when blood glucose levels drop. The first step may 
involve activation of the alpha 2 subunit of the AMPK.  This turns on catabolic processes, 
which generate ATP while turning off anabolic ATP consuming processes.  AMPK activation 
phosphorylates neuronal NO synthase (nNOS) leading to NO production in GI neurons. It has 
been shown that this nNOS is a critical step for the full generation of the CRR (Fioramonti, 
Marsollier et al. 2010).  NO further activates AMPK via the NO receptor soluble guanylyl 
cyclase which increases cyclic GMP (cGMP).  AMPK amplification via this method is 
needed for depolarisation of GI neurons in response to low glucose.  Finally, this leads to 
closure of a chloride channel which many speculate could be cystic fibrosis transmembrane 
regulator (CFTR) (Murphy, Fakira et al. 2009)  GI activation has been also shown to increase 
neurotransmitter release (McCrimmon, Shaw et al. 2008) associated with the initiation of the 
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counterregulatory response.  A potential mediator of this response is thought to be GABA 
which is expressed in 56% of GE and 36% of GI neurons.(Kang, Routh et al. 2004).  In acute 
hypoglycaemia, this inhibitory neurotransmitter decreases, potentially releasing the tonic 
inhibition of the GI neurons and leading to amplification of the counterregulatory response.  
This is demonstrated during in-vivo antagonism of VMH GABA (Chan, Cheng et al. 2008).    
Finally the VMN has projections to pre-autonomic networks present in the paraventricular 
nucleus of the hypothalamus (PVH) and the retrochiasmatic (RCH) area through which it is 
able to initiate the autonomic responses to acute hypoglycaemia (see figure ).  
The PVH is also thought to play a role in initiating the counter-regulatory response (CRR).  
Descending PVH (found in the lateral, dorsal and ventral) projections have been shown to 
regulate the pancreas and adrenal medulla, whereas the medial parvocellular part of the PVH 
drive the ACTH and glucocorticoid responses to hypoglycaemia.    These signals along with 
signals from the LHA provide a direct way for the hypothalamus to interact with the 
autonomic motor components of counter-regulation.   
There are also important glucose sensors present peripherally.  These glucose sensors are  
present  in the oral cavity, gut,  portal mesenteric venous (PMV) system(Hevener, Bergman 
et al. 1997) and the carotid body (Heptulla, Tamborlane et al. 2001, Pardal and Lopez-Barneo 
2002) (see figure 5). PMV neurons detect the glucose in the portal circulation before it enters 
the liver.  The portal vasculature is richly innervated with afferents from both the vagus and 
spinal nerves.  It has been proposed that the vagal and spinal nerves may be analogous to the 
functions of the GE and GI neurons, with the vagal signals (by promoting feeding) implicated 
in restoration of euglycaemia during hypoglycaemia.  The signals are then relayed onto the 
higher brain centres, such as the hypothalamus (Watts and Donovan 2010).  
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There has been much debate as to whether these peripheral sensors contribute to the 
generation of the counter-regulatory response.  Studies have shown that maintaining systemic 
hypoglycaemia in the context of euglycaemia in the porto-venous system by direct infusion 
of glucose into the portal vein(Donovan, Cane et al. 1991) diminishes the CRR. These 
neurons lie within the portal vein, and are mediated by spinal nerves(Hevener, Bergman et al. 
1997). This finding was also recently confirmed by canine studies, showing that portal 
denervation also leads to blunting of the CRR during hypoglycaemia(Ionut, Castro et al. 
2014).  A study using rodent models demonstrated that the rate of glucose decline may 
determine whether peripheral or central sensors predominate(Saberi, Bohland et al. 2008).  
Peripheral sensors namely the hepato-portal sensors have been shown to be responsible for 
nearly 90% of the CRR, when blood glucose levels drop slowly(Saberi, Bohland et al. 2008).  
This may be of particular relevance when hypoglycaemia develops overnight, when the 
decline is slow and as a result of the basal insulin. However in the context of hypoglycaemia 
following meals or with exercise, where the decline is rapid, it may be the brain sensors that 
predominate in the sensing mechanism.  
The other key part of the glucose sensing machinery is the glucose transporter.  Glucose 
transporters are responsible for shifting glucose into and out of both the neuronal and 
astrocyte population.  Circulating glucose enters the brain interstitium (without the need for 
insulin) through the blood brain barrier (BBB) predominantly via GLUT-1 (55kDA) which is 
expressed in the micro vessels of the BBB. (this is in contrast to adipose and muscle cells 
which need insulin for action of GLUT-4, its main glucose transporter)  Glucose is then 
transported into neurons and astrocytes via predominantly GLUT-3 and GLUT-5 
respectively.(Vannucci, Maher et al. 1997)  During euglycaemia, the rate limiting step is the 
phosphorylation by the enzyme hexokinase 1, however the glucose uptake through the BBB, 
becomes the rate limiting step during hypoglycaemia. (Fanelli, Porcellati et al. 2004). There 
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is also evidence now that GLUT-2(Marty, Dallaporta et al. 2005) (particularly in glucagon 
secretion) and GLUT-4(Puente 2009) are necessary for both glucose sensing and initiation of 
the CRR. Entry of glucose into the cell leads to phosphorylation by glucokinase which in turn 
causes a rise in the ratio of adenosine triphosphate to adenosine monophosphate levels (ATP: 
AMP).   
However, during energy depletion, there is a resultant increase in AMP/ATP ratio that leads 
to activation of 5' AMP-activated protein kinase (AMPK). AMPK is a serine/threonine kinase 
that is activated during energy depletion and suppresses ATP consuming pathways and 
activates ATP generating pathways.  AMPK within the hypothalamus is usually activated 
during fasting or central glucoprivation.  It has been shown in rodent models that local in 
vivo activation of AMPK in the VMH amplifies the CRR while selective AMPK down 
regulation suppresses the CRR.(McCrimmon 2008)  
Ultimately, the information collected through central and/or peripheral glucose sensors is 
then integrated at the central level, in the hypothalamus, hindbrain and autonomic ganglia, 
which are then responsible for effecting autonomic and neuroendocrine responses through to 
the pancreatic islets, adrenal medulla and the anterior pituitary resulting in a co-ordinated 
response.(Watts and Donovan 2010). 
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Figure 5; Diagram showing the neural network responsible for generation of the CRR system.  
Shown are both the peripheral and central components that feed into hindbrain and hypothalamic integrative networks, 
which along with other inputs generate the autonomic and neuroendocrine responses. Taken from (Donovan and Watts 
2014) 
   
 
 
As the first study (STUDY 1) explores the therapeutic benefits of an agent that modulates the 
KATP channel, discussion of these channels in further detail will follow.   
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KATP channels 
 
Cloning studies have revealed that the KATP channels consists of a large regulatory subunit 
(SUR) and small potassium subunits (Kir-) forming the channel pore (see Figure 6). (Aguilar-
Bryan, Bryan et al. 2001)  SURs are regulatory subunits which bind sulphonyureas.  Their 
formation is controlled by the Sur1 and Sur2 genes that encode the high affinity SUR-1 and 
low affinity SUR2A and SUR2B respectively. SUR-1 is widely expressed in neuroendocrine 
cells and neurons whilst SUR-2A is found in heart and skeletal muscle; SUR-2B in smooth 
muscle. The pore subunits termed Kir-, or potassium inward rectifiers derives its name, 
because they are more efficient at transporting potassium into the cell and they come in 2 
isoforms (Kir 6.1 and Kir 6.2).  SURs preferentially bind to Kir 6.1 and Kir 6.2 to form large 
octameric channels.   These are assembled in the Endoplasmic reticulum and the presence of 
a retrieval signal –RKR- ensures that only correctly assembled KATP channels are transported 
to the cell membrane (Zerangue, Schwappach et al. 1999).  KATP channels are expressed 
within a number of cellular compartments (nucleus, sarcolemma, plasma membrane) and 
different tissues types, where the conformation of the channel largely determines its function.  
Five different types of KATP channels are currently known(Ashcroft and Ashcroft 1990). The 
best characterised KATP unit is the Type 1 channel and has been identified in a number of 
different cell types and are known to be calcium and voltage independent.   
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Figure 6; A schematic representation of the ATP sensitive potassium channel.  
The Kir 6.2 subunits form the selective potassium pore, and are surrounded by the SUR1 subunits.  This configuration of the 
KATP channels are found in both the pancreas and glucose sensing neurons.  NBD1 and 2 are nucleotide binding domains.  
Taken from (Bonfanti, Alcazar et al. 2015) 
KATP channels were initially located on the cardiac myocytes (Noma 1983) and the pancreatic 
beta cell (Cook and Hales 1984).  In the pancreatic beta cell,  these KATP channels are 
constantly open, leading to K+ efflux and hyperpolarisation, however, with increasing levels 
of glucose and ATP, this would then act to close these channels, leading to intracellular K+ 
accumulation followed by membrane depolarisation resulting in calcium influx and 
ultimately in insulin release in pancreatic beta cells.(Howell 1984). Further information about 
the KATP channel has been gained through the study of a mutation that affects the channel 
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such as occurs in Persistent Hyperinsulinemic Hypoglycaemia of Infancy (PHHI).  In PHHI, 
there is uncoupling of the electrical activity of the cell to the metabolic status leading to 
permanent depolarisation of the membrane and an inappropriately high insulin secretion. 
(Aguilar-Bryan and Bryan 1999)  
Activation (opening) of the KATP channels in the agouti related peptide (AgRP) expressing 
neurons has also been shown to be potentiated by  insulin, which has also been shown to 
reduce gluconeogenesis, and reduce hepatic glucose production, contributing to the glucose 
lowering action of insulin(Pocai, Lam et al. 2005).   
Therefore, glucose metabolism can be linked to the electrical activity of the beta cell through 
the KATP channel.  KATP channels also exist in virtually all cell types including vascular 
smooth cells (Beech, Zhang et al. 1993) and glucose responsive neurons (Miki, Liss et al. 
2001).  The sensitivity of the KATP channel to the internal ATP concentrations vary between 
cells and act to couple metabolism to electrical activity. Ashford et al(Ashford, Boden et al. 
1990) in 1989 showed in isolated neuronal cell recordings, that increased extracellular 
glucose and increased production of ATP,  inhibited a K+ channel and increased action 
potential generation.  Therefore, in periods of low stress due to plentiful fuel, ATP closes the 
channel by binding to Kir 6.2, producing membrane depolarisation and increased electrical 
activity.  In contrast, during periods of high stress such as during hypoglycaemia, Mg-
nucleotide binding at the nucleotide binding domains (NBD) of SUR stimulates channel 
opening and hyperpolarisation.   Agents such as cromakalim (an opener of the KATP channel) 
were shown to decrease the discharge of action potentials without altering their amplitude or 
duration in rodent neurons. (Finta, Harms et al. 1993)   
Most glucose sensing neurons have mRNA for sulphonylurea receptor (SUR-1) and Kir 6.2 
subunits. (Kang, Routh et al. 2004)   Centrally, the KATP channel has been shown to be an 
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important link between glucoprivic feeding and the activity of the Glucose sensing neurons 
(GS).   KATP channel activation (opening) sufficient to abolish activity of Pro-
opiomelanocortin (POMC) neurons in the arcuate nucleus leads to hyperphagia and increased 
body weight (Plum, Ma et al. 2006).  However partial activation which does not completely 
disrupt electrical activity has shown to blunt glucose sensing, and lead to impaired glucose 
tolerance (Parton, Ye et al. 2007).  KATP channel activity has been shown to be regulated by 
lipids, such as PIP2 and PIP3, which increase the likelihood of the channel being open, and 
decrease its responsiveness to ATP.   
Decreased glucose has been shown to activate (open) KATP channels in the ventromedial 
hypothalamus, leading to glucagon and catecholamine release (Miki, Liss et al. 2001). 
Studies using electrophysiological recordings of both rat and mouse hypothalamic slice 
preparations and also  local in-vivo application of KATP channel blocker (closer) have shown 
that closing the channel suppresses CRR while agents that open the KATP channel amplifies 
the CRR.(McCrimmon 2008)  The importance of these channels were highlighted in rodent 
studies with deletion of the pore forming subunit of the KATP channel (Kir 6.2
-/-), which 
showed both lack of GR neurons in slices of VMH and a severely impaired counter-
regulatory responses and abnormal feeding responses to hypoglycaemia.  (Miki, Liss et al. 
2001)  In addition, KATP channels have been found to be important in modulating glucose 
uptake in muscle and in the central control of hepatic glucose output.     
There also exists a common polymorphism in Kir 6.2 (E23K) which has predisposed 
individuals to Type 2 Diabetes (T2D). The functional effects of the E23K polymorphism are 
still controversial. Studies have shown both increases and decreases (Schwanstecher, Meyer 
et al. 2002, Riedel, Boora et al. 2003) in ATP sensitivity.  A potential decrease in sensitivity 
would lead to an increased likelihood of an open channel.   
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In summary, during hypoglycaemia, direct detection of glucose by central glucose sensing 
neurons is integrated with afferent information from peripheral sensors, fed through the 
Nucleus Tractus Solitarus (NTS) to gauge systemic glucose levels.  These hypothalamic and 
hindbrain neural networks then project to the paraventricular (PVN) nucleus of the 
hypothalamus.  PVN activation is crucial in activating the main components of the CRR; the 
parvocellular neurons in the PVN activate the sympathetic nerve activation in the spinal cord, 
the DVN (dorsal motor nucleus to regulate the vagal parasympathetic efferent neurons) and 
the medial parvocellular of the PVN activates CRH which then activates the anterior pituitary 
to release corticotrophin (ACTH). (Reno, Litvin et al. 2013) 
Direct in vivo local application of SUR-1 agonists to the ventromedial hypothalamus (VMH) 
has been shown to amplify (McCrimmon, Evans et al. 2005) while local SUR-1 antagonism 
suppresses (Evans, McCrimmon et al. 2004) the counterregulatory response to acute 
hypoglycaemia in rats.  Moreover, systemic delivery of a SUR-1 selective agonist amplified 
counterregulatory responses during hyperinsulinemic-hypoglycemic clamp studies in normal 
and recurrently hypoglycemic rats, an effect that could be reversed by VMH KATP  channel 
antagonism (McCrimmon, Evans et al. 2005, Fan, Ding et al. 2008). Based on these rodent 
studies, we hypothesized that therapeutic agents that activate SUR-1 selective K ATP channels 
are likely to offer a potential means for restoring defective counterregulatory responses to 
hypoglycaemia in T1D.   
The only licensed agent which is known to activate or open KATP channels is diazoxide and 
therefore we exploited this drug, to determine whether it could be used to potentiate the 
counter-regulatory responses to hypoglycaemia. 
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Diazoxide; a KATP channel opener 
 
Diazoxide (C 8 H 7 ClN 2 O 2  S) was discovered through studies of the antibacterial effects of 
sulphonamides in the 1930s. This period of research into the active moieties of 
sulphonamides led to the synthesis of acetazolamide, the first useful diuretic, and 
subsequently led to the discovery of chlorthiazide. Diazoxide was initially developed as a 
non-diuretic hypotensive agent as a result of vasodilation  (Rubin, Roth et al. 1962), an action 
for which it is still used clinically, before it was also noted to have a significant effect on 
raising blood sugars.  More recently it has been shown to protect against cardiac ischemia due 
to its ability to induce ischaemic preconditioning (Oldenburg, Critz et al. 2003).  
Diazoxide was previously,  primarily indicated for the treatment of severe hypertension 
(particularly when associated with renal disease) (Standen, Quayle et al. 1989) and is still 
used for the treatment of chronic intractable hypoglycaemia occurring for instance in the 
context of an insulinoma (Trube, Rorsman et al. 1986).  Usually given in a tablet form, 
Diazoxide is prescribed orally, and its use has been limited due to its multiplicity of effects 
which gives rises to a range of side effects including increased hair growth on the head, back, 
arm and legs, a change in taste, loss of appetite, stomach upset, diarrhoea, headache and 
tiredness.   
Research in the last few years have suggested other potential uses for diazoxide including 
hypoglycaemia unawareness in type 1 diabetes, hyperlipidaemia and obesity and, perhaps 
more surprisingly, type 2 diabetes.   
Pharmacology  
 
Diazoxide is a benzothiadiazine derivative (7-chloro-3-methyl-2H-1, 2, 4-benzothidiazine 1, 
1 dioxide), that is closely chemically related to chlorthiazide.  It was initially used for its 
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vasodilator and hyperglycaemic effects (in severe and refractory hypertension and 
insulinomas respectively)(1971).   It is extensively protein bound (more than 90%) and is 
excreted by the kidneys.  The plasma half-life following iv administration is 28.0 +/-8.3 
hours. It appears that the maximal hypotensive effect occurs at about 5 hours after dosing 
which parallels the maximum blood levels(Pearson 1977).  The primary mode of action of 
diazoxide is through the ATP-sensitive potassium (KATP) channels, which are a type of 
potassium channel gated by ATP and hence play a critical role as sensors of the metabolic 
status. KATP channels are composed of Kir6.x-type subunits and sulphonylurea receptor 
(SUR) subunits, along with some additional components. The Kir6.x- (either Kir6.1 or Kir6.2) 
subunits form the inward-rectifier potassium channel, while the SUR (SUR-1, SUR2A or 
SUR-2B) are transmembrane proteins that allow nucleotide modulation of the potassium 
channel.  
Diazoxide exerts its effects through binding to  the SUR subunit of the KATP channel which 
has the effect of ‘opening’ the channel leading to increased potassium entry into the cell and 
hyperpolarization of the cell membrane (inhibiting the generation of cell membrane 
potential). Sulphonyureas have the opposite action and once bound to the SUR subunit of 
KATP channels, have the effect of ‘closing’ the channel.  
Pancreatic β-cells for instance, express SUR-1. Diazoxide binding leads to the KATP channel 
opening, and increases potassium membrane permeability leading to membrane 
hyperpolarisation, inhibition of calcium influx and diminished insulin secretory release.  In 
contrast, cardiac, skeletal and vascular and non-vascular smooth muscle predominantly 
contain KATP channels of the SUR-2A sub-type. Diazoxide binding to this sub-unit leads to 
vasodilation, hence its use as a treatment for severe hypertension and is an explanation of the 
well-recognized adverse effects like reactive hyperaemia. 
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Trials of safety and efficacy 
 
Diazoxide is a well-established treatment for congenital hyperinsulinemia and insulinoma and 
has been used in this context for over 40 years. Trials have been small, and have looked at the 
medical management of insulinomas as an adjunct to surgery or in those who are inoperable.  
To date there has not been a large randomised control trials looking at the efficacy of this 
treatment.  Recent studies have suggested a number of possible novel indications for the use 
of diazoxide in obesity and both type 1 and 2 diabetes. 
Obesity and Metabolic Syndrome  
Studies of cell culture and animal models have demonstrated that diazoxide induces 
membrane hyperpolarisation in adipocytes, an action that suppresses lipogenesis and 
increases lipolysis through the regulation of key insulin sensitive enzymes.  Diazoxide 
therapy in rats produces a reduced lipogenic state and results in lower levels of plasma leptin.  
In an open-label non-placebo controlled study of obese humans subjects, oral diazoxide when 
combined with a reduced calorie intake and increase physical activity resulted in additional  
reductions in both fasting and post-meal peak insulin levels by about 65% (p<0.001), body 
weight  by 9.4 kg(p<0.001)], waist circumference by -9.2cm (p<0.001)], diastolic blood 
pressure by 10.9mmHg( p<0.001), and an increase in HDL (p<0.05)(van Boekel, Loves et al. 
2008).  The results are comparable to currently available anti-obesity medications such as 
orlistat.   
Type 1 and type 2 DM 
A more recent development has been the study of diazoxide to prevent beta-cell decline in 
both type1 and type 2 diabetes. It is well recognized that preservation of beta-cell function in 
diabetes is associated with a reduced incidence of microvascular complications, such as 
retinopathy and nephropathy. Interventions that reduce beta-cell apoptosis therefore represent 
a potentially important therapeutic target in type1 and type 2 diabetes.  There are a number of 
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on-going trials using immune-modulatory agents at diagnosis of type 1 diabetes to determine 
whether it might be possible to reduce disease progression. These agents are expensive and 
associated with frequent severe adverse events. Studies in animals have suggested that 
diazoxide might reduce beta-cell apoptosis by reducing the stress within the endoplasmic 
reticulum as well as through their action to hyperpolarise the plasma membranes and inhibit 
insulin release, both actions leading to ‘beta cell rest’. 
Bjork et al showed that supplementary diazoxide treatment at the onset of type 1 antibody 
positive adults for three months can preserve residual insulin secretion after a year.  This is 
through initial suppression of insulin production providing a period of ‘beta cell rest’ which 
then preserves residual insulin secretion even after a year.(Bjork, Berne et al. 1996) The same 
group has also shown that inhibition of insulin secretion reduces autoimmune antigen 
expression.   
Based on the similar hypothesis that beta-cell rest will preserve beta-cell function in the long-
term, a proof of concept study in patients with type 2 diabetes showed that diazoxide given 
with night time insulin improved beta cell function, as demonstrated by the improved C- 
peptide glucagon tests, but there was higher post-prandial blood glucose in the morning.   
This can be explained through a selective action, as diazoxide prevents the insulin stimulating 
effects of glucose, but not that of glucagon. (Qvigstad, Kollind et al. 2004). Glycaemic 
control was not affected. Further human studies have shown that for long term glycaemic 
regulation, diazoxide should be given with insulin.   
As a consequence of its non-selectivity of the SUR subunits within the KATP channel, it 
carries a side effect profile that could limit its use. Side effects seem to be limited to 
continuous use (multiple dosing daily) rather than intermittent use (once daily dosing).  
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Hyperglycaemia and oedema are the main dose limiting side effects, but these are usually 
reversible with dose adjustment (van Boekel, Loves et al. 2008).  
The recent revelation of the mechanisms of diazoxide, i.e. KATP channel opening effects has 
opened up potential therapeutic roles for diazoxide as an option in diabetes.  It may prove to 
be beneficial in the early stages to provide beta cell rest and it may potentially be used to 
improve awareness in those who have recurrent hypoglycaemia.  The first study (STUDY-1) 
will seek to explore the therapeutic benefit of Diazoxide in patients with T1D (Bingham, 
Hopkins et al. 2003).   
Two previous studies (Bingham, Hopkins et al. 2003, Raju and Cryer 2005) in non-diabetic 
patients failed to show an effect of diazoxide on the counter-regulatory response to 
hypoglycaemia. Both these studies delivered diazoxide to the subjects prior to induction of 
hypoglycaemia and gave diazoxide orally (5mg and 6mg/kg respectively). Diazoxide is highly 
protein bound (>95%) and so it is possible that the systemic levels reached were very low, 
although the drug would have been persistent given the long half-life (approximately 23 hours) 
of diazoxide.  It is possible that KATP channel opening in hypothalamic glucose sensing neurons 
during moderate hypoglycaemia in non-diabetic individuals may already be near maximal and 
therefore this may be the reason for the lack of effect in the above human studies. By 
comparison,  subjects with type 1 diabetes and IAH, it is likely that the hypothalamus has 
impaired glucose sensing and the KATP channel is therefore, less likely to be in the open-state 
and more likely to respond to KATP channel activators.  To address this hypothesis we designed 
a study to specifically test the hypothesis that KATP channels were integral to the detection of 
hypoglycaemia in individuals with established T1D.  
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Methodology 
 
This first study was a single-center, double-blinded, placebo-controlled randomized controlled 
trial (RCT).  The study protocol, participant information sheets, informed consent forms were 
all approved by an independent research ethics committee (REC), Medicines Healthcare 
Products Regulatory Agency (MHRA) and also by NHS Tayside Research and Development 
(R&D).  The study was carried out in accordance with the Declaration of Helsinki.  Written 
informed consent was obtained for each participant before inclusion in the study.   Eligible 
participants were all adults between the ages of 18-60 who met the eligibility criteria.  Inclusion 
and exclusion criteria are detailed below.  
INCLUSION CRITERIA 
1. Healthy adults (aged 18-55) with >5 years disease duration  
2. On intensive insulin therapy (CSII or multiple daily injections) 
3. HbA1C <8.0% 
4. Ability to give written informed consent to participate in the study 
5. BMI between 20-29 
 
EXCLUSION CRITERIA 
 
1. History of significant cardiac, hepatic, renal or neurological disease. 
2. Significant head injury, epilepsy or hypoglycaemia-induced seizures. 
3. Pregnancy. 
4. Breast feeding mothers. 
5. Participants on thiazide diuretics 
6. Participants on other potassium channel openers (nicorandil, minoxidil) 
7. Participants on medications with vasodilatory properties such as methyldopa, reserpine, 
theophylline and nitrites. 
8. Participants on hydantoins (fosphenytoin, phenytoin) 
9. Significant anaemia Hb<11.0 and Hct<33%. 
10. If they have donated blood in the last 30 days. 
11. All those who have participated in a clinical trial of an investigational medicinal 
produce (CTIMP) in the last 3 months 
12. Participants who are already on diazoxide or who have a past history of allergy to 
diazoxide 
 
 
Potential participants were identified using the Scottish Diabetes Research Network (SDRN), 
which is a register of patients who have pre-consented to be contacted for future clinical trials.  
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Other avenues of recruitment included approaching patients at diabetes clinics and through the 
various education programs offered for those with T1D.  The study took place at the Clinical 
Research Centre, Ninewells Hospital, Dundee.   
After initial screening which included collection of demographic information, each subject 
attended the Clinical Research Centre (CRC) on 4 separate occasions. On two of these visits, 
separated by at least 2 weeks the subject was given oral diazoxide or placebo before undergoing 
the hyperinsulinemic hypoglycemic clamp studies. Independent pharmacists dispensed either 
the active or placebo over-encapsulated capsules according to a computer generated 
randomization list.  The Diazoxide and placebo were in capsule form and identical in 
appearance and pre-packed in bottles and given to the participant by the investigator prior to 
the clamp study.  Both the participants and investigators were blinded to allocation of 
treatment.  
The other 2 visits were to fit each participant with a continuous glucose monitor (RT-CGM), 
with low-glucose suspend  (set at 4.5 mmol/l) where applicable, for 48 hours prior to each 
clamp study, to ensure that there were no significant hypoglycemic episodes (<2.5mmol/L), 
for at least 48 hours prior to each clamp study.  Per protocol, the clamp was rescheduled if any 
sensor readings were less than 2.5mmol/L.   
Real time Continuous glucose monitoring (CGM) as a tool for avoiding 
hypoglycaemia prior to clamp studies 
 
CGM devices measure glucose via the glucose oxidase reaction in interstitial fluids and then 
translates this using a calibration reading into a plasma glucose value.   The sensor is located 
on the tip of the needle.  The Guardian Real-Time (Medtronic MiniMed, Northridge, CA, 
USA) device was used for these studies. The sensor was inserted using the auto insertion 
device.    Due to the fact that antecedent hypoglycaemia over the previous 48 hours impairs 
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the counter-regulatory response to further hypoglycaemia and affects the glucose threshold 
for adrenaline release, it was important to employ a strategy designed to reduce all 
hypoglycaemia below 2.5mmol/L prior to the hyperinsulinemic hypoglycaemia clamp.  The 
low glucose suspend (set at 4.5mmol/L) feature was also utilised to alert patients of their 
blood sugar and take appropriate corrective measures if necessary.  Alarms at pre-set 
thresholds have shown to detect 90.1% of hypoglycaemia in subjects who wore the Enlite TM   
sensors (Medtronic Diabetes, Northridge, CA) (Keenan, Mastrototaro et al. 2012).   
Assessment of Impaired Awareness of Hypoglycaemia 
 
Several validated scoring systems exist.  The most common of which are the Gold, Clark and 
Pedersen-Bjergaard (P-B) questionnaires.  Gold method (Gold, MacLeod et al. 1994) has 
been used in these studies to assess awareness. It asks the question “Do you know when your 
hypos are commencing?” The participants respond by scoring on a 7 point Likert scale, with 
“1” for always aware and “7” for never aware.  Greater than or equal to a score of 4 has been 
considered consistent with IAH.   However, this method may lack sensitivity.  For instance, 
individuals who do infrequent testing and have erratic control may not realise that they are 
experiencing hypoglycaemia. This was demonstrated in a CGMS study which identified 40-
60% of all hypoglycaemic episodes which had gone unrecognised even in those who did 
SMBG regularly.(Cook, Bryzinski et al. 2013).      
The Clark method(Clarke, Cox et al. 1995) contains 8 questions with much more detail on the 
symptomatic responses to hypoglycaemia as well as the subjects exposure to having moderate 
to severe hypoglycaemia with further exploration of glycaemic thresholds(Clarke, Cox et al. 
1995).  The questions explore symptom generation during biochemical hypoglycaemia (BH), 
frequency of moderate and severe hypoglycaemia and recognition of hypoglycaemia.  A 
score of ≥4 is thought to be suggestive of IAH.   
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The (P-B) method asks the patient “can you feel when you are low?” with the possibility of 4 
answers (always, usually, sometimes or never).  Apart from always, all the other responses 
put the patients into the IAH category.  This method is thought to be less selective and 
sensitive to clinical issues of importance.  
The Gold and Clark methods show high correlation (rs 0.866 p=0.001), whereas correlation is 
poor between these methods and the P-B method with the latter tending to estimate a much 
greater frequency of IAH (24, 26 and 62.5% respectively)(Geddes, Wright et al. 2007). It has 
been suggested that the P-B method is over-simplified, insensitive and unable to discriminate.  
However in the absence of any agreed gold standard measure except for the glucose clamp 
technique, no formal comparative study has been made.  
The composite method is a further assessment tool, with six different diagnostic self-report 
criteria of IAH (change of symptoms, recognition, and threshold, experience of moderate and 
severe hypoglycaemia in the last year).  Finally, the last criteria, which was the composite 
criteria detected IAH if a minimum of 3 out of the 5 previous criteria were positive(Janssen, 
Snoek et al. 2000).   
A more detailed assessment of hypoglycaemia awareness, the Hypo A-Q questionnaire was 
recently developed and used in the HypoCOMPASS Study.  This 18 item profile, asks 
patients to recall episodes of hypoglycaemia when awake and asleep.  It also accounts for 
frequency of testing when feeling low, glycaemic thresholds and symptom generation 
amongst other parameters.   
Assessment of hypoglycaemia awareness (HA) during a hyperinsulinemic, hypoglycaemic 
clamp study (and using a threshold of <3 mmol/L for autonomic symptoms) has been 
suggested as the gold standard in assessing HA. A study(Janssen, Snoek et al. 2000) looking 
at the agreement of various measures to the clamp study, showed that recognition criteria 
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(most similar to the Gold score) had a poor kappa 0.31, whereas the composite score had a 
greater agreement (κ of 0.49) with the clamp studies.  There was also a very poor agreement 
with clamp threshold data and a patient hand held computer, where patients’ would enter 
blood glucose estimations followed by home blood glucose monitoring (HBGM) and also 
degree of symptomatic awareness (κ of 0 with sensitivity and specificity of 50% each) .  
Experimental stepped hyperinsulinemic hypoglycemic clamp.  
 
Human counter-regulation can be studied robustly using the hyperinsulinemic hypoglycaemic 
clamp method, whereby an insulin infusion at a relatively high, constant dose is infused 
alongside a variable dextrose infusion.  
The  clamp technique was initially described by DeFronzo et al (DeFronzo, Tobin et al. 
1979).  It works on the principle that in the post absorptive state in non-diabetic individuals, 
the rate of endogenous glucose production (from liver 95% and renal 5%) matches whole 
body glucose utilisation, keeping the blood glucose in a tight physiological range. When 
exogenous insulin is added to this system, it suppresses endogenous glucose output, and 
increases whole body glucose utilisation, leading to a fall in the blood glucose.  To prevent 
this fall, and maintain euglycaemia, a variable glucose infusion is started.  The rate of this 
infusion must be sufficient to account for both the glucose flux into the glucose utilising cells 
and the reduction of glucose production.  The hyperinsulinemic state induced by exogenous 
insulin must be sufficient to completely suppress the endogenous glucose output. Therefore 
the variable glucose infusion rate would be equivalent to the glucose utilisation into cells, in 
order to maintain euglycaemia.   
Performing a glucose clamp requires two intravenous lines which need to be kept patent, one 
to deliver the insulin and glucose and the other to allow frequent blood sampling of 
arterialised blood.  The 2 cannulae are usually placed in the antecubital fossa and the 
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contralateral hand.  The insulin and glucose infusions go through the cannula in the 
antecubital fossa and need to run with finely tuned calibrated pumps that allow fine 
adjustment.  The second cannula is placed into the contra-lateral hand and blood is drawn for 
glucose measurements. The hand is heated so that arteriovenous shunting occurs, which is 
most representative of the blood glucose “seen” by the brain. We used the arterialised 
sampling technique, which was done by placing the cannula into a hand vein, but then 
placing it in a heated box at 60 degrees C.  This technique allowed heat induced 
vasodilatation and shorter blood transit time, and it has been found that the concentration of 
glucose and other metabolites is similar to that of arterial blood.  (McGuire, Helderman et al. 
1976) This technique eliminates differences seen in glucose commonly seen in arterial or 
even venous sampling that arise from variable insulin sensitivity in individuals.    The 
arterialised blood sugar at a pre-determined level is “clamped” at a fixed pre-determined 
level.  Glucose concentrations must be measured quickly, ideally within 1 minute, to allow 
adjustment of the glucose infusion.  During each of the glucose nadirs, symptomatic, 
neuroendocrine and cognitive responses can be assessed.  
The insulin infusion acutely raises the plasma insulin concentration to a hyperinsulinemic 
plateau for the duration of the clamp experiment.  We used insulin infusion rate of 
1.5mU/kg/minute.  In order to accelerate the desired plateau of insulin concentration, we 
applied a priming dose of insulin (15u/hr) for all our studies during the euglycaemic period.  
This does lead to an initial overshoot of plasma insulin above the steady state achieved later 
in the clamp, however it does lead to shorter times to reach steady state.  (DeFronzo, Tobin et 
al. 1979)   
There have been many algorithms developed to calculate glucose infusion rates, but most of 
these have resulted in manual override to achieve required glycaemia as in our studies.  A 
20% glucose infusion is used and is preferable to a 10% glucose infusion, because of its 
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lower volume and to prevent over hydration.  We found that the glucose infusion rates 
required to maintain euglycaemia increased within the first 40minutes from the start of the 
insulin infusion.  This maybe as a result of the complete suppression of endogenous glucose 
production by insulin completely suppressing with a resultant increase in glucose utilisation.   
Interstitial brain levels of glucose are thought to be 15-30% of the plasma glucose levels and 
this is consistent even in the hypoglycaemic range (Silver and Erecinska 1994).  Plasma 
glucose was determined at 5 minutely intervals according to previously published literature. 
(Bergman, Finegood et al. 1985)  Studies in non-diabetic humans, showed that it takes up to 
20mins after the hypoglycaemic nadir (Evans, Pernet et al. 2000) before there is adequate 
generation of the counter-regulatory responses and therefore guided the design of our clamp 
experiment. Our clamp design, used a slow fall hypoglycaemia challenge, whereby each 
glucose nadir was maintained for 40mins during which CRR was assessed after the first 
20mins and at the end of each nadir (to finish at 40mins).  Symptoms and cognitive function 
testing was also done after 20mins and at the end of each nadir. 
Thresholds are often calculated by a step wise multiple step clamp experiment.  This, as in 
the first study (STUDY 1) drops the plasma glucose at regular intervals by a pre-specified 
amount and then the plasma glucose is clamped so that assessments such as counter-
regulatory response, symptomatic and cognitive assessments can be made.  This is continued 
until the lowest nadir is reached.  Several methods have been described for calculation of 
thresholds with some investigators using baseline values (during the euglycaemic phase) to 
then calculate thresholds during the subsequent period of hypoglycaemia whilst others do two 
separate studies on two separate days; i.e. euglycaemic and hypoglycaemic studies.   The 
latter ensures a reliable baseline for the above measures, from which thresholds are then 
calculated.   
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The evening prior to attendance, each participant was advised to reduce their night time long 
acting insulin by approximately 20% in order to avoid any overnight hypoglycemic episodes 
and advised to fast for at least 8 hours, and omit further short acting insulin, prior to coming to 
the Clinical Research Centre at 0800AM.  On the morning of the clamp, a cannula was inserted 
into a dorsal hand vein of the non-dominant hand in a retrograde fashion and then placed in a 
heated box at 55⁰C to arterialize venous blood (Liu, Moberg et al. 1992).  This line was used 
for blood sampling during the clamp study.   In the contralateral arm, the ante-cubital vein was 
cannulated for insulin and glucose infusions.    
Participants were given either oral diazoxide (7mg/kg) or matched over-encapsulated placebo 
in a double blind, randomized manner, 2 hours before the start of the euglycaemic plateau. The 
timing of oral Diazoxide ingestion was based on the available literature indicating that its 
hypotensive and anti-hypoglycemic effect lasted on average ≈ 3-12 hours with a peak action at 
≈ 5 hrs. (Pearson 1977).     Participants were initiated on 50ml/hr of insulin for priming purposes 
and this was continued until the blood glucose dropped to below 7mmol/L.  Thereafter the 
intravenous infusion of insulin was continued at rate of 1.5mU/kg/min for the duration of the 
clamp.  A variable dextrose infusion (Braun, Infusomat Space) (20% dextrose in saline), was 
started when the blood glucose dropped to below 7mmol/L, and this was adjusted every 5 
minutes to reach the desired plateaus.  Plasma glucose was brought down to between 4.0-
5.0mmol/L over the first 2 hours.  Euglycaemia was then maintained for the next 40 minutes.  
This was then brought down by 0.5mmol/L every 40 minutes until a blood glucose plateau of 
2.5mmol/L was reached.  The subject was blinded to their glucose level throughout the study.    
Following the completion of the hypoglycemic state, intravenous insulin was reduced to a third 
of the maintenance rate and iv glucose was given at 150% of the euglycaemic rate to enable 
quick recovery.  Participants were given a meal and discharged when euglycaemia (>4-
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5mmol/L) was maintained.  The clamp was then repeated at least two weeks later, to allow a 
sufficient wash out period for diazoxide.    
Physiological measurements 
 
Adrenomedullary adrenaline has been shown to be primarily responsible for the increase in 
pulse rate and cardiac output and for the widening of pulse pressure(Hilsted 1993).  This 
appears to be a response to net vasodilation as a result of hyperinsulinemia and provides a 
compensatory mechanism to prevent hypotension.  Blood pressure and pulse rate were 
measured every 10 minutes using an Accutorr Plus Monitor (Datascope Corp., Mahwah, New 
Jersey, USA).   
Measurement of sympathetic nervous system 
 
Several methods have been used to measure the outflow of the sympathetic nervous system 
(SNS), such as assessment of the heart rate and BP variability, microneurography, estimation 
of noradrenaline (NA)/adrenaline (A) spillover by isotope dilution and also through 
measurement of plasma noradrenaline/adrenaline. The spill-over technique only gives an 
indication of amount of NA released from the post-ganglionic sympathetic neurons.  Most of 
the NA is subsequently used locally or re-uptake into axon terminals.  There are also regional 
differences in sympathetic neural activity, which again complicates interpretation.   
Single isotope derivative (radio enzymatic) methods used for the measurement of adrenaline 
have proved to be precise as well as sensitive and specific assays. However this measurement 
has a number of limitations.  Plasma concentrations are dependent on both influx and efflux 
rates and rates of both these processes can vary.  Most noradrenaline (NE) released by the 
postganglionic neurons may also never enter the systemic circulation, and be utilized locally.  
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Since NE is produced both by sympathetic neural and adrenomedullary activation, plasma 
levels will not discern its source.   
Circulating noradrenaline is mainly produced from adrenergic post-ganglionic neurons, but 
under resting conditions, the SNS is the main (92-98%) source, with substantial greater 
increments in plasma NA on taking up an upright position (even in patients who are 
adrenalectomised).  Hyperinsulinaemia also raises plasma NE (not plasma adrenaline), and 
also NA spillover (Paramore, Fanelli et al. 1998)...   
Hypoglycaemia is a powerful stimulus for catecholamine release(Segel, Paramore et al. 2002) 
from the adrenal medulla, suggesting a suppression of SNS in the context of fasting or 
hypoglycaemia(Young, Rosa et al. 1984) (Cryer 1984, DeRosa and Cryer 2004). This was 
confirmed by a study comparing adrenalectomised patients with controls and found no 
adrenaline response in the latter group (DeRosa and Cryer 2004).  Also, there is a poor 
correlation between A and NA, in the supine and standing position in healthy humans, 
however during hypoglycaemia, the correlation becomes highly significant (r=0.829, 
p<0.001), suggesting the adrenal medullae as the common source in this context.   
Arterialized blood for insulin and counter-regulatory hormones (adrenaline, noradrenaline, and 
glucagon) were taken at midpoint and end of each plateau.   
Laboratory assays.  
 
Whole blood was measured at the bedside by a glucose oxidase method (Analox GM9D 
(Analox instruments, London, UK)). Samples were centrifuged to separate the plasma within 
2 hours, and then stored at -80⁰c prior to assay.   Hormones (Insulin-RIA-Diasorin; CV inter -
6.7%, intra -5.8%), (Glucagon-RIA-MilliporeUK; CV inter 4.9%, intra 8.8%), (Adrenaline-
EIA-Alpco; CV inter 22%, intra 16%), (Noradrenaline-EIA-Alpco; CV inter 16%, intra 22%) 
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were measured by ELISA, and samples were analysed in duplicate according to the 
manufacturer’s instructions. Genomic DNA was prepared from whole blood using an Auto 
pure DNA preparation robot (Qiagen).  Genotyping of rs5219 was performed by TaqMan based 
allelic discrimination (Thermo-Life Technologies) according to manufacturer’s instructions.   
Symptom assessment 
 
Autonomic symptoms are generated by sympatho-adrenal activation, whereas the 
neuroglycopenic symptoms are provoked by cerebral glucopenia and cerebral 
dysfunction(Benzo 1983).  Most of these symptoms are due to neuronally released 
transmitters rather than adrenomedullary catecholamines as most of the symptoms are lost by 
ganglionic blockade, cervical cord section(Pedersen-Bjergaard, Hoi-Hansen et al. 2007) and 
sympathectomy but not by adrenalectomy. Sweating and tremor(Fellows, Macdonald et al. 
1986) in particular have both been shown to be well correlated with circulating 
concentrations of adrenaline.   
We used the Edinburgh Hypoglycaemic Scale to assess symptoms during the clamp 
experiments.  This scale was developed through partitioning the most commonly reported 
symptoms of hypoglycaemia reported by 295 insulin treated outpatients.  This exercise 
revealed 11 key hypoglycaemic symptoms which were then categorized into three factors 
(autonomic, neuroglycopenic and malaise).  These factors were validated on a separate group 
of 303 insulin treated patients (Deary, Hepburn et al. 1993) and showed good coefficients of 
congruence of the factors across the 2 groups studied.  The scale measures the intensity of 
these 11 key hypoglycaemic symptoms on a 7 point Likert scale.   
Subjects rated symptoms at the mid-point of every glucose plateau.  Symptoms were scored on 
a validated questionnaire, the Edinburgh Hypoglycaemia Scale, scoring from 1 (not at all) to 
7(very severe) on a visual analogue scale.  Symptoms included autonomic (hunger, 
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palpitations, sweating, shaking), neuroglycopenic (drowsy, confused, odd behavior, speech 
difficulty, incoordination) and non-specific symptoms (nausea, headache) (Deary, Hepburn et 
al. 1993) 
Cognitive function tests.  
 
A recent meta-analysis (Brands, Biessels et al. 2005) showed that specific cognitive domains 
are affected in patients with T1D. There is typically a mild-moderate slowing of mental speed 
and a diminished mental flexibility, with learning and memory (modalities which are 
susceptible to early brain disease) not being affected.  The presence of microvascular disease 
was found to be of greater significance than hypoglycaemia exposure or glycaemic control, in 
determining the extent of cognitive dysfunction in the long term.   
Numerous studies during acute hypoglycaemia have shown that during complex tasks, 
accuracy is often preserved, at the expense of speed(Strand, Anderson et al. 1934).  In 
contrast to the effects of longstanding T1D on cognitive domains, acute hypoglycaemia 
impairs memory particularly working and delayed memory(Vindedzis, Marsh et al. 2013), 
attention, information processing, psychomotor function and spatial ability.  The threshold for 
cognitive dysfunction is around 3mmol/L.  One of the earliest studies(Maran, Lomas et al. 
1995) showed that cognitive dysfunction (assessed through 4CT) occurs at a higher glucose 
level  in those who were intensively treated compared to those who were on conventional 
treatment and non-diabetics respectively(3.2 +/- 0.3, 3.2 +/- 0.2 and 3.0 +/- 0.2 mmol/l, 
respectively (p = NS)), suggesting the reason for poor mental responses to hypoglycaemia in 
this group.   
Insulin Induced Hypoglycaemia (IIH) has also been shown to affect several aspects of 
attention.  It predominantly affects visual and auditory selective attention (ability to select 
information from one source, or of one kind rather than another) and attentional switching 
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(when attention is divided by 2 tasks), with preservation of sustained attention (vigilance or 
alertness).  Psychomotor function and spatial ability have also been shown to deteriorate 
during IIH, although it appears to be less prominent in those with T1D than control subjects.  
A recent study(Graveling, Deary et al. 2013) showed that executive function (ability to plan, 
initiate, sequence, monitor and inhibit complex behaviours) was also impaired in the context 
of acute hypoglycaemia.   
We selected 4 cognitive function tests which are known to be sensitive to the effects of acute 
hypoglycaemia and are easily repeatable in a short period of time.   
Trail making B (Gaudino, Geisler et al. 1995) (TMB) 
This is a test of motor speed and visual attention. Part A requires the subject to connect 25 
consecutive numbers with lines, however part B, which was done as part of the battery of 
tests during hypoglycaemia requires the subject to alternate between numbers and letters.  
Part B is a more challenging task with greater demands on motor speed and visual search.   
Digit Symbol Substitution (DSS) 
This test derived from the Wechsler Adult Intelligence Scale(Wechsler 1981) is a test 
assessing the ability of the subject to code performed at speed.  Total of 100 small blank 
squares arranged in 4 rows have a randomly assigned number symbol.  A printed key on the 
opposite page, shows each symbol paired with a number.  Both the DSS and TMB have been 
shown to be affected by moderate hypoglycaemia.   
Digit span forward and backward(Wechsler 1981) 
Digit span tests particularly assess verbal working memory (VWM) as confirmed by the 
activation of prefrontal cortical activities(Stern, Owen et al. 2000).  The test involves the 
examiner reading out a progressive list of numbers, and the subject repeating the list either in 
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a forward or backward direction.  The DSS has also been shown to have excellent internal 
reliability (0.70-0.90)(Conway, Kane et al. 2005) 
4CT(Deary, Liewald et al. 2011) 
This is a measure of reaction times.  With greater discrimination during hypoglycaemia, we 
chose the choice reaction time D-L task, which requires the individual to make a response to 
one of a number of stimuli.  This measure has been shown to be associated with measures of 
general fluid intelligence(Mortensen, Jensen et al. 2006) and also with survival over the next 
15 years(Shipley, Der et al. 2006) .  Internal consistency was also very high for the D-L task, 
with Cronbach’s alpha to be 0.97 for correct responses.  
These cognitive function tests were done in the same order starting at the midpoint of each 
plateau -Trail making B(TMB)(Kortte, Horner et al. 2002), Digit span backward(Dig-
B)(1997), Digit symbol substitution test(DSST)(Wechsler 1981) and Four choice Reaction 
time (4CRT)(Deary, Liewald et al. 2011)  
Data and statistical analysis.  
 
The pre-specified primary endpoint was the magnitude of adrenaline responses at a glucose 
level of 2.5mmol/L.  Secondary outcomes examined included, whether oral Diazoxide would 
affect glucose thresholds for activation of hormonal, symptomatic and cognitive responses or 
result in significant changes in heart rate or blood pressure. Data are presented as mean (SE).  
For the primary endpoint, normally distributed data were compared using paired samples t tests, 
while non-normally distributed data were compared using the Wilcoxon signed rank test.  
Statistical analyses were conducted using GraphPad Prism version 6.00 for Windows, 
GraphPad Software, La Jolla California USA, www.graphpad.com and p<0.05 was considered 
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statistically significant.  Repeated measures ANOVA was used to determine differences in 
other parameters measured over time, with t-testing used to localize effects where indicated.  
Glucose thresholds for onset of symptoms, counterregulatory hormone responses and cognitive 
function were determined according to published protocols (Cranston, Lomas et al. 1994, 
Bingham, Hopkins et al. 2003).  Glucose thresholds for onset of hormone responses were 
defined as the time of onset of a sustained (≥2 successive time points) increase in hormone 
concentrations ≥ 2 SDs above the mean of the two baseline measurements for that hormone 
(using individual values).    Thresholds for the total symptoms were determined as the time at 
which the symptom score increased ≥2 over baseline on ≥2 successive time points.  If no 
defined change occurred, then the lowest measured glucose was used as the threshold for that 
individual, in a similar fashion to other published literature.    The glucose level at which there 
was a greater than 4% in the error rate was used to define thresholds of the Four Choice 
Reaction test.   
Results 
Participant characteristics.  
 
Recruitment was from Jan 2012 to September 2012 (see Figure 1).  Of the 24 participants 
screened, 6 did not meet the inclusion criteria and 4 withdrew consent; 14 subjects were 
randomized; 2 subsequently withdrew after the first clamp study. 12 participants (6 male and 
6 female) completed all stages of the study (2 clamps).  The median (range) age for this group 
was 43 (range 18-52).  Duration of diabetes was 24(6-40) years and median HbA1c was 
7.6%/60mmol/mol (6.9-8.0% (52-64mmol/mol)).  There was an equal number of subjects on 
multiple daily injections (MDI) and those on continuous subcutaneous insulin infusion (CSII) 
therapy.  5 out of 12 participants had Impaired Awareness of Hypoglycaemia as classified by 
the Gold criteria (score ≥4) (Gold, MacLeod et al. 1994).  However during the placebo clamp 
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studies, 11 out of 12 participants had an autonomic symptom threshold below or equal to 
3mmol/L)(Geddes, Wright et al. 2007).  
Figure 7; Consort diagram for STUDY 1. 
 
Participation of subjects from initial screening to completion of studies. Once randomised subjects with long 
standing type 1 diabetes received either oral diazoxide or placebo in two hyperinsulinemic glucose clamp 
studies separated by at least 2 weeks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screened for suitability (n=24) 
Excluded=10 
-Not meeting inclusion criteria 
(n=6) 
-Declined to participate (n=4) 
    
 
 
 
 
 
Allocated to treatment (n=14) 
 
Analysed from final analysis (n=12)  
Did not like the experience of 
hypoglycaemia during clamp 
(n=2) 
 
 
 
 
 
 
 
Received 2 allocated treatments (n=12) 
 
Randomized (n=14) 
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Hyperinsulinemic hypoglycemic clamp studies.  
 
Mean (SEM)  baseline blood glucose levels on the day of the hypoglycemic clamp studies for 
the Diazoxide (D) and Placebo (P) studies did not differ significantly between the two study 
days (10.6 (0.7) vs 11.8 (1.0) D vs. P p=0.90).  Glucose levels during the two clamp procedures 
were also well matched.   
Figure 8 Glucose profiles during stepped hyperinsulinemic hypoglycemic clamp studies.   
The Hyperinsulinemic hypoglycemic clamp technique was utilized to slowly drop the blood glucose from 
euglycaemia (4.0mmol/L) to hypoglycaemia (3.5, 3.0, 2.5mmol/L).  The drug (diazoxide or placebo) was given 
at 0mins, and after 120minutes, blood sugars were slowly dropped to euglycaemia during that time. Following 
which the clamp was commenced. Each nadir was achieved over 20mins, and then maintained for 20mins.  
Average blood glucose achieved at each of the desired steps during both the diazoxide and placebo clamp 
studies is shown in the bar chart below.  
 
 
As expected, plasma glucose dropped with time (see Figure 2) over the stepped clamp (main 
effect of time F (16,187) =37.60 p<0.05).  This drop was comparable in the two treatment 
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groups (main effect of treatment F (1,187) =0.2882 p=0.59, with no time X treatment 
interaction (time x treatment F (16,187) =0.4403 p=0.97). We maintained a mean insulin level 
of 79 (3.0) vs. 76 (2.8) mU/L (D vs. P) throughout the clamp period (p=ns).    
Primary outcome  
 
The primary outcome measure for this trial was the adrenaline response during the maximal 
hypoglycemic stimulus (2.5mmol/L). Baseline average adrenaline was 0.07 in both arms which 
rose to 0.29ng/ml and 0.40ng/ml in the placebo and diazoxide arms respectively. In support of 
our hypothesis, we found that following oral administration of Diazoxide, there was a 37% 
increase in mean (SEM) adrenaline responses (0.40 (0.06) vs. 0.29 (0.05) ng/ml, D vs. P; 
p<0.05) and a 44% increase in mean (SEM) noradrenaline (0.85 (0.07) vs. P; 0.59 (0.06) ng/ml, 
D vs. P; p<0.05) at plasma glucose of 2.5mmol/L.  (See Figure 3) 
Although glucagon levels remained, as expected, suppressed during hypoglycaemia, there was 
a non-significant trend towards higher mean glucagon levels in the Diazoxide arm (57.8 (11)  
vs. 50.0 (7.1) ng/l, D vs. P; p=0.21). Consistent with the amplified catecholaminergic response 
to hypoglycaemia glucose infusion rates (GIR) required to maintain the hypoglycemic plateau 
were significantly lower different at 2.5mmol/L following oral diazoxide (71.6 ± 1.8 vs 77.5 ± 
2.1, D vs. P; p<0.05).  
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Figure 9;  Diazoxide amplifies catecholaminergic responses during acute hypoglycaemia in long standing Type 
1 Diabetes.  
(a) Plasma adrenaline and (b) plasma noradrenaline levels during baseline and each hypoglycemic plateau.  
Placebo group shown as open bars, Diazoxide as closed bars.  Values shown as mean (±SEM). *p<0.05.  
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Despite the improved counterregulatory hormone response to hypoglycaemia participants 
experienced similar total symptom scores at an arterialized plasma glucose of 2.5 mmol/l 
following administration of Diazoxide (22 (3) vs. 19 (3), D vs. P; p=0.32).  Similarly, the 
overall increase in autonomic symptoms following Diazoxide was not significant (10 (1) vs 9 
(1) p= 0.26).  Cognitive performance of participants during the 2.5 mmol/l step was mixed (see 
Figure 4), with no significant impact of Diazoxide on Trail making B (30 (4) vs. 33 (5) s, D. 
vs. P; p=0.65),  Digit symbol backward (6 (1) vs. 7 (1) , D. vs. P; p=0.38), or on 4 choice 
reaction time (547 (21) vs. 543 (18), D. vs. P; p=0.82), and a significant deterioration in Digit 
symbol substitution following Diazoxide (70 (9) vs. 81 (8);  D. vs. P; p<0.05)   
Figure 10;  Cognitive function testing comparing Diazoxide to placebo at each of the glucose nadirs.  
Of the 4 cognitive function tests performed, only Digit symbol substitution showed significant deterioration of 
performance with oral Diazoxide. (a)Trail making (b) Digit symbol substitution (c) Digit span backwards score 
(d) 4 choice reaction time scores are shown at baseline and at each hypoglycaemic plateau.  Values shown as 
mean (±SEM). *p<0.05.  
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Secondary outcomes 
 
Secondary outcomes in this study were to determine whether diazoxide would lower (higher 
glucose for initiation) the glucose thresholds for onset of hormone responses. Thresholds were 
defined as the time of onset of a sustained (≥2 successive time points) increase in hormone 
concentrations ≥ 2 SDs above the mean of the two baseline measurements for that hormone.  
Although the glucose threshold for generation of both adrenaline and noradrenaline responses 
to hypoglycaemia were lower following administration of diazoxide these did not reach 
significance. (See Table 4)  
Table 4 Glucose thresholds for the key counter-regulatory hormones and symptoms for the Diazoxide study. 
The glucose threshold defined as the glucose level at which there is a sustained (>2 successive Time Points) increase in 
hormone concentrations or symptom scores above the mean of the two baseline measurements for that hormone or symptom. 
Values reported as mean ±SEM.   
Glucose Thresholds 
(mmol/L) 
Placebo Diazoxide P value 
Adrenaline 
 
3.1±0.4 3.2±0.3 0.75 
Noradrenaline 
 
2.8±0.5 2.9±0.4 0.49 
Glucagon 
 
2.8±0.5 2.6±0.3 0.24 
Symptoms 
 
   
Autonomic 2.7±0.3 
 
2.8±0.4 0.39 
Neuroglycopenic 2.8±0.4 2.8±0.4 0.17 
 
 
Genetic analysis- E23K polymorphism 
 
The E23K polymorphism in the K ATP  channel results in an increase in the likelihood of the K 
ATP  channel being open in the resting state (Schwanstecher, Meyer et al. 2002, Hamming, 
Soliman et al. 2009) and influences individual responses to sulphonyureas (Javorsky, 
Klimcakova et al. 2012). To determine whether the E23K polymorphism might influence 
individual responses to Diazoxide all 12 participants were genotyped and the cohort divided 
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into diazoxide-responders and diazoxide-non-responders. A diazoxide-responder was defined 
as an individual who had a greater than double the standard error of the mean increase in 
adrenaline responses at 2.5mmol/L following diazoxide.  In our study cohort, 7 of the 12 
participants (58%) carried the K23 allele (2-KK, 5-EK), while the rest were of the wild type 
homozygous E23.  Intriguingly, participants who expressed only the wild type E23 allele were 
all diazoxide-responders (see Figure 6), while those hetero- or homozygous for the K23 allele 
were significantly less likely to respond to Diazoxide (Pearson’s chi squared, χ=6.12; p=0.013) 
(see Figure 6).  Those who expressed the wild type E23 allele also showed greater magnitude 
of adrenaline response particularly as the blood glucose dropped down to 2.5mmol/L (see 
Fig5).   
 
Figure 11 Epinephrine (adrenaline) response at the end of each glucose nadir.  
 
This shows that there was fairly minimal adrenaline responses up to 250mins (achieving 3.0mmol/L plasma 
glucose), but responses diverge as the blood glucose drops down to 2.5mmol/L.  Closed circles represent those 
with the wild type (WT) homozygous E23, and closed boxes are those with the K23 allele.  
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Figure 12 Epinephrine responses depending on genotype 
E23K polymorphism in Kir 6.2 predicts response to Diazoxide during acute hypoglycaemia.  This figure shows the 
magnitude of the adrenaline response during acute hypoglycaemia (2.5mmol/L) following placebo or diazoxide in 
individuals who expressed (a) Wild type (EE) or (b) Homo or heterozygous (KK,EK) for this E23K polymorphism for the Kir 
6.2 channels.  Results for each individual under the two conditions are shown. 
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Adverse events. Systolic BP was comparable between the two groups, with no effect of 
treatment (main effect of treatment F (1, 22) =0.001228 p=0.97).  Similarly there was no effect 
of treatment on Diastolic BP (main effect of treatment F (1, 22) =0.4602 p=0.50) or on pulse 
rate (main effect of treatment F (1, 22) =2. 893 p=0.10) see figure below. 
 
Figure 13;  Haemodynamic responses during the clamp studies.  
There was no significant change in any of the haemodynamic parameters during the clamp studies.  The figure 
shows (a)systolic BP (b)diastolic BP(c)pulse rate from time 0 (drug given) to the conclusion of the clamp studies.  
Open circles represent the placebo arm, and closed circles are the diazoxide arm.   
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One participant had nausea and vomiting which was short lived in the recovery phase of both 
Diazoxide and Placebo studies, and reported nausea as being one of her usual symptoms during 
hypoglycaemia. One participant had nausea and a bout of vomiting in the recovery stage after 
receiving Diazoxide. There were no serious adverse events/reactions.   
Discussion 
 
In the current study, we demonstrate for the first time in individuals with type 1 diabetes of 
long duration that oral diazoxide (7mg/kg) given prior to acute hypoglycaemia can significantly 
increase the magnitude of both adrenaline and noradrenaline counterregulatory responses. 
Moreover, we make the novel observation that the E23K polymorphism in the Kir6.2 subunit 
of the K ATP channel predicts response to diazoxide therapy during hypoglycaemia in T1D  
The importance of KATP channels to hypothalamic glucose sensing was first proposed by Mayer 
(Mayer 1953), and the critical role of KATP channels in hypothalamic glucose sensing has since 
been demonstrated in cell culture models (Beall, Hamilton et al. 2012), ex-vivo hypothalamic 
slices (Ashford, Boden et al. 1990), transgenic mouse models (Miki, Liss et al. 2001) and 
following local pharmacological agonism or antagonism  of hypothalamic ATP channels in the 
rat (Evans, McCrimmon et al. 2004, McCrimmon, Evans et al. 2005). More recently, the 
potential utility of KATP channel openers to improve counterregulatory responses to 
hypoglycaemia has also been demonstrated in rodent models of type 1 diabetes and defective 
counter regulation. (Fan, Ding et al. 2008).  
The mechanism by which diazoxide improves the neuroendocrine response remains unclear. 
While the in vitro and in vivo rodent literature support a central action of KATP activators, all 
glucose-sensing cells both centrally and peripherally have been shown to contain Kir 6.2 and 
Sur-1 components of the KATP channel. It therefore possible that oral diazoxide acts primarily 
through peripheral K ATP  channels, such as those in the hepato-portal veins (Saberi, Bohland et 
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al. 2008).  The comparatively ‘slow-fall’ in glucose with the multi-step clamp would also be 
consistent with activation through hepato-portal sensors (Saberi, Bohland et al. 2008). In 
contrast, studies of direct hypothalamic modulation of KATP channels in rodents during 
hypoglycaemia (Evans, McCrimmon et al. 2004, McCrimmon, Evans et al. 2005) support a 
central action of diazoxide, as do the findings in both our own study and that of Bingham et al. 
(Bingham, Hopkins et al. 2003) of an effect of diazoxide on tests of psychomotor speed in 
human subjects. In a related study, Kishore et al. (Kishore, Boucai et al. 2011) demonstrated 
in the rodent model that the extra-pancreatic action of diazoxide to suppress hepatic glucose 
production could be reversed through ICV delivery of the KATP channel blocker, glibenclamide.  
Moreover, this group performed time course studies and were able to detect diazoxide in the 
CSF of rodents rapidly after oral ingestion reaching levels of 0.26±0.06 μg/ml 1 hour after 
gavage and 0.78 ±0.03 μg/ml by 4 hours, providing convincing evidence that diazoxide 
penetrates the blood-brain-barrier (BBB) (Kishore, Boucai et al. 2011). Species differences 
may effect BBB permeability to Diazoxide, however Diazoxide contains an ionisable 
sulphonyl group making it extremely lipid soluble and therefore able to partition into the lipid 
bilayer and it has a pKa of 8.5, a favorable constant, for penetration through the BBB (Kamp, 
Kizilbash et al. 2003).  Overall, the favorable pharmacological properties of Diazoxide as well 
as the human and rodent in vivo studies to date provide support for the hypothesis that its effect 
to amplify the counterregulatory response to acute hypoglycaemia is through a direct action on 
key hypothalamic glucose sensing regions. 
Our findings contrast with those of Bingham et al. (Bingham, Hopkins et al. 2003) and Raju et 
al. (Raju and Cryer 2005) who failed to see significant effects of oral diazoxide on 
counterregulatory responses to hypoglycaemia in non-diabetic subjects. However in the study 
Bingham et al. (Bingham, Hopkins et al. 2003) did report that hypoglycaemia-induced peak 
adrenaline levels were higher following diazoxide (adrenaline 7.37±1.89 vs. 6.18±2.28 nmol/l, 
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respectively, p=0.055). Similarly, although Raju et al. do not provide actual values to compare 
adrenaline and noradrenaline responses during the latter stages of the mild hypoglycaemic 
challenge (3.0mmol/L), these appear greater in those subjects given diazoxide (Raju and Cryer 
2005). Both studies used lower doses of diazoxide (5 and 6 mg/kg, respectively) which may 
contribute to their failure to see a significant effect.  In addition, it is possible that KATP channel 
opening in hypothalamic glucose sensing neurons during moderate hypoglycaemia in non-
diabetic individuals may already be near-maximal. By comparison,  subjects with type 1 
diabetes and IAH, the hypothalamus may have impaired glucose sensing and the KATP channel 
is therefore, less likely to be in the open-state and more likely to respond to KATP channel 
activators.  Consistent with this hypothesis, even within our own study cohort responsiveness 
to Diazoxide was significantly reduced by the presence of the K23 allelic form of the Kir6.2 
subunit which predicts an increased likelihood of the KATP channel being in the open state. 
In this present study oral Diazoxide was able to augment the counterregulatory response 
sufficient to significantly reduce requirements for exogenous glucose during the clamp 
procedure suggestive of a real impact on whole body responses. Despite this we did not see a 
statistically significant change in glucose thresholds for counter regulation or for overall 
symptom responses. However, the subjects in this study had diabetes of relatively long 
duration and despite only 5 of the 12 participants having IAH as defined by Gold criteria, 11 
out of 12 participants had an autonomic symptom threshold below or equal to 3mmol/L 
during the clamp studies.  However, the above questionnaires rely on the patient having an 
insight into their lack of hypoglycaemia awareness.  These scores therefore could be an 
underestimate of the degree of awareness, and as they are often used in the literature to 
quantify the problem.   Indeed the studies so far have asked the patient to SMBG at least 4 
times a day, and then if the patient’s results have been less than 3mmol/L, they have been 
asked to complete the Edinburgh Hypoglycaemia Scale (EHS).  However, in the majority 
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most patients would not be testing their blood glucose 4 times a day every day, and so 
assessment of hypoglycaemia in these patients is entirely reliant on symptomatic awareness 
(and not on SMBG).  There have been no studies looking at the agreement between the Gold 
score and routine BG monitoring as determined by the patient, and not enforced by a clinical 
trial.  
In this study, all subjects had a profound defect in symptom and hormonal counterregulatory 
responses to hypoglycaemia. It is likely that our study would only have detected large effect 
sizes in these secondary outcomes.  In addition, a limitation of our study is that we calculated 
thresholds based on the euglycaemic period prior to the induction of hypoglycaemia as reported 
by others (Leelarathna, Little et al. 2013). An additional euglycaemic control arm to the study 
would have both reduced baseline variability and controlled for effects of time dependent 
changes.  
Individuals with IAH often have long-standing type 1 diabetes, higher thresholds (first 
significant increase at a lower glucose level) for hormonal and symptom counter regulation, 
and a higher risk of severe hypoglycaemia (Cryer 1994, Mokan, Mitrakou et al. 1994). The 
higher threshold for symptom generation in particular is viewed as being a major risk for severe 
hypoglycaemia in that loss of usual warning symptoms means that hypoglycaemia when 
experienced is likely to be more severe and less likely to lead to appropriate corrective 
behavior. A clear goal of therapeutic intervention is therefore to restore thresholds for 
hypoglycaemia symptom generation. In this study, and consistent with others (Bingham, 
Hopkins et al. 2003), diazoxide did not significantly affect threshold for hypoglycaemia 
generation or for counterregulatory hormone responses. Despite this, following diazoxide 
activation of symptom and counterregulatory responses all tended to be initiated at higher 
glucose levels and it is likely that our study would only have detected large effect sizes.  
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It can be argued that the background noise is very different between real life and during 
clamp experiments.  Patients are often fasted from midnight before the day of the clamp, as a 
result, the presence of hunger was often not a discernible symptom specific to 
hypoglycaemia.   Subjects are supine for the duration of the clamp, and therefore discerning 
neuroglycopenic symptoms may be challenging for the subjects. It is possible that symptoms 
are more noticeable to them in the context of activity rather than when they are supine as in 
this study. Our study also had a slow fall in glucose and our lowest nadir was only 
2.5mmol/L (chosen for ethical reasons).   The slowness of the glucose fall and the lack of 
activity, may have implications in accurately determining the neuroglycopenic symptom 
complex experienced by the individual during the studies.   
The order in which tests are done could also influence symptoms.  The glycaemic threshold 
for the symptoms could also as suggested previously(McCrimmon, Deary et al. 2003), be 
influenced by the cognitive tasks undertaken.  In this study, symptoms were assessed using 
the EHS, before assessment of cognitive function. In retrospect, performing the cognitive 
function tests prior to symptom assessment, may elicit greater neuroglycopenic symptoms 
particularly in this group of subjects with IAH, where symptoms are subtle.   
However another study (Suhaimi, Le Compte et al. 2010) looking at symptom generation 
during insulin induced hypoglycaemia suggested a good allocation of symptoms to either 
autonomic or neuroglycopenia symptoms.   In those who had neuroglycopenic symptoms as 
their initial symptoms, the overwhelming initial symptom in 82% of subjects was an inability 
to concentrate.  However the study protocol was different from STUDY 1, in that all subjects 
tested retained good awareness of hypoglycaemia, the method of induction of hypoglycaemia 
was through the insulin infusion technique where the fall of glucose was rapid 
(0.10±0.005mM/min)  and plasma glucose levels were lower (1.3-2.0 mM/L) potentially 
capturing the neuroglycopenic threshold for symptom generation.  A meta-analysis of 9 
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separate studies (McCrimmon, Deary et al. 2003) (all in control subjects and T1 with good 
hypoglycaemia awareness) however showed that the method of induction (insulin infusion vs 
hyperinsulinemic glucose clamp) had a close agreement with reported hypoglycaemia 
symptoms.  In conclusion, it may be that in a cohort of subjects as in our study who in the 
majority had IAH (11/12), that a lower induced glucose nadir and performance of cognitive 
tasks prior to symptom assessments may elaborate greater neuroglycopenic scores, and allow 
greater ability to distinguish between treatments (D v P).  
An interesting further finding in the current study was the effect of Diazoxide on the DSS task. 
This psychomotor task is often used in hypoglycaemia studies and provides a robust and 
sensitive measure of cognition, despite there being no clear agreement on the cognitive 
processes engaged by this task (Peeters, Nicolson et al. 2004). Bingham et al, (Bingham, 
Hopkins et al. 2003) reported that non-diabetic subjects showed a significant prolongation on 
the 4-choice reaction time (4CRT) task during hypoglycaemia following diazoxide, but no 
effect was seen on Stroop and finger tapping tasks. In the present study, we did not see a 
significant effect on 4CRT. However the findings of Bingham et al. (Bingham, Hopkins et al. 
2003) are convincing in that diazoxide and glibenclamide were shown to have the opposite 
effect on 4CRT performance during hypoglycaemia. Overall, therefore, it is likely that KATP 
channel openers may reduce psychomotor speed during hypoglycaemia, and possibly lower the 
threshold for cognitive deterioration. The question is whether this change has clinical 
significance. During hypoglycaemia all neuronal cells will be exposed to low glucose and are 
likely to adapt to this physiological stressor. This is consistent with our findings of a greater 
counterregulatory hormone response and deterioration in cognitive performance (as well as a 
tendency to lower thresholds for change) following diazoxide in long-standing type 1 diabetes. 
In agreement with our findings, long-term avoidance of hypoglycaemia in T1D (Fanelli, 
Epifano et al. 1993) as well as surgical removal of insulinoma to cure chronic hypoglycaemia 
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in non-diabetic subjects (Mitrakou, Fanelli et al. 1993) results in lower thresholds for cognitive, 
symptomatic and hormonal counterregulatory responses to hypoglycaemia while 
experimentally induced chronic hypoglycaemia does the converse (Boyle, Kempers et al. 
1995). In the context of the present study therefore oral diazoxide appears to have widespread 
effects on brain function leading to an overall reversal of hypoglycaemia-induced adaptations 
in brain glucose sensing and psychomotor performance. 
Finally, in this study we make the interesting observation that the presence of the E23K 
polymorphism predicted to a large extent whether an individual would respond to diazoxide 
during hypoglycaemia. The exact prevalence of the E23K polymorphism has previously never 
been studied in the T1D population.  This polymorphism was first identified in a meta-analysis 
study in French Caucasians, which showed that the single nucleotide polymorphisms (SNPs) 
at codon 23 (E23K,rs5219) in Kir 6.2 (which is encoded by the KCNJ11, gene) was associated 
with Type 2 Diabetes (Hani, Boutin et al. 1998) and also with better response to sulphonyureas 
(Javorsky, Klimcakova et al. 2012). The K23 variant of the KATP channel results in a 60% 
increase in the likelihood of the KATP channel being open in the resting phase compared to the 
wild type E23 form, and although this variant is in the pore-forming Kir6.2 channel, it 
demonstrates strong allelic association with a coding variant (A1369S) in the neighbouring 
SUR1 gene thus predicting response to sulfonylureas (Florez, Burtt et al. 2004, Sesti, Laratta 
et al. 2006). In our small cohort of 12 participants with well-established T1D, we found 58% 
carried the K23 variant. This is comparable with the prevalence of 51% (41% hetero- and 10% 
homozygote) for the E23k polymorphism reported in participants with pre-diabetes in the 
Diabetes Prevention Program (Florez, Burtt et al. 2004) and with 63% and 59% respectively 
of type 2 diabetic subjects in the UKPDS and normoglycaemic control subjects (Gloyn, Hashim 
et al. 2001). Although the small size of our study cohort limits the conclusions we can reliably 
draw from this analysis, our data suggest that the E23K polymorphism may identify individuals 
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with T1D both at increased risk of developing IAH and/or requiring a greater dose of diazoxide 
to amplify the counterregulatory response to hypoglycaemia. Future studies will be required to 
address this hypothesis.  
In summary, we have shown for the first time in human subjects, that the KATP channels are 
integral to hypoglycaemia detection and in the generation of an adequate CRR to acute 
hypoglycaemia.  We report that, the KATP channel opener diazoxide, when given orally prior 
to a hypoglycemic stimulus to subjects with long-standing T1D and IAH, results in a 37-44% 
increase in the magnitude of the catecholaminergic counterregulatory hormonal response. 
Moreover, our data suggest more widespread central actions of diazoxide on neuronal 
populations involved in psychomotor responses and symptom generation.  Finally, we have 
made the novel observation that the E23K polymorphism in the Kir6.2 subunit of the K ATP 
channel predicts response to diazoxide therapy during hypoglycaemia in T1D. 
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CHAPTER 4 
 
So our first approach to reducing hypoglycaemia in patients with T1D, was through 
modulation of the glucose sensing apparatus, but a further likely target which has recently 
come to light is that of glucose variability (GV).  GV has been shown to be important in short 
term outcomes,  and has been shown to predict periods of marked glucose excursions 
particularly hypoglycaemia{Cox, 1994 #24946}{Kilpatrick, 2007 #24947}.  Particularly the 
combination of elevated HbA1c and increased GV has been shown to be associated with 
increased frequency and severity of hypoglycaemia, with increased GV shown to precede 
episodes of hypoglycaemia (Kovatchev, Cox et al. 2000). A re-analysis of the DCCT cohort, 
showed that both mean blood glucose (MBG) and GV were able to independently add to 
HbA1c in predicting risk of hypoglycaemia. It was shown that a mean rise of 1mmol/L in 
MBG resulted in a 1.05 reduction in SH, whereas a 1 mmol increase in standard deviation 
(SD), showed a 1.07 increase in risk of hypoglycaemia(Kilpatrick, Rigby et al. 2007).   
GV has also been found to have a relationship with the counter-regulatory responses 
generated during acute insulin induced hypoglycaemia.  In a univariate analysis of 28 
adolescents with T1D, the coefficient of variation (CV), a measure of GV, was shown to be 
negatively correlated with glucagon concentration during insulin induced hypoglycaemia, 
however in the multivariate analysis, only Continuous overall net glycaemic action 
(CONGA), another measure of GV, was shown to be negatively correlated with a glucagon, 
which was independent of other factors such as HbA1c and duration of diabetes.  However, 
other counter-regulatory hormones were not affected (Alghothani and Dungan 2011).  Low 
Blood Glucose index (LBGI), an index which is designed to be sensitive to hypoglycaemia 
alone, also showed that the higher the LBGI (suggestive of increased burden of 
hypoglycaemia), the lower the magnitude of epinephrine responses during induced 
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hypoglycaemia (p=0.009).  GV as assessed through measurement of SD of blood glucose 
(from 70 SMBG readings over 4 weeks) in a separate cohort of T1D patients at baseline 
however was also shown to be a highly significant predictor of hypoglycaemic unawareness 
(p=0.001)(Bragd, Adamson et al. 2008)  
Apart from increased GV possibly resulting in a defective counter-regulation and symptom 
generation during hypoglycaemia, GV has also been shown to induce proinflammatory, 
prothrombotic pathways and induce oxidative stress.  Insulin induced hypoglycaemia clamp 
studies have shown production of adhesion molecules, intracellular adhesion molecules 
(ICAM), vascular cell adhesion molecules (VCAM), E selectin, P-selectin, cytokines, 
interleukin-6, plasminogen activator inhibitor-1 (PAI-1) and vascular endothelial growth 
factors (VEGF) factors 
Therefore our 2nd study (STUDY 2) seeks to determine if an adjunct therapeutic agent could 
be utilised to reduce glycaemic variability and hence reduce the frequency of hypoglycaemia 
thereby improving symptom generation and awareness in those with T1D.  Prior to discussion 
of STUDY 2, following is a discussion on GV, what it is, its importance and how it can be 
reliably measured? 
Glucose variability 
Definition 
 
Glucose variability is defined by the swings in blood glucose.   HbA1c has been the gold 
standard for assessment of glycaemic load, but it includes glucose excursions from 
hypoglycaemia to euglycaemia to fasting and post-prandial hyperglycaemia.  HbA1c 
therefore only marginally represents the full dynamics of glucose regulation, and clearly 
other parameters are needed to assess the role of glycaemic variability in health and disease.   
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Why does it occur in Type 1 Diabetes? 
 
Glucose variations seen in those with T1D are usually a result of the interplay between 
diminished glucose counter-regulation during hypoglycaemia and the shortcomings of current 
available insulin therapy that lead to hyperglycaemia.  The result is that glucose homeostasis 
is profoundly disturbed and the individual with T1D may experience profound shifts in 
prevailing glucose levels throughout the day. This occurs even in the context of optimal 
glycaemic control in well-motivated patients, and can be a source of significant morbidity, 
with patients having to regularly use supplemental insulin and glucose in order to reduce 
these fluxes.  The problem is exaggerated in less motivated patients with recurrent insulin 
omission leading to significant glucose fluxes, with significant rises in glucose, prompting 
large correction doses, often with resultant hypoglycaemia.   
Measuring Glucose variability 
 
There is currently no gold standard measure of glucose variability and most groups actively 
researching in this field use composite measures that provide an index of both the extent 
(essentially standard deviation from the mean) and duration of glucose exposure outside of 
the normal range to gauge the total burden experienced by any one individual. 
So far we see that the majority of studies have used the DCCT cohort (using 7 point SMBG 
readings for calculation of GV) and the remaining studies in CGM have only used small 
timescales of monitoring in order to establish relationship between GV and long term 
outcomes.  Clearly there is a need for establishing the best way of measuring GV- possibly 
through longer periods of monitoring using CGM.   
Most measures of blood glucose variability are primarily dependant on hyperglycaemic blood 
glucose excursions and are generally insensitive to hypoglycaemia due to the asymmetry of 
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the blood glucose scale.  Since the varying measures have inherent properties depending on 
the nature of the problem, different measures cannot be used interchangeably. Although 
measures of GV are closely correlated in non-diabetic subjects (correlation coefficients 
>0.92), this has not been the case in those with T1D(Cameron, Donath et al. 2010). The 
consensus is that measures cannot be clumped together, and rather should be chosen on the 
merits of the index. 
A reanalysis of the ADAG data (Kuenen, Borg et al. 2011), showed that there is a significant 
relationship between mean glucose and HbA1c (r=0.876), which is more pronounced in the 
higher HbA1c levels.  Kuenen et al (Kuenen, Borg et al. 2011) showed that both SD and 
CONGA had a significant relationship with this mean-HbA1c relationship.  However once 
again they also showed that this relationship is poor around the optimal HbA1c range.  
Therefore it may be more pertinent to measure glucose variability in well controlled patients 
(optimal HbA1c) as in this group, it would be difficult to predict GV without some form of 
CGM.  
GV has 2 primary components; the vertical and horizontal. The vertical component relates to 
intra-day variability, corresponding to the within day fluctuations (e.g. SD, MAGE, M value, 
CONGA, ADRR) whereas the horizontal component relates to day to day glucose 
fluctuations (MODD).   
Below is a list of the glucose variability indices that will be measured in STUDY 3.   
 
Measure: This is a within day variability index. 
Advantages: This is easy to calculate 
Disadvantages:  Does not consider amplitude or frequency of fluxes.     
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Standard Deviation  
 
Measure: Measure of dispersion rather than of true glucose variability.  It shows a linear 
relationship to mean glucose with an r of 0.56. (Rodbard 2011)  Hirsch suggests that in T1D, 
SD should be no more than mean/2 (and mean/3 in T2D).   
Advantages: ease of measurement.  SD shows the least change at all measurement intervals.  
SD has been shown to be higher in T1D with microvascular complications, despite no 
differences in average glucose levels (HbA1c) (EASD abstract 2012).  It can be a tool used in 
clinical practice as it can be calculated from seven point glucose curves.  However even a 
seven point curve may miss significant excursions, making this less reliable measurement.  It 
(within day SD) has however been shown in an analysis of the DCCT cohort to be an 
independent predictor for time to first severe hypoglycaemic event (Kilpatrick, Rigby et al. 
2007).   
Disadvantages: No weighting for minor or major variations.  
Glucose profile data has often non-Gaussian distribution, and therefore has a potential for 
widely different glucose curves to have the identical numerical value of SD.  As a result of 
the hypoglycaemia range being narrower than the hyperglycaemia range, it is much skewed, 
and therefore, SD would be very influenced by hyperglycaemia excursions and would not be 
sensitive to hypoglycaemia.   
J index 
 
Measure: 0.324 (MBG + SD) 2 the relationship between SD and the absolute value of the 
arithmetic mean glycaemia or J-index.  Ideal control 10-20. Good control 20-30.  Poor 
control>40 
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Advantages: It removes the need for glycaemic reference points.  Measures both mean level 
and glycaemic variability.   
Disadvantages:  However when first designed, the authors warned that it is invalid for 
glucose readings less than 1.67 or 3 or more consecutive readings less than 2.78mmol/L. So it 
is important when reporting this measure, that authors give info about number of hypo and 
hyperglycaemic episodes (Wojcicki 1995).   
Mean absolute glucose  
 
Measure: Summation of all absolute changes in glucose divided by the time over which 
measurements were taken.  (Hermanides, Vriesendorp et al. 2010) 
Advantages:  2 excursions of same extent but of different duration have different values. 
Strong correlations were found between MAG and SD, MAGE, and CONGA. 
(p<0.001)(Kohnert, Heinke et al. 2013)  
Disadvantages:  Poor correlation between MAG and mean glucose r=0.246 /0.378 
respectively. No real advantage over other measures of GV.  
Mean Amplitude of Glycaemic Excursions (MAGE)  
 
Measure:  It was developed using hourly blood glucose sampling over 48 hours.  The 
arithmetic mean of the glycaemic excursions (amplitudes) greater than a pre-specified 
threshold size (usually 1 SD) for a period of study is the value of MAGE (Service, Molnar et 
al. 1970) 
Advantages:  MAGE is not dependent on the mean glucose value, and only looks at major 
excursions and excludes minor ones (<1SD) 
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Disadvantages: The outcome differs depending on whether ascending or descending limbs 
are used for the calculation of MAGE, with as much as 7% difference.  Only excursions 
greater than 1SD are included, and therefore, exclusion of anything else, may exclude 
clinically relevant excursions.  Due to the asymmetry of the glucose range, MAGE tends to 
have a bias towards hyperglycaemic peaks and is largely insensitive to hypoglycaemic nadirs. 
There are still no normal ranges for people with diabetes.  MAGE becomes very unreliable if 
there glucose measurements are more than 1h apart (due to connection failure)(Baghurst, 
Rodbard et al. 2010).  
Mean of the daily differences (MODD) 
 
Measure:   This is a measure of inter-day glycaemic variability, and measures the mean of 
the absolute differences between glucose values at the same time of the day during different 
days of measurement. 
M value of Schlichtkrull: 1965 
 
Measure:   Mean of the logarithmic transformation of the deviation from a reference value of 
6 blood sugar measurements taken over a 24 h period plus an amplitude correction 
factor.(ACF) (ACF=max – min blood sugar for a 24 hour period divided by 20).  The ideal 
glucose value of 6.6mmol/L was first assigned based on 20 patients with T1D(Schlichtkrull, 
Munck et al. 1965)   However, the ideal glucose value can now be allocated by the individual 
investigator, making comparison of studies challenging.  M value is 0 in healthy controls, 
rising with increasing variability or poorer glycaemic control, so it is difficult to distinguish 
between high variability and high mean glucose.  Hypoglycaemia has a bigger impact on the 
M value than hyperglycaemia.   
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Advantage: More emphasis on Hypoglycaemia than hyperglycaemia.  Hybrid measurement 
of variability and mean glycaemia.  A single M value expresses both mean glucose value and 
the effect of glucose swings.  
Disadvantages:  Inappropriate for CGM use. 
 
Continuous overall net glycaemic action (CONGA-n)  
 
Measure: It is a good measure of rapid glucose variability.  Designed for CGM readings.   
For each glucose point after the first n hours of observations, the difference between current 
glucose and the glucose n hours previous is calculated.  CONGA is expressed as the SD of 
the differences.  Higher CONGA readings indicate greater GV.  
Advantage:  Designed specifically for CGM. It is not affected by the asymmetry of the blood 
glucose range.  It also does not require identification of peak or nadirs according to arbitrary 
definitions. 
Disadvantages:  Full dataset required.  The SD of the differences are not normally 
distributed, and therefore has implications on calculation of the CONGA.   
Low Blood Glucose Index and High Blood Glucose Index 
 
Measure: It involves correction of the skewness of glycaemia (narrow hypoglycaemia vs 
broad hyperglycaemia) through a symmetrisation process around zero. 
(=112.5mg/dL/6.2mmol/L) by expanding the hypoglycaemia range and reducing the 
hyperglycaemia range(Kovatchev, Cox et al. 1997) The JDRF CGM study showed that CGM 
hypoglycaemia>30% of the day was highly correlated with LBGI, AUC and each of these 
increased the probability of SH by 8 fold, but because SH is a rare event, cannot be used as a 
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predictor. (Fiallo-Scharer, Cheng et al. 2011)  However another study showed a history of SH 
and LBGI calculated from the previous month’s SMBG accounted for 40% of variance of SH 
over the following 6 months.  (Kovatchev, Cox et al. 1998) LBGI has been shown to be 
predictive of SH with a modest sensitivity rate of 58-60% among 100 T1D.  (Cox, Gonder-
Frederick et al. 2007) LBGI; 4 categories of LBGI have been reported with regard to risk of 
future hypoglycaemia. Those in the minimal risk experienced no severe hypoglycaemic 
episodes, however those in the high risk experienced on average of 5 severe episodes over the 
following 3 months. (Kovatchev, Cox et al. 2003)   
Advantages: LBGI has been shown to be a powerful predictor of severe hypoglycaemia.  
The accepted ranges are LBGI<1.1; Minimal risk, 1.1<LBGI<2.5; Low risk, 2.5<LBGI<5 
Moderate risk, >5 High risk.   
High Blood Glucose Index. 
Measure: Estimate of the risk and magnitude of hyperglycaemic excursions.  
Advantages: HBGI was found to be correlational to the HbA1c.  The accepted categories 
currently are HBGI<4.5 Low risk; 4.5<HBGI<9 Moderate Risk and >9 High risk  
Disadvantages: LBGI and HBGI do not correlate with their opposite blood glucose ranges.   
Glycaemic risk assessment diabetes equation (GRADE) 
 
Measure: This was designed for both SMBG as well as CGM data.  Each BG value is 
converted to a GRADE value.  The higher the GRADE, higher is the GV. In order to know 
where the major problems lie, the percentage of time spent in hypoglycaemia (GRADE <3.9), 
euglycaemia (3.9<GRADE>7.8) and hyperglycaemia (GRADE>7.8) are also calculated.  So 
percentage gives the reader an estimate of where the majority of the fluxes lie.  It is therefore, 
a measure of risk consequent of GV, rather than a measure of GV. 
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Advantages: Can be used for CGM.  Independent of observer bias and being able to deal 
with asymmetric profiles.   
Average Daily Risk Range  
 
Measure: It was initially used for SMBG readings (at least 3-5 readings/day) for 30 days, but 
increasingly is also used in CGM profiles.  The dataset (39T1D, 31T2D) used for the 
development of this ADDR, showed that ADDR was correlated to future extreme 
hypoglycaemia (<2.2) and extreme hyperglycaemia (>22.2) by 0.40 and 0.53 respectively and 
the correlation between ADDR and mild hypo (<3.9) and mild hyper (>10) were 0.41 and 
0.63(Kovatchev, Otto et al. 2006).    Its values have been stratified into three categories; low 
risk ADRR<20; Moderate risk ADDR 20-40; High risk ADDR>40 
Advantages:   Unlike the other measures, which focus more on the either hypoglycaemia or 
hyperglycaemia, the ADRR, is designed to equally sensitive to hypoglycaemia and 
hyperglycaemia.  It has been found to be a good predictor for glucose fluctuations as well as 
higher frequency and severity of events.  It has been shown to be the best predictor for both 
extremes of the glucose range, with a 6 fold increase and 3.5 fold increase in the likelihood of 
hypoglycaemia and hyperglycaemia respectively across the risk categories. Risk scores are 
used for calculation rather than actual blood glucose values, and therefore glucose range is 
given less weight.   
Disadvantages: No formal assessment with CGM.   
The above measures were chosen in STUDY 3, because they included methods that relate to 
SD (Mean, SD, J index, MAG), methods which relate to glucose excursions (MAGE, 
GRADE) methods relating  to day to day variability (MODD-mean of daily differences)) and 
methods that look at short term variability over hours (CONGA-Continuous overall net 
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glycaemic action and M value). We also looked at measures which calculated the burden of 
hypoglycaemia and hyperglycaemia (LBGI and HBGI) and a combination of them both 
(ADRR).   
So far the literature does not suggest a universal measure of GV, making comparison of 
studies challenging.  So currently,  measures need to be chosen on their own merit, and 
according to the particular component of variability that is of interest to the researcher, and 
answers a relevant question.  
 
Technicalities of measuring GV 
 
It is important to collect data which is able to give reliable and consistent measures of GV.  It 
has been shown that as the interval between observations increase, so does the variability of 
GV indices(Baghurst, Rodbard et al. 2010).  SD appears to be the most hardy of all the 
measurement intervals, however if the time interval is greater than 2 hours apart, both SD and 
CONGA4 becomes unreliable, with MAGE exhibiting the highest systematic change 
(unreliable if readings >1 hr apart).  Most of the current CGM devices available on the 
market, give 5 minute readings, so the above is only a consideration, if there is gap in the 
CGM trace/incorrect calibration/temporary disconnection of sensor).   
Subjects invariably change behaviour when attached to a CGM monitor, and optimal duration 
of measurement is still under debate.  Conclusions regarding long term complications have 
been made on monitoring periods as short as 72 hours in several studies (Sartore, Chilelli et 
al. 2013).  This assumes this period of monitoring is reflective of their usual glycaemic 
control.  However, unless there is some standardisation of both diet and exercise, any changes 
from the norm of these, can result in abnormal glucose variations being captured in the period 
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of monitoring and influence measures of GV significantly.  A recent study in a paediatric 
cohort (20pts) compared varying number of days (2-30) days of CGM data with the gold 
standard 90 day measurement of GV. There were significant gaps in the CGM trace (mean 
446.2±239 hours per 90day period, so only SD and CV could be used for reporting. Naturally 
as CGM duration increased, there was a reduction in %error from the 90 day value, but 
reached a median value of <10% error at 12 days. However in a study in adults, 6 days was 
thought to be sufficient to assess GV using MAGE.  This shorter time period maybe because 
of increased stability of the glucose profile in adults(bugler 2008).   
Associations between GV indices 
 
A study was done in Japan (20 T1D, 68 T2D), with CGM looking at the association between 
different measures of GV{Saisho, 2015 #24945}.  Strong correlations were found between 
SD and MAGE, CONGA-1, MODD and M value (all r>0.8, p<0.05).  Mean glucose was 
correlated with J index and M value (r>0.8, p<0.05).  SD was more strongly correlated with 
hypoglycaemia than was mean glucose, with a combination of Mean and SD increasing the 
predictive value of hypoglycaemia.  
Is it important? 
 
There is much debate as to whether glycaemic variations in those with T1D are clinically 
pertinent.  It was shown recently, that despite patients having an identical HbA1c in the 
conventional and intensive arms of the DCCT, the former group had an accelerated risk of 
progression of retinopathy over time.  This difference was initially attributed to markedly 
higher glucose variability in those on conventional treatment compared to those on intensive 
insulin therapy.(Brownlee and Hirsch 2006). Other factors which have thought to be 
contributory include fasting glucose levels, post-prandial hyperglycaemia(Ceriello 2005) and 
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longer term variability (HbA1c variability-HR 2.26 for every 1% increase in A1c SD, 
p<0.0001)(Kilpatrick, Rigby et al. 2008).  Indeed the ADAG study, an international 
multicentre study, showed there is a wide range of average blood glucose readings associated 
with a particular HbA1c(Nathan, Kuenen et al. 2008).   This was confirmed by the Juvenile 
Diabetes Continuous Glucose Monitor Study(Wilson, Xing et al. 2011)  which once again 
showed wide mean sensor glucose concentrations for a calculated HbA1c.   
However, debate as to the significance of these fluctuations continued as reanalysis by the 
DCCT/EDIC cohort showed that after adjusting for retinopathy at baseline and adjusting for 
updated HbA1c as a time dependant covariate, it was found that HbA1c indeed accounted for 
96.2% of all the treatment effect.  (Lachin, Genuth et al. 2008).   
A further DCCT re-analysis by Kilpatrick et al, (Kilpatrick, Rigby et al. 2008) showed using 
multivariate Cox regression analysis that HbA1c variability itself, adds to the risk score of 
development of microvascular complications.  They found that for every 1% increase in 
HbA1c standard deviation, the risk of retinopathy increases by 54% (95%CI 1.07-2.32 
p=0.02) and for nephropathy 42% (95% CI 1.00-2.00 p=0.05) suggesting that more long term 
variability is more harmful that short term variability.  This relationship continued to exist on 
follow up, when the EDIC data (after 4 years follow up), showed that both mean A1c and 
mean glucose were highly predictive of retinopathy (p<0.001), with mean A1c being also 
predictive of nephropathy.  However as hinted by the original DCCT, EDIC also showed that 
GV (assessed with standard deviation (SD) and mean amplitude of glycaemic excursions 
(MAGE) did not predict the development of  diabetes related microvascular 
complications(Kilpatrick, Rigby et al. 2009).   
The underlying idea for considering glucose variability is that it, similar to hyperglycaemia,  
may be associated with mortality by increasing oxidative stress, neuronal damage, 
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mitochondrial damage, and coagulation activity(Brownlee 2005, Monnier, Mas et al. 2006, 
Egi and Bellomo 2009).  It is well established that hyperglycaemia leads to end organ 
damage, through accumulation of non-metabolizable sugars.  This is through several 
mechanisms such as polyol pathway particularly used in those tissues which are non-insulin 
requiring (nerves, lens), whereby glucose enters, and is converted to non-metabolised sugars 
such as fructose and sorbitol, causing both osmotic changes and depletion of key cellular 
components such NADPH.  Furthermore there is also glycation of proteins such as collagen 
resulting in tissue and organ damage, formation of advanced glycosylated end products 
(AGEs), which can be a trigger to multiple cytokine pathways, which eventually lead to 
activation of protein kinase C, mitogen activated protein kinase (MAPK) and nuclear factor 
kappa B, which ultimately lead to oxidative stress.     
However, rapid fluctuations of blood glucose is thought to produce even more oxidative 
stress and be more detrimental to vascular endothelium that sustained 
hyperglycaemia(Monnier, Mas et al. 2006, Giacco and Brownlee 2010) More recently, a 
number of studies in rodent models, albeit in different organ systems, have suggested that this 
effect is exacerbated in those animals exposed to hypoglycaemia. For instance, glucose re-
perfusion following a period of hypoglycaemia was shown to stimulate superoxide 
production and induce neuronal death (Quagliaro, Piconi et al. 2003).  Interestingly, the 
extent of superoxide production was found to be directly proportional to the final glucose 
concentrations achieved during reperfusion.  
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Preclinical studies 
 
Studies in different cell lines have shown that mesangial and tubulo-interstitial cells  when 
exposed to intermittent high glucose concentrations showed an increase in matrix production 
whereas in pancreatic β cells(Shi, Ren et al. 2011) and endothelial cells(Risso, Mercuri et al. 
2001), increased apoptosis was noted.  These changes were markedly greater than placing the 
cells in high glucose continuously(Ceriello and Ihnat 2010).     
In vitro and vivo studies(El-Osta, Brasacchio et al. 2008) show that intermittent spikes of 
hyperglycaemia (6-16 hours) can cause epigenetic changes in the promotor region of the 
NFKappa B of aortic endothelial cells and consequently cause increase in p65 gene 
expression.  This increases expression of the pro-inflammatory proteins monocyte 
chemotactic protein-1, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
molecule-1(ICAM-1), interleukin-6 and inducible nitric oxide synthetase.  The duration of 
these spikes are typically not thought to affect average HbA1c and so would not be accounted 
for by the crude measurement.   
In vivo and rodent models have shown that both hyperglycaemia and glucose fluxes are 
damaging to cells through the process of oxidative stress. It has been proposed that during 
these short term swings in glucose, cells are unable to up-regulate their anti-oxidant potential 
sufficiently to prevent development of diabetes related complications.   Particularly, it has 
been shown that there is an exaggeration of cell damage during hyperglycaemia following 
hypoglycaemia (similar to reperfusion injury), than there is, during prolonged 
hyperglycaemia.  This has been shown to occur  predominantly because of the reperfusion 
injury caused by increased NADPH oxidase which is exaggerated if blood sugars are left to 
rise into the hyperglycaemic range.(Cryer 2007).   
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Effect of GV on the vasculature 
 
Although the in-vitro and vivo studies convincingly show that glycaemic variability causes 
much oxidative stress, the results in patients with T1 have been less convincing. Wentholt et 
al, showed that glucose fluctuations (MODD, MAGE, CONGA-n) assessed during CGM 
(over 3 days), bore no relationship with oxidative stress (measured by urinary excretion of 
15(S)-8-iso-PGF2α.) , although patients with T1 had higher levels of oxidative stress than 
control subjects(Wentholt, Kulik et al. 2008).   
This lack of relationship of GV and oxidative stress seen in those with T1, may be explained 
by the anti-oxidant property of insulin (Monnier, Colette et al. 2010).  Insulin when added to 
vascular smooth muscle cells was shown to inhibit activation of NF-ĸB, which is known to be 
a pro-inflammatory transcription factor activated by glucose.   This was seen when there was 
increased activation of oxidative stress in non-insulin treated T2D patients compared with T2 
patients on insulin and T1D patients.   
However, Ceriello et al, have performed numerous clamp studies on controls and patients 
with T1D, which has convincingly shown that fluxes in glucose (particularly hyperglycaemia 
following hypoglycaemia) can be deleterious to several parameters affecting the endothelium, 
(significant worsening of FMD –marker of endothelial dysfunction, and sICAM-1, IL6 –
markers of inflammation(Ceriello, Novials et al. 2012) (significant increases in vWF, 
thrombin-antithrombin III complexes, P selectin, plasminogen activator inhibitor 1, 
nitrotyrosine and 8 iso-prostaglandin F2α – markers of thrombosis activation and oxidative 
stress)(Ceriello, Novials et al. 2014).  The increase in these factors however, were partially 
suppressed when vitamin C was co-infused.  Thus, in the post-hypoglycaemic state, 
reperfusion of cells with super physiological levels of glucose, a situation that is very 
commonly seen in clinical practice, may evoke a more marked oxidative stress response.  
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Taken together, these studies suggest that increased glucose variability with recurrent 
exposure to hypoglycaemia may induce a pro-inflammatory state that exacerbates endothelial 
dysfunction in T1D over and above that seen with chronic hyperglycaemia alone.    
The relationship appears stronger between GV and cardiovascular outcomes.  A study in 
those with T1D examined a group using RT-CGM and blinded CGM, showed that overall 
standard deviation (all glucose values) and standard deviation of the mean glucose of each 
day, showed that these measures of GV (over 3-5 days) were significantly correlated with 
coronary artery calcification (CAC).  This relationship was only present in men. It is known 
that healthy men have a higher degree of oxidative stress compared to pre-menopausal 
women. The combination of this background level and increased GV, may then explain this 
association which was only found in men(Ide, Tsutsui et al. 2002).   No association was 
found between HbA1c and CAC(Snell-Bergeon, Roman et al. 2010).  Similarly a 
retrospective analysis(Kilpatrick, Rigby et al. 2008) of the DCCT/EDIC dataset showed a 
stronger association between 7 point SMBG (mean blood glucose calculated) and 
cardiovascular outcomes than with HbA1c.   
However with the increased use of continuous glucose monitoring (CGM) systems, studies 
can now utilise this technology prospectively to investigate the relationship between short 
term glucose variability and adverse outcomes, and overcome some of the difficulties with 
SMBG.    
Effect of GV on Diabetes related complications 
 
Studies have shown that those with T1D have much higher levels of GV and 24-hour urinary 
urine 8-iso Prostaglandin F2 alpha (PGF2),a marker of oxidative stress, compared to those 
with T2D and non-diabetic subjects(Wentholt, Kulik et al. 2008) and those with 
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complications have been shown to have a further worsening in their GV(Soupal, Skrha et al. 
2014). 
Both the DCCT (1993) and the UKPDS (Stratton, Adler et al. 2000) have shown good 
correlation between protein glycosylation and risk of diabetes related complications.  It has 
therefore been seen as the main driving force for development of complications.  Although 
there is inconclusive evidence as to whether GV is related to long term outcomes, particularly 
after the reanalysis of the DCCT data which showed GV was not related to microvascular 
complication(Kilpatrick, Rigby et al. 2009).   
A recent systematic review(Nalysnyk, Hernandez-Medina et al. 2010) examined the link 
between GV and diabetes related complications.  Studies in T1D (8 studies) showed that GV 
had little impact on development of diabetes complications. Only 2/8 showed any association 
between GV and microvascular complications (not macro). This showed that the majority of 
studies regarding microvascular complications, were from the DCCT/EDIC database (5 out 
of 8 studies).  The main limitation using this database was the form of assessment of GV.  
GV in the DCCT cohort was measured by 7 point SMBG- which were pre and post-prandial 
laboratory measurements over the wakening period on one day, every 3 months throughout 
the trial(Rohlfing, Wiedmeyer et al. 2002).  This did not take into account nocturnal readings, 
and therefore could have missed important glucose fluctuations.  Currently there is only one 
study looking at CGM data and microvascular complications.  This study combined both 
patients with T1D and T2D, probably to increase statistical power, and once again showed no 
significant relationship in multivariate analysis between GV (measured by SD, MAGE, and 
CONGA-2) and diabetic retinopathy. Combining T1 and T2 may not be very informative, as 
studies looking at solely at patients with T2D, suggest an opposite effect to those in T1D, 
with GV (particularly in fasting plasma glucose) having a greater impact on microvascular 
complications in those with T2D(Smith-Palmer, Brandle et al. 2014).  GV was shown to 
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increase urinary markers of oxidative stress in patients with T2D (Monnier, Mas et al. 2006), 
and it is thought that the rise in reactive oxygen species (ROS) contributes to the 
development of complications.  Monnier et al(Monnier, Colette et al. 2012), proposed that 
GV may have a differing effect in T1D and T2D, because exogenous insulin has been shown 
to have an inhibitory effect on the activation of oxidative stress pathways, and thereby may 
potentially blunt the effect of glucose fluxes on the vasculature.   
A recent study utilising CGM (5 day) in patients with T1D, showed that LBGI- an index of 
GV reflecting hypoglycaemic stress was associated with reduced low frequency (LF) and 
high frequency (HF) heart rate variability, which can indicate impaired autonomic function.  
HbA1c did not however correlate to these measures(Jaiswal, McKeon et al. 2014).  This was 
a stark contrast to the findings from the reanalysis of the DCCT cohort, which utilised 7 
SMBG readings, and found no correlation between GV and autonomic function.   
Effect of GV/recurrent hypoglycaemia on the Hypothalamo-pituitary-adrenal axis 
(HPA) 
 
Hypoglycaemia presents a profound stimulation to the HPA axis and stimulates a rise in 
peripheral glucocorticoid, while repeated hypoglycaemia may eventually lead to a 
dysregulation of this response.  GV through its strong association to recurrent hypoglycaemia 
could potentially also cause dysregulation of the HPA system.   This represents a form of 
‘stress habituation’, which could potentially lead to blunting of cortisol diurnal variation 
(Heim, Ehlert et al. 2000). In the Whitehall II study, blunting of the diurnal cortisol curve was 
linked to increased risk of all-cause mortality (Kumari, Shipley et al. 2011).   Diurnal cortisol 
decline has also been related to increased coronary calcification in the CARDIA study. 
(Matthews, Schwartz et al. 2006). Thus, we hypothesized that increased glucose variability 
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and repeated hypoglycaemia may, independently from chronic hyperglycaemia, contribute to 
cardiovascular disease (CVD) mortality in TIDM through dysregulation of the HPA axis,.     
If there is indeed blunting of the cortisol decline, this would be in parallel to an increase in 
cortisol AUC.  It is well recognised that pathological hypercortisolaemia seen for instance in 
conditions like  Cushing’s syndrome can result in glucose intolerance, insulin resistance and 
other cardiovascular risk factors such as hypertension and hyperlipidaemia.  However, even 
within the physiological range, variations of cortisol may also contribute to the development 
of these risk factors.  Hypercortisolism, hypocortisolism, and a blunted diurnal cortisol slope 
have all been associated with adverse measures of mental and physical health.  (Champaneri, 
Wand et al. 2010).  Kirschbaum and colleagues have suggested that the HPA axis can be 
useful marker for the consequences likely to occur as a result of prolonged exposure to 
stress(Kirschbaum and Hellhammer 1999).   
Role of Glucocorticoids (GC)  
 
GC has regulatory functions involving metabolism whereby, it stimulates gluconeogenesis in 
the liver(Jitrapakdee 2012) and controls deposition and breakdown of lipids. Cortisol (the 
main GC present in humans) has been implicated in the rise in insulin resistance seen in the 
early hours of the morning, associated with a peak in its level.    It regulates several immune 
and inflammatory responses  (Munck and Naray-Fejes-Toth 1992).  Cortisol has a range of 
effects including blood pressure elevation and modulation of cell growth.  It has a multitude 
of central effects such as changes in mood and behaviour, it affects food intake, body 
temperature and nociception. (Chrousos and Kino 2007) and plays a role in memory 
formation. (Trollope, Gutierrez-Mecinas et al. 2012) Cortisol also has a sleep regulatory 
function, with a study(Born, Spath-Schwalbe et al. 1989) suggesting that rises in cortisol 
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decreased the time spent in Rapid Eye Movement (REM) sleep but increased the time spent 
in Slow Wave Sleep (SWS). 
Normal cortisol patterns 
 
There is a distinct pattern of cortisol secretion resulting in a circadian rhythm, reaching a 
nadir around 3am to reach a peak around 9am, and then falling throughout the day. (Krieger, 
Allen et al. 1971). In humans, this prominent circadian rhythm (Stratakis and Chrousos 1995) 
is seen in both plasma cortisol and corticosterone concentration with an approximate 13:1 
ratio maintained throughout the 24 hour day.  This circadian rhythm (also involving ACTH) 
also reflects an underlying ultradian rhythm(Veldhuis, Iranmanesh et al. 1989) (Henley, 
Leendertz et al. 2009).  The ultradian pattern was discovered in one of the earliest 
studies(Veldhuis, Iranmanesh et al. 1989) whereby blood samples were taken at 10 minute 
intervals over a 24 hour period in 6 healthy men and showed randomly occurring cortisol 
bursts at a mean frequency of 19±0.82 events per day (interpulse interval 77± 4 mins). The 
burst frequency and amplitude varied 2.2 and 6.6 fold respectively over the 24 hour period.   
Burst amplitude rather than the burst frequency is thought to influence the circadian 
rhythm(Liu, Kazer et al. 1987), as these rapid fluctuations have been shown to affect the 
responsiveness of the glucocorticoid responsive genes(Lightman, Wiles et al. 2008). 
The levels of GC are higher during the activity period in most mammals with the highest 
levels in the 2nd part of the night with peak levels at the start of the activity period (morning 
for humans). Following this, there is a decline in cortisol levels with the lowest levels in the 
first part of the night.  Many investigators have suggested that the “crispness” of the cortisol 
response is of vital importance i.e. a good sharp rise in the morning, followed by an elegant 
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decline, for good health.  This pattern has been repeatedly been shown to be associated with a 
healthy population. 
Overlying this basal rhythm, the HPA axis is also responsive to several stressors including 
hypoglycaemia, and reaches a peak at 15-30 mins after HPA activation, returning back to 
basal levels within 60-90 minutes (de Kloet, Joels et al. 2005), and plays a key role in the 
body’s adaptive responses to various types of stress.  
Components of the normal diurnal pattern 
Morning rise- Cortisol Awakening Response (CAR) 
 
In addition to the normal diurnal pattern of cortisol secretion, there is an additional burst of 
cortisol (rise of 50-100%) release within the first 30-60 minutes following wakening, which 
is known as the cortisol awakening response (CAR).  Wakening is a potent stimulus of the 
HPA axis, and the rise in cortisol seen is thought to be a marker of stress 
reactivity/adrenocortical activity. In particular the increased level of glucocorticoids in the 
morning prepare the body for the impeding day, and by increasing energy levels, are able to 
enable foraging behaviours.   
It has been shown to be more in tune with our natural sleep/wake cycle and superimposes the 
underlying increase in cortisol seen in the early morning hours as a result of the activation of 
the HPA axis.  (Wilhelm, Born et al. 2007).  It usually peaks at about 30 mins after waking 
and can remain elevated for up to 60mins. CAR is thought to be crucial in attainment of full 
alertness through possible activation of the prefrontal cortex.   
It has recently come to light that regulation of CAR is under neural control.  The SCN 
appears to provide direct neural stimulation of the adrenal zona fasciculata (innervated by 
sympathetic neurons) which increases its sensitivity to ACTH from the pituitary, and 
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enhances cortisol secretion in the immediate wakening period(Clow, Hucklebridge et al. 
2010).   
Furthermore, hippocampal volume has been positively associated with magnitude of CAR, 
with those with either lesions or those with retrograde amnesia, showing no CAR 
response(Fries, Dettenborn et al. 2009).  However, the role of the hippocampus on the HPA 
axis is still debated.  The high concentration of gluco- and mineralocorticoid receptors on the 
hippocampus suggests a crucial role. Some studies suggest a role in the negative feedback 
regulation of the HPA axis, whereas others provide evidence for a stimulatory role on the 
axis(Fries, Dettenborn et al. 2009).    
If done with strict adherence to the sampling protocol (measurements done within the first 
30-60mins after wakening), then CAR has been shown to have a relatively good intra-
individual stability across days and weeks (Pruessner, Wolf et al. 1997, Wust, Wolf et al. 
2000).   However Kudielka et al, showed that flattening of the CAR was in certain individuals 
associated with non-compliance when they were electronically monitored. (Kudielka, 
Broderick et al. 2003). It has also been estimated that about 15% of individuals will not have 
a cortisol rise.(Dockray, Bhattacharyya et al. 2008).  The CAR is often assessed by self-
collection of salivary collections usually in a domestic setting.  Several samples need to be 
obtained within the first 60 minutes after wakening.  The mode of wakening (with or without 
an alarm clock) has not been shown to impact on the CAR(Wust, Wolf et al. 2000).   
Literature suggests that there is a certain heritability of morning cortisol levels (Kupper, de 
Geus et al. 2005, Steptoe, van Jaarsveld et al. 2009).   A recent study has indicated that a 
novel GLP-1 variant (rs1042044) is associated with HPA axis function, with children 
homozygous for the phenylalanine allele showing significantly higher salivary cortisol levels 
cf leucine homozygosity(Sheikh, Dougherty et al. 2010).   
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CAR has been shown to be independent of time of awakening, total time slept and sleep 
quality(Wust, Wolf et al. 2000). In four independent studies involving 509 adult subjects, it 
has been shown that neither age, use of oral contraceptive pills, habitual smoking, wakening 
time (when it was in the normal range), total time slept had any impact on the CAR(Wust, 
Wolf et al. 2000). However if subjects got up out with of the normal range, (between 4 and 
5am or between 11.30 and 2.30), then it has been shown to cause either an enhanced or 
diminished CAR response respectively(Wust, Wolf et al. 2000). The magnitude of rise has 
been shown to be influenced by gender (females have a larger CAR)(Wust, Wolf et al. 2000) 
and age (increasing age associated with lower CAR) pain-(attenuated elevation-lower CAR) 
(Geiss, Varadi et al. 1997) and chronic stress-(lower CAR). Disturbances are thought to relate 
to changes in the HPA axis, and may serve as an indicator of allostatic load (cumulative 
minor stresses over a period of time).    
The significance of CAR is still highly debated, despite many published studies on the 
function of this rapid rise in cortisol after wakening.  However, there are a few findings that 
have been repeated in different studies.  It appears that CAR is only mounted when the 
individual gets out of bed and starts on their daily routine.  There appears to be no CAR 
response at other wakening periods (waking up in the middle of night to go back to sleep, 
after a short nap –up to 2 hours).  CAR appears to be increased in subjects with increased 
anticipated demands on their time after wakening, with increased CAR on work days 
compared to non-work days.  It is also more influenced by upcoming demands on the day, 
rather than chronic stress over a period of time.  These observations therefore suggest that 
CAR is highly associated with anticipation of upcoming demands, rather than allostatic load.   
The association between physical health outcomes and CAR have been inconsistent, with 
difficulties in salivary sampling and the inability to control external factors such as upcoming 
stress making analysis challenging.  CAR has also recently been found to be associated with 
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executive functioning.  A recent paper in the healthy old, showed that there was a strong 
relationship between CAR profiles and measures of Trail making test performance (which is 
a frontal lobe dependant domain).  The study in 50 participants showed that those who had 
better executive functioning had an earlier peak and greater magnitude of the CAR (Evans, 
Hucklebridge et al. 2012).  A study in Netherlands showed that an absent CAR was 
associated with increased cardiovascular event rate (Vreeburg, Kruijtzer et al. 2009).  To look 
at in greater detail, various measurements can be calculated 
.Table 5 CAR has been measured in a variety of ways in published studies 
Measure of CAR  Description 
AUC(i)(Pruessner, 
Kirschbaum et al. 2003) 
Area under the curve with 
respect to the increase 
Measure of the dynamic of 
the CAR 
 
AUC (g)(Pruessner, 
Kirschbaum et al. 2003) 
Area under the curve with 
respect to the ground. 
Total cortisol in the 1st hour 
of wakening 
 
Mean increase 
(Wust, Wolf et al. 2000) 
 Subtracting the baseline 
from the mean of the other 
values in the first hour 
(F0.5+F0.75)/2 –F0 
Slope 
 
In healthy individuals, HPA axis has a diurnal rhythm with peak cortisol levels usually after 
30 minutes on wakening, and then declining cortisol levels over the day, with the lowest level 
around 3am. A pronounced decline over the day is evident in many studies in healthy 
individuals, whereas a more gradual decline, may indicate continued HPA over-stimulation.  
A flatter slope can represent a long term response to chronic stress. This can be seen in non-
pathological high stress situations seen in those with marital problems, unemployed 
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individuals, women undergoing separation anxiety.  (Grossi, Perski et al. 2001, Powell, 
Lovallo et al. 2002, Barnett, Steptoe et al. 2005) This pattern has also been seen in many 
different disease cohorts (poor maternal relations, post-traumatic stress disorder, poor 
prognosis in breast cancer patients, poor declarative memory and in those with increased 
perceived stress (Evans, Fredhoi et al. 2011).  The Whitehall II study was the first large 
prospective cohort study (n=4047) to show flatter slopes were associated with increased all-
cause mortality (1SD reduction in slope HR 1.30 (1.09-1.55), and this was mostly attributed 
to cardiovascular deaths (HR 1.87 (1.32-2.64) (Kumari, Shipley et al. 2011).  A flattened 
diurnal rhythm has also been shown to be linked with the metabolic syndrome (Rosemond, 
Dalman et al. 1998).   
Often the slope is calculated using both a morning sample and the last sample (either before 
bed or 12 hours after wakening). There is currently no consensus, as to which morning 
sample to use, as there is a sharp rise in cortisol in the first hour after wakening, and so 
method of analysis can significantly affect the results.  However this may be more of a 
problem when comparing different studies.  So currently, as long as the method is consistent 
within a study, then comparisons may be made between groups.  Investigators have used the 
wakening sample, the peak CAR (or 45 min sample) or 3 hours following wakening sample 
for use as the first sample.  The last sample has been either the sample before bed or the 12 
hour wakening sample.  It has been established that CAR (0-45 minute samples-awakening 
samples) and diurnal (45 mins to 12 hours) patterns are under different regulatory inputs, 
with poor correlation between these 2 measures(Edwards, Clow et al. 2001).     
Since the fastest decline is usually in the first few hours.  We calculated the slope in this 
study using 2 different methods, exploring different sections of the curve.   
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A. We considered both the 45 minute sample (last wakening sample) and the 3 hour sample 
to calculate the initial downward slope.    
B. We also considered the rest of the day samples, and calculated the slope by utilising the 45 
minute sample and 12 hours sample.   
The last sample can either be 12 hours or prior to sleep.  We used 12 hours after awakening.  
This can be calculated by subtracting the value at last sample from the sample at awakening, 
and dividing it by the number of hours in between the 2 samples.  (Bhattacharyya, Molloy et 
al. 2008).  Other investigators have suggested that the slope can be calculated by subtracting 
the value at last sample from the peak sample, and once again dividing it by the hours in 
between the 2 samples.   
Area under the curve (AUC) – cortisol  
 
AUC gives a measure of cortisol exposure during the day.  As the early rise and slope are 
under different regulatory controls, investigators suggest that an AUC is calculated for the 
first 45mins and then for the remaining day.  AUC has been shown to be linked with almost 
all psychosocial measures (such as anxiety, hostility and calmness). Significant 
hypercortisolaemia (Cushing’s and exogenous steroids) and more subtle elevated cortisol has 
been shown to be linked to cognitive dysfunction.  The excess cortisol has been shown to 
cause widespread effects within the central nervous system.  One of the most vulnerable areas 
is the hippocampus (an area which is important in cognitive function) with its high expression 
of glucocorticoid receptors(McEwen and Magarinos 1997).  It is thought that glucocorticoids 
inhibit the long term synaptic potentiation (important in memory and learning) (Stranahan, 
Arumugam et al. 2008). The literature in animals also shows that the baroreflex activity can 
be altered by circulating corticosterone concentrations (Darlington, Kaship et al. 1989).  
There has been a suggestion that increased cortisol may contribute to an increased sympatho-
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adrenal tone. This is shown in patients with T2D, where there is evidence of hyper-
cortisolaemia where counter-regulation are initiated at normoglycaemic thresholds, indicating 
an elevated sympathetic neural outflow (Spyer, Hattersley et al. 2000).   
Chronic elevation of endogenous glucocorticoids can result in continuous transcription, 
abnormal mRNA and protein levels.  This pattern is seen in many stressful situations such as 
those with high work stress, lower income and a negative affect.  (Steptoe, Kunz-Ebrecht et 
al. 2003, Ritvanen, Louhevaara et al. 2006).  One study showed a significantly (p=0.035) 
higher AUC in adult men who had experienced childhood parental loss (Nicolson 2004).  
However evidence of a link to concrete physical outcomes is still sparse.  
Factors that may affect diurnal patterns 
 
Age 
 
It has been shown that age affects the basal patterns of cortisol release particularly between 
2000 and 0130.    This is associated with a flattening of the diurnal amplitude, but not the 
overall pulsatility of the system.  (Deuschle, Gotthardt et al. 1997).  It is not surprising that 
more recently, advancing age has also been associated with higher level of cortisol 
secretion(Wrosch, Miller et al. 2008) with an increased cortisol response to challenge(Otte, 
Hart et al. 2005).  However a recent study showed that these higher levels of cortisol were 
only detrimental to functional abilities, if there was poor use of control strategies (emotional 
well-being and good sleeping  patterns)(Wrosch, Miller et al. 2009), this finding may account 
for some of the conflicting data previously about HPA activation and well-being in the older 
population.  The increased exposure to cortisol is likely to lead to accumulation of visceral 
fat, bone softening and inflammatory dysregulation, and thereby affect a person’s ADLs.     
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Sex 
 
A large non-selected cohort of people (n=1811) in Sweden were examined for differences in 
cortisol production.  Both morning and mean cortisol were significantly elevated in women 
compared to men(Larsson, Gullberg et al. 2009), whereas males have been shown to have a 
flatter CAR but a steeper decline in slope(Vreeburg, Kruijtzer et al. 2009).  
Smoking 
 
Nicotine binds to the cholinergic receptors in the locus coeruleus and hypothalamus, and 
activates CRH release and therefore is a potent stimulator of the HPA axis.  (Rosecrans and 
Karin 1998) 
Oestrogen 
 
In the context of high oestrogen levels (in those using oestrogen containing contraceptives or 
in pregnancy women), cortisol released from the adrenal cortex, is more readily bound to the 
increased levels of cortisol binding globulins, and therefore there is lower concentration of 
free cortisol which is then measured in the saliva but a higher concentration of total cortisol.    
It was also found that the peak in cortisol levels was found to be later in the day, suggesting a 
delay in activation of the HPA axis in the morning.  (Meulenberg and Hofman 1990).  
Obesity 
 
Studies have shown that those with marked abdominal obesity have a flattened diurnal curve 
of cortisol secretion.(Putignano, Dubini et al. 2001). Furthermore, the recent Multi-Ethnic 
Study of Atherosclerosis showed that increasing BMI was positively correlated with an early 
decline slope (30mins to 2 hours post wakening), despite adjustment for age, race, gender, 
diabetes status, social status, confounding drugs and smoking status(Champaneri, Xu et al. 
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2013). In contrast, those with anorexia nervosa have been found to have an overdrive of their 
HPA axis (Licinio, Wong et al. 1996).   
Exercise 
 
The effect of physical activity on basal levels is not known, however there is a clear link of 
the stimulatory effect of exercise on the cortisol levels, with it being less pronounced in 
trained as opposed to untrained individuals. (Luger, Deuster et al. 1987, Kirschbaum and 
Hellhammer 1994) A recent study in Netherlands showed increased activity was associated 
with increased CAR and a steeper decline in the slope (Vreeburg, Kruijtzer et al. 2009).  
Sleep deprivation 
 
It has been shown to cause a pronounced response to breakfast, and is associated with greater 
AUC with flattening of the slope.  This has been shown to be related to higher evening 
cortisol(Alexander 2003).  
Abnormal patterns 
 
A large study- the Whitehall II study looked at 2802 middle aged men and women, and 
identified two patterns of abnormal diurnal cortisol secretion.  They were described as 
“normative (prevalence 73%)” and “raised (prevalence 27%)”.  Raised curves were notably 
different from the normative curve with a lower cortisol awakening response and a “flatter” 
pattern of release.  This “raised” pattern was associated with increasing age, the male sex, 
smoking, and stress on the day, slower walking speed and shorter sleep duration.  This pattern 
was also seen to be associated with adverse health behaviours and poor physical 
functioning(Kumari, Badrick et al. 2010). 
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Patterns of abnormal regulation of the HPA axis has been shown in many cohort studies as 
detailed below.  
 
Healthy cohort  Pattern Association 
97 healthy older men (age 
65-70) (MacLullich, Deary 
et al. 2005) 
Higher 9am cortisol Worse age related overall 
cognitive change, not age 
related brain atrophy 
4047 non-clinical cohort  
(Whitehall II study) 
(Kumari, Shipley et al. 2011) 
Flatter diurnal slope Increased risk of all-cause 
mortality and cardiovascular 
mortality.   
Cohort  with disease Pattern  
Edinburgh T2 Diabetes study 
1,066 men and women with 
T2D (age 60-75)  
Higher fasting cortisol  Associated with estimated 
cognitive change (this was 
calculated after adjusting 
current cognitive function for 
estimated prior cognitive ability.   
-lower general cognitive ability 
-poorer scores on working 
memory 
-poorer processing speed. 
Young Chinese T2D- 90 
(age 33±5 years) (Lee, Chan 
et al. 1999) 
Higher basal cortisol Associated with central obesity 
Veterans with T2D-154 T2 
+52 C(Liu, Bravata et al. 
2005) 
Higher late night 
salivary cortisol (LNSC) 
Higher LNSC was associated 
with diabetes and increasing age 
Veterans with T2D- 216 
T2D(Oltmanns, Dodt et al. 
2006) 
 
Higher cortisol pre-
standardised lunch 
Associated with higher 
SBP/DBP 
Cohort with cardiovascular 
disease ± risk factors 
Variable  
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(Engvig, Fjell et al. 2012) 
(Manenschijn, Schaap et al. 
2013) 
(Reynolds, Walker et al. 
2010) 
mean cortisol 
 
mean cortisol 
 
 
17 controls and 19 in-
patients with major 
depression(Pitts, Samuelson 
et al. 1995) 
Blunted ACTH response 
to CRH 
Increased cortisol 
response to CRH 
Hyperactivity seen in patients 
with major depression 
Major depression 
(Gragnoli 2014) 
mean cortisol 
evening cortisol 
inappropriately ACTH 
and CRH 
 
Lupus 
erthythematosis(Weiner and 
Allen 1991) 
 Hyporeactivity  
Alzheimer’s disease and 
mild cognitive impairment 
(MCI) 
(Arsenault-Lapierre, 
Chertkow et al. 2010) 
basal cortisol 
throughout 
 
Poorer cognitive 
performance 
(Power, Li et al. 2008) 
(Evans, Fredhoi et al. 2011) 
steep decline from 
early morning peak 
CAR 
 
Those with an an increased 
propensity for infections 
(Mason 1991) 
cortisol throughout  
Metastatic breast cancer 
(Abercrombie, Giese-Davis 
et al. 2004) 
High peak cortisol, and 
then blunted decline 
 
165 
 
Conditions associated with 
sleep disturbances; sleep 
apnoea, chronic fatigue 
→metabolic 
abnormalities(Spiegel, 
Leproult et al. 1999) 
evening cortisol  
 
 
Chronic fatigue(Demitrack, 
Dale et al. 1991) 
Low flat curves  
Post-traumatic stress 
disorder(Yehuda, Giller et al. 
1991) 
Low flat curves  
 
Other factors affecting the pattern 
 
As studies were reporting deviations of cortisol in both directions in the setting of chronic 
stress, a review by Miller, Chen and Zhou looked at the specific factors which may affect the 
deviation.  (Miller, Chen et al. 2007)  In particular they looked at 
Time since onset of stress 
 
The meta-analysis showed that there is a time dependant pattern, whereby as time passes, this 
activity diminishes, and cortisol secretion rebounds to below normal.   
So they found, that the more months had elapsed, since first appearance of the stress, the 
lower a person’s morning cortisol, daily volume, ACTH and post-dexamethasone cortisol.  In 
our context, the duration of diabetes may therefore be important in predicting the pattern of 
cortisol release, as it could hypothesise that cumulative frequency of hypoglycaemia is 
greater in those with longer duration disease.    If however, the stressor was still present (still 
experiencing hypoglycaemia), then daily cortisol output could be significantly higher.  
However if the stressor was no longer present, morning and post-dexamethasone cortisol was 
significantly lower.  However, the major limitation in these studies is that the majority are 
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looking at HPA through cross sectional studies. Although this gives us some indication of 
response of the HPA over time, it does not provide any information on the evolution of the 
HPA with time.   
Nature of stress 
 
This revealed that stress that threaten physical integrity produced a diurnal pattern that was 
high and flat.  Morning cortisol was lower, but evening was much higher, leading to an 
increased daily output of cortisol.  This can be justified, because in the presence of continued 
physical threats, the elevated HPA activity facilitates cognitive, metabolic, immunological 
and behavioural adaptations that maximise survival.  However, a threat to the social self, was 
associated with significantly higher morning and evening cortisol levels, since people 
confronted with a social threat, need to acutely boost cortisol levels.   
Controllability of stress 
 
It is proposed that the controllability of a situation impacts on the stress that situation may 
conjure.  Uncontrollable stress has been shown to elicit a flat, high diurnal pattern of cortisol 
secretion, manifested by a lower morning output, and higher afternoon/evening secretion 
(elevation in total daily volume of cortisol).  However, other studies, have shown, when 
people encounter chronic stress that is uncontrollable, HPA activity decreases, and then 
behaviours such as withdrawal and disengagement emerge.  However, if the stress was 
deemed to be controllable, the meta-analysis showed increased morning levels of cortisol, 
potentially preparing them to engage in active coping behaviours.  Hence the patient’s 
perception of hypoglycaemia, and in particular whether they felt it could be avoidable or not, 
may have an impact on the degree of HPA dysfunction.   
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Emotions elicited by stress 
 
If a situation was though to elicit shame, it was associated with significantly higher 
afternoon/evening cortisol, whereas if it involved loss, this had a flatter diurnal profile.  This 
profile had a lower morning cortisol and a higher afternoon/evening cortisol.  The shameful 
situation may be associated with troubling social interactions for the rest of the day, however 
in the situation of loss, there may be a context of social isolation or withdrawal from other 
social activities.   
Individual psychiatric sequale 
 
Psychiatric sequale of chronic stress has been shown to be a determinant of HPA activity 
with individuals showing markedly higher cortisol after the dexamethasone suppression test.   
Perceived distress 
 
Subjective distress has been found to be related to HPA activity perturbations.  If a person 
had a higher level of distress, they showed greater total daily output, though morning levels 
were found to be lower.   
Early life experiences 
 
This has been particularly highlighted in studies on rodents, whereby early life experiences 
have been shown to program HPA functions at the genomic level, such that it remains 
unaltered throughout adulthood.  (Liu, Diorio et al. 1997).  A person’s early experiences of 
hypoglycaemia may therefore influence their coping strategies, and particularly have an 
impact on the degree of HPA dysfunction later on in life.  
So in summary, although we know that the HPA axis is activated during periods of stress, the 
axis is modulated by other factors relatin g to the stressful stimuli.  The factors relate to the 
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nature, controllability and timing of the assessment in relation to the stress.  In addition, the 
immediate sequale of the stress such as the emotions it elicits and the perception of the stress 
also appear to impact on the HPA axis.  
 
Regulation of the HPA axis 
 
Glucocorticosteroids (GC) is the end product of the HPA axis and is the main steroid 
hormone produced by the adrenal glands in man. The HPA axis is regulated by the supra-
chiasmatic nucleus (SCN) which contains the body’s “master-clock”.  (Abe, Kroning et al. 
1979). The central clock is synchronised to the environment through signals from the retina.  
There are also peripheral “clocks” which are molecular oscillators in most cells and the pace 
of these clocks are set by the SCN (Dunlap 1999).  Cortisol acts as a messenger between the 
peripheral and central clocks.   The circadian output of the adrenal glands is now well known 
to play a part in resynchronisation of the internal environment with the external environment.    
In mammals, it has long been known that there are dominant clock elements in the central 
nervous system and that the sleep/wake cycle of about 24 hours could be maintained even 
without any environmental clue.  This was first described by Pincus where a diurnal variation 
of urinary ketosteroids was discovered in 1943.  (Pincus 1943)  Andrews and Folk discovered 
that circadian rhythms persisted in the isolated endocrine glands.  (Andrews and Folk 1964)  
Discovery that removal of various endocrine organs did not abolish the circadian rhythm 
shifted attention to the CNS.  In 1972, retinal fibres were found to not only project to the 
lateral geniculate nucleus, but also to a small nucleus in the anterior hypothalamus; the 
suprachiasmatic nucleus (SCN) (Hendrickson, Wagoner et al. 1972), and later on that year, it 
was shown that selective destruction of the SCN resulted in complete disappearance of the 
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circadian rhythm in adrenal corticosterone content  (Moore and Eichler 1972) resulting in the 
understanding of the pivotal role of the SCN.  
 
The circadian rhythm is organized in a hierarchical manner called the CLOCK system, and is 
a highly ubiquitous, conserved molecular system that synchronises endocrine daily rhythms 
to solar time through retinal afferents.  The SCN lies at the top of this hierarchy, and is 
composed of densely packed neurons that have self-sustaining rhythmic capacity. (Herzog 
2007)  It has also been found that most mammalian cells also have their own circadian clocks 
(peripheral clocks), with a molecular makeup similar to that in the SCN neurons.    The SCN 
acts as a co-ordinating centre for all the other peripheral clocks and thereby harmonizes the 
circadian rhythm throughout the organism.  The SCN maintains continuous communication 
with the peripheral clocks, through multiple neural and hormonal signals.  (Levi and Schibler 
2007) SCN appears to influence peripheral clocks through the splanchnic nerve 
innervation(Jasper and Engeland 1997) to the adrenal gland and GC may be a hormonal link 
between SCN and the peripheral clocks and a mediator of the synchronicity of the circadian 
system.    
 
The SCN provides input to the PVN which also receives afferent information from both the 
limbic areas of the central nervous system which are involved in detection of cognitive and 
emotional stress, and also the PVN receives information about physical stresses such as 
inflammation and hypotension from the brainstem.  CRH and AVP containing parvocellular 
neurons in the PVN project to the median eminence of the hypothalamus, and CRH and AVP 
are released into the hypothalamic-pituitary portal circulation.  They stimulate the 
corticotrophs cells in the anterior pituitary, which then releases corticotrophin (ACTH) into 
the general circulation. ACTH is formed from the cleavage of pituitary pro-opiomelanocortin 
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(POMC) by pro-hormone convertases.  ACTH binds to the melanocortin-2 receptors in 
fasciculate zone of the adrenal cortex. This binding stimulates adenylyl cyclase, which 
activates protein kinase A resulting in gene transcription involved in glucocorticoid (GC) 
production.  A series of biochemical steps result in GC formation from cholesterol.  These are 
catalysed by cytochrome P450 enzymes which involve terminal hydroxylation reactions, 
which lead eventually to production of cortisol (predominant steroid in humans) and 
corticosterone. ACTH also stimulates release of oxytocin, adrenaline and noradrenaline 
which predominantly intensify the effects of CRH(Kudielka, Bellingrath et al. 2006).   
Upon activation of GC onto its ligand, it undergoes a conformational change leading to the 
active component dissociating and entering the nucleus binding to the glucocorticoid 
response elements on the DNA. The rapid cycling of the receptor on and off the chromatin is 
thought to determine the ultradian rhythm(Conway-Campbell, Pooley et al. 2012).    
GC acts on target tissues by binding to cytosolic receptors (glucocorticoid and 
mineralocorticoid receptors). There are two types of glucocorticoid receptor, with the low 
affinity Glucocorticoid receptor (type II) being only occupied during periods of high 
glucocorticoid secretion (mediating response to stress) and the high affinity mineralocorticoid 
receptor (MR) remaining in a bound state even in basal conditions, suggesting it is more 
involved with tonic HPA activity (De Kloet, Vreugdenhil et al. 1998).   Upon binding, a 
conformational change occurs and the receptor is translocated to the nucleus, and influence 
gene expression.  There is a negative feedback mechanism, with GC binding to the 
glucocorticoid and mineralocorticoid receptors in the brain turning off the HPA, and restoring 
a steady state.  (Stratakis and Chrousos 1995)  Negative feedback also occurs to the pituitary 
gland, PVN and hippocampus to inhibit ACTH release.  There is a forward/feedback 
relationship between the pituitary gland and the adrenal cortex(Walker, Spiga et al. 2012), 
and it has been shown that a constant CRH concentration generated in the hypothalamus is 
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sufficient to generate an ultradian rhythm of both ACTH and glucocorticosteroids. However 
it is disrupted with higher levels of CRH suggesting that dose of CRH is more important than 
pattern in maintaining this ultradian rhythm.  (Walker, Spiga et al. 2012) Loss of this 
ultradian rhythm in GC replacement, in patients for example with Addison’s have been 
suggested to contribute to increased mortality in this patient group.  However an acute 
administration of GC, has been shown to induce phase synchronisation in a wide range of 
peripheral clocks both in vivo and in vitro.  (Balsalobre, Brown et al. 2000) 
 
However the adrenal gland also appears to have an intrinsic mechanism which contributes to 
the diurnal rhythm of GC by controlling the daily variation in the adrenal sensitivity to 
ACTH. (Oster, Damerow et al. 2006).  Specifically, steroidogenic acute regulatory protein 
(StAR) is thought to be the link between glucocorticoids synthesis from the adrenals and the 
CLOCK system(Son, Chung et al. 2011).  
In summary, the HPA axis is regulated primarily by the SCN, which also receives input from 
retinal fibres.  The SCN then synchronises peripheral clock mechanisms, with cortisol being 
the main messenger between the central and peripheral systems.   
Dysregulation of the HPA axis 
 
Acute prolonged periods of hypoglycaemia stimulates cortisol release from the adrenal 
glands, but the literature is sparse, with regard to impact of recurrent stimulation on various 
aspects of this axis.  Stress is a culmination of dramatic stressful events but also the 
combination of the many events of daily life that lead to an increase in activity of 
physiological systems.  This has been termed as wear and tear “allostatic load”(McEwen and 
Seeman 1999).  It has been described as being reflective of the many life experiences, but 
also of genetic load, individual habits (diet and exercise) and developmental experiences, 
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which are important in the underlying physiological reactivity.  Allostatic load occurs as a 
result of increasing external demands (see Figure 14)  and excessive adaptive efforts, and this 
in turn can lead to dysregulation of the HPA axis, with impaired feedback and a disturbance 
in the diurnal patterns of cortisol release.  This central dysregulation in turn has been shown 
to cause disturbances in other physiological systems such as the immune and cardiovascular 
systems, energy balance and fat deposition.  
Dysregulation of the HPA axis has been hypothesized to be an early indicator of allostatic 
load (Abercrombie, Giese-Davis et al. 2004).  Chronic stress has been shown in numerous 
studies to be associated with dysregulation of the HPA axis.  Chronic dysregulation of the 
HPA axis is thought to be related with development of psychosomatic and psychiatric 
disorders.  
We can glean some insight by looking at other systems of chronic stress models.  For 
example, in a model of repeated stress involving repeated public speaking challenges, it was 
shown that there was lack of adaptation, resulting in prolonged exposure to the stress 
hormones(Kirschbaum, Prussner et al. 1995), with an inability to shut off the stress response 
even after the stress stimulus is terminated(Gerin and Pickering 1995).  A further model 
suggests that chronic activation leads to exhaustion of the HPA(Seeman and Robbins 1994).  
The hippocampal region has been shown to be particularly vulnerable with many adrenal 
steroid receptors(McEwen and Magarinos 1997), wear and tear of this region, has been 
shown to be associated with dysregulation of the HPA axis and cognitive 
impairment(Sapolsky, Krey et al. 1986).  The hippocampus is responsible for consolidating 
short term memory, however cortisol appears to suppress these mechanisms(Kirschbaum, 
Wolf et al. 1996). It is now becoming evident that chronic stress causes atrophy of pyramidal 
neurons in the CA3 region of the hippocampus(McEwen, Albeck et al. 1995). MRI studies 
have confirmed this hippocampal atrophy occurs in those with stress related disorders, such 
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as recurrent depressive illnesses and also in disorders with excessive cortisol, such as in 
Cushing’s disease(McEwen and Magarinos 1997).    
 In contrast, short lived stress is usually accountable for reversible atrophy.   
Apart from the system that controls the diurnal variation of GC, particular stressors are also 
able to activate the system.  Here the HPA response often starts in the amygdala, which is an 
important part of the limbic system and is responsible for co-ordinating the negative 
emotional response to a stimuli which is deemed to be threatening. From here, the amygdala 
sends signals to the hypothalamus resulting in HPA activation.  However, if there is 
continued stress and therefore high production of cortisol, GC has been shown to bind to the 
hippocampus and modulate brain function, thereby protecting the body from the effects of 
chronic hyper stimulation of the HPA axis(Graeff, Garcia-Leal et al. 2005).  
Therefore, we know in summary that there is acute activation of the HPA system with 
stressful stimuli such as seen during hypoglycaemia.  Chronic activation of stress systems or 
increasing allostatic load has in models of stress shown dysregulation of the HPA system.  
This dysregulation has presented in several ways in the literature as illustrated below (Figure 
14).  In severe cases of dysregulation, it has also led to hippocampal atrophy.  
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Figure 14; Allostatic load.  
 Top panel shows the normal allostatic response, with an initial stressor, sustained for an appropriate time, and then turned 
off. Remaining shows 4 abnormalities in this response; repeated hits from multiple stressor; lack of adaptation; prolonged 
response due to failure of negative feedback, and inadequate response with compensatory hyperactivity of other mediators.   
 
  
 
Potential impact of dysregulation of the HPA axis on end-organs 
 
There are now an increasing number of pathological conditions associated with a 
dysregulated secretion of glucocorticoids, and altered rhythmicity are frequently seen in 
many human diseases.  (Chung, Son et al. 2011).  It is still unknown whether the chronic 
dysregulation is a feature of the pathological process or is as a result of the process.  We 
know that in the end, dysregulation leads to a disruption of carbohydrate and lipid 
metabolism, immune responses, cardiovascular activity particularly atherosclerosis of the 
carotid arteries (Dekker, Koper et al. 2008), mood and cognitive and brain functions. This is 
classically seen in Cushing’s syndrome, with chronic exposure to glucocorticosteroids being 
175 
 
associated with obesity, insulin resistance, hypertension and hyperlipidaemia.   Common 
psychiatric and/or somatic complex disorders, such as anxiety, depression, insomnia, chronic 
pain and fatigue syndromes (Pasquali, Cantobelli et al. 1993).  
In specific, the uncoupling of the ACTH and cortisol which are necessary for the HPA axis 
regulation, has been shown to occur in many diseases states, and maybe as a result of 
autonomic or extrinsic causes.   Disruption of the circadian rhythm such as chronic exposure 
to shift work, or sleep deprivation have shown to be linked to metabolic syndrome,  
characterised by impairment of carbohydrate and lipid metabolism, cardiovascular and 
haemostatic morbidity. (Garaulet and Madrid 2009)  
 
Impact of glucose on the HPA axis 
 
There are several similarities between the complications posed by diabetes and Cushing’s 
syndrome, such as hypertension, immune suppression, myopathy and increased risk of 
depression, and this has questioned many investigators to suggest that diabetes could cause an 
abnormality in the HPA axis(Andrews, Herlihy et al. 2002).  Cross sectional studies in 
patients with T1D have shown an increased levels of GC as well as increased urinary free 
cortisol levels(Roy, Roy et al. 1998).  Possible explanations for this have included the effect 
of hyperglycaemia-induced stress and may be related to activation of the polyol pathway, 
which presents an alternative route for glucose metabolism, in the context of the adrenals 
producing high levels of aldose reductase(responsible for catabolism of GC in adrenal 
glands)(Matsuura, Deyashiki et al. 1996).  Animal models of T1D have also shown an 
impairment in the GC negative feedback sensitivity, with higher levels of AVP, increased 
POMC expression and therefore increased levels of ACTH, with a high expression of MCR2 
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(ACTH receptors) in the adrenal glands,  however a down regulation occurs of  GR and MR 
in pituitary gland leading to the problems with negative feedback.  
Insulin deficiency has also been shown to cause a hyper activation of the HPA system, 
however this deficiency through its actions on other hormones has also shown to be 
contributory. Namely both increases in glucagon and decreases in leptin has been shown to 
lead to the hyperactivity of the HPA axis (Chan, Chan et al. 2001).  Glucagon has a central 
effect on the hypothalamus (Honda, Kamisoyama et al. 2012)stimulating eventual cortisol 
release, whereas leptin acts at all levels of the axis, inhibiting GC production(Roubos, 
Dahmen et al. 2012).   
This hyper activation of the HPA axis, and therefore increased levels of glucocorticoids can 
pose difficulties in control of several diabetes related complications.   
Impaired wound healing is a problem for many with diabetes.  Hypercortisolaemia can impair 
collagen synthesis with reduced proliferation of fibroblasts.  GC can also increase ROS 
production, and inhibit angiogenesis by reducing VEGF expression(Bitar 1998).   
Although hyperglycaemia causes impairment of the ability of the body to fight against 
infection, the high circulating GC could also contribute to the increased infection rates with 
abnormalities in both neutrophil properties as well as defects in antibody responses(Dixon, 
Abrahamowicz et al. 2012). Hyperactivity of the HPA axis also leads to a hypertensive state, 
through activation of MR, with renal sodium retention, volume expansion and increase in BP 
and through up regulation of angiotensin II type 1 receptors on smooth muscle cells.  GC also 
has an interaction directly with cardiac and vascular walls, which can facilitate plaque 
development(Baid and Nieman 2004). Finally HPA hyperactivity has been shown to be 
related to impaired hippocampus-depended memory, synaptic plasticity and 
neurogenesis(Stranahan, Arumugam et al. 2008), and this hyperactivity (through stimulation 
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of catecholamines) may also explain the high incidence of depression in patients with 
diabetes(Muller, Zimmermann et al. 2003).  
HPA hyperactivity seen in diabetes may also be compounded by acute hypoglycaemia (AH) 
which also activates various pathways involved in the regulation of the neuroendocrine stress 
response.  There is currently very little in the literature on the effects of recurrent 
hypoglycaemia on the HPA in humans.  Hypoglycaemia can be considered as a stressor, as it 
certainly activates the HPA.   
Therefore this thesis seeks to explore the effect of recurrent hypoglycaemia/GV on the HPA 
axis with exploration of whether hypoglycaemia worsens the dysregulation of the HPA axis 
already assumed in patients with T1D.  There is currently no clinical studies looking at this 
effect in a cohort with T1D.   
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CHAPTER 5 
STUDY 2; Does adjunct DPP-4inhibitors in patients with T1D improve 
glucose variability, hypoglycaemic responses and glycaemic control? 
Background 
 
The loss of insulin secretion in patients with T1D leads to severe abnormalities in glucose 
metabolism that present as hyperglycaemia.  Chronic hyperglycaemia leads to the 
development of micro- and macrovascular complications.  Despite the variety of insulin 
replacement strategies and devices, there are numerous barriers to intensive insulin therapy in 
diabetes which include current limitations of insulin therapy (usually delivered 
subcutaneously by injection in a non-physiological manner), risks associated with hyper-
insulinaemia,  the risk of severe disabling hypoglycaemia, the need for daily and frequent 
capillary glucose monitoring and the psychosocial problems inherent in any chronic disease 
pathology, with most individuals with T1D still having suboptimal glucose control(Nathan, 
Cleary et al. 2005).   
As a result of these limitations of insulin therapy, and since the rates of hypoglycaemia have  
remained unaltered over the last 20 years particularly in adults, there is currently a need to 
look at alternative adjunct therapies, to improve glycaemic control and reduce the burden of 
hypoglycaemia in patients with T1D.  The last 90 years have focused on insulin as being the 
primary problem in T1D, however, it is now known that through multiple layers of evidence 
that there is a dysregulation of glucagon secretion.  Of particular interest, is the therapeutic 
targeting of abnormal glucagon secretion in T1D?  The pancreatic α-cell product glucagon 
acts primarily in the liver to stimulate glycogenolysis and gluconeogenesis and therefore to 
increase hepatic glucose production. 
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Abnormalities of the α cell  
 
The importance of glucagon and its role in the catabolic manifestations of T1D, was largely 
overlooked for around 5 decades after the discovery of insulin.  Suppression of glucagon in 
patients with T1D with agents such as leptin and somatostatin (Gerich, Lorenzi et al. 1975) 
was able to completely suppress the catabolic manifestations of total insulin deficiency.  
Recent studies in animal models have also shown that T1D (induced chemically in transgenic 
mice) models which lack functional glucagon receptors do not develop diabetes, confirming 
the importance of glucagon in the development of hyperglycaemia (Lee, Wang et al. 2011).  
It has also been shown in patients with T1D that there is a paradoxical increase in basal and 
post-prandial glucagon(Porksen, Nielsen et al. 2007) levels and this contributes to increased 
hepatic glucose output and glucose variability through a direct action of glucagon on the liver 
(Edgerton and Cherrington 2011). A recent study(Kramer, Borgono et al. 2014)  showed that 
there was a significant paradoxical increment in glucagon (p<0.001) following an oral 
glucose tolerance test regardless of prevailing glucose (either euglycaemia and 
hyperglycaemia).  There was no difference (p=0.1) in the rise of the glucagon in either of 
these conditions (when the ratio of change of glucagon was compared with change of glucose 
between the two states) in patients with longstanding T1D.  This suggests that the 
normalisation of glucose (euglycaemic study) with exogenous insulin as in this study, did not 
correct this aberrant glucagon response, which therefore suggests limitations in the current 
intensive insulin therapy regimes. Notably elevations in glucagon levels are seen as early as 
the first year following diagnosis and appear to be correlated with blood glucose, with a 20% 
increase in glucagon release seen with every 10mmol/L increase in blood glucose, however it 
has been shown that this had little impact on overall HbA1c(Porksen, Nielsen et al. 2007).   
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On the contrary, patients with T1D have an inability to release glucagon in response to 
hypoglycaemia(Gerich, Langlois et al. 1973).   
Therefore an agent which may be able to suppress the hyperglucagonaemia both in the fasting 
and the post-prandial phase, but not affect the counter-regulatory responses during 
hypoglycaemia,  may have a potential impact on reducing the significant GV seen in this 
context in patients with T1D, and subsequently reduce the significant burden of 
hypoglycaemia (which is closely linked to GV).   
DPP-4 inhibitors (DPP4-i); their potential utility in hypoglycaemia 
 
In 1929, La Barre was the first to purify the glucose lowering component of gut extracts, and 
name it incretin (Zunz 1929).  The incretins, both GLP-1 and GIP are secreted from the gut 
following intake of glucose or other nutrients.  They act primarily through G protein coupled 
receptors, the GIPR and GLP-1R. The binding activates cyclic adenosine monophosphate, 
resulting in insulin secretion from the pancreas and also cause glucagon suppression from the 
cells.   However both these incretins are rapidly deactivated by dipeptidyl peptidase-4 (DPP-
4).  We will therefore utilise the DPP-4 i (primarily for its glucagon suppressive action), 
which are currently used in the treatment of T2D, to determine whether it could be a suitable 
adjunct agent in patients with T1D.   
Dipeptidyl-peptidase 4 inhibitors (DPP-4 i) are a class of orally active compounds designed 
to inhibit DPP4 enzyme activity, resulting in increased circulating levels of the incretins 
glucagon-like peptide 1 (GLP-1) and gastrointestinal peptide (GIP) (Thornberry and Gallwitz 
2009). GLP-1 is an incretin that is secreted by ileal L cells in response to the presence of 
nutrients (carbohydrate, protein and lipid) in the lumen of the small intestine. Once in the 
circulation, GLP-1 has a half-life of less than 2 minutes, due to rapid degradation by the 
enzyme dipeptidyl peptidase-4 (DPP4). GLP-1 acts in a glucose-dependent way to augment 
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insulin secretion while at the same time suppressing glucagon secretion, and additionally 
GLP-1 delays gastric emptying and increases satiety. There is evidence that GLP-1 infusion 
reduces fasting glucose concentrations (Creutzfeldt, Kleine et al. 1996)and post-prandial 
glucose levels (Dupre, Behme et al. 2004) in association with a reduction in glucagon in type 
1 diabetes, although this is not evident in all studies(Raman, Mason et al. 2010). In a more 
recent study, Kielgast and colleagues (Kielgast, Asmar et al. 2010) demonstrated that 
infusion with GLP-1 in nine c-peptide negative type 1 diabetic patients clamped at 20 mmol/l 
significantly decreased the total area under the curve of glucagon by nearly 40%, and also 
suppressed arginine induced glucagon release.   
GLP-1 receptor signalling pathway also enhances β-cell proliferation and regeneration and 
diminishes apoptosis, resulting in a greater β-cell mass (Mudaliar and Henry 2010). Based on 
these findings GLP-1 is a potential adjunct therapy in both c-peptide positive (β-cell 
preservation and proliferation) and c-peptide negative  (α-cell suppression, reduced post-
prandial glucose excursion, weight loss) type 1 diabetes(Thornberry and Gallwitz 2009) 
(Ellis, Moser et al. 2011, Farngren, Persson et al. 2012, Garg, Moser et al. 2013). Also 
reassuringly,  during hypoglycaemia DPP-4 i  does not further suppress glucagon secretion 
(Farngren, Persson et al. 2012) and in individuals with T2D might even improve glucagon 
counter regulation (Ahren, Schweizer et al. 2011).  
These findings suggest that DPP-4 i adjunct therapy in T1D, could improve glucose 
variability by reducing both exposure to and duration of post-prandial hyperglycemia and 
hypoglycaemia.  In T1D, increased GV is predictive of severe hypoglycaemia risk(Cox, 
Kovatchev et al. 1994), while recurrent hypoglycaemia leads to suppression of symptom and 
counterregulatory responses to subsequent hypoglycaemia; a clinical condition referred to as 
impaired awareness of hypoglycaemia (IAH)(McCrimmon and Sherwin 2010). This raises 
the intriguing possibility that DPP-4 i  therapy in T1D may through reducing GV and 
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exposure to hypoglycaemia improve hypoglycaemia awareness and therefore prove a novel 
useful adjunct therapy in T1D irrespective of its ability to improve glycaemic control. 
The available DPP-4 i can be divided into 2 main groups; those that are similar to the 
dipeptide structure of DPP4 substrates (sitagliptin, vildagliptin and saxagliptin) and those that 
are not (alogliptin and linagliptin).  Nevertheless they are all competitive reversible inhibitors 
of DPP4.  Differences exist in the binding processes; with sitagliptin, alogliptin and 
linagliptin forming non-covalent interactions with residues in the catalytic site, but 
vildagliptin and saxagliptin forming a reversible covalent enzyme-inhibitor complex with a 
slow rate of binding and dissociation, resulting in equilibrium between active and inactive 
forms.   This slow equilibrium explains the longer duration of DPP4 inhibition activity in the 
latter group despite a shorter half-life. Vildagliptin and saxagliptin are cleared much quicker 
than sitagliptin resulting in shorter half-lives compared to alogliptin and linagliptin.    A 
comparative study (sit, vild, sax, alo and lina) showed similar effect of DPP4-inhibition in 
vitro (95-97% for vilda and sit).  Most of the DPP4 inhibition (90%) is attained within 15 
minutes of inhibitor administration with a lesser amount (70-90%) sustained for 24 hours 
after administration.  However there were differences in potency (IC50  1nm for linagliptin vs 
19nm (sita) 62nm (vilda)50 nm (saxa).  (IC50; conc of a drug required for 50% inhibition of 
enzyme).  However used at the current therapeutic doses, the potencies are broadly similar. 
Oral bioavailability as a result of negligible protein binding for the DPP-4 i  is generally high 
(87% for sita, 85% for vilda and 67% for saxa), with DPP-4 inhibition seen within 5 minutes.  
Saxagliptin is metabolised by the liver through the P450 CYP3A4/5 system to produce 5 
hydroxyl saxagliptin; BMS-510849 (which is also a reversible inhibitor of DPP4) and is 
renally eliminated as both a metabolite (21-52%) and as parent drug (11-29%).  However 5 
hydroxy saxagliptin is twofold less potent than saxagliptin but has greater selectivity than 
saxagliptin for DPP4 over DPP8 (948 fold compared to 391 fold) and DPP9 (163 fold vs 75 
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fold).  Data suggest that the volume of distribution for DPP-4 i inhibitors is high, suggesting 
that they are widely distributed within tissues, however the highest concentration is found in 
tissues with the highest DPP-4. (E.g. intestines, kidney and liver).  Most (75%) DPP-4 i  are 
excreted primarily via the kidneys through a combination of glomerular filtration and active 
transport(Deacon 2011).  DPP-4 inhibitors have a good safety profile.  The terminal 
elimination half live (t ½) for both saxagliptin and its metabolite are 2.5 and 3.1 hours, 
respectively.  
A recent meta-analysis and systematic review of the gliptin RCTs(Esposito, Chiodini et al. 
2015) revealed that all available DPP-4 i  shown a clinically meaningful reduction in blood 
glucose both in the fasting and post-prandial states  with an average HbA1c  reduction from 
baseline of -0.77% (95 CI -0.82 to -0.72), however there was high heterogeneity between 
trials. (I 2 =96%) with most of the total variance (58%) due to baseline HbA1c (34%) and 
fasting glucose (24%).  Head to head trials of which there have only been 2 RCT have shown 
similar results between saxagliptin vs sitagliptin.  Since their action is glucose-dependant, 
they have also been found to have a low risk of hypoglycaemia and weight gain (Ahren 
2009).   
Trials using DPP4-I in Type 1 Diabetes  
 
A recent double blinded cross-over trial published showed in a group of 20 patients with 
T1D, sitagliptin (DPP-4i) given for 4 weeks dropped their mean glucose by 0.67mmol/L 
(p=0.012) and showed a reduction in the daily insulin dose (least-square 
means ± sd = −0.051 ± 0.018, P = 0.012), however there was no significant change in 
measures of GV (LBGI, MAGE, CV, SD) and in fact, there was a trend towards greater time 
spent in the hypoglycaemic ranges (Ellis, Moser et al. 2011). Although this trial was a cross-
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over trial, there with no washout period incorporated in the design and there was a significant 
Hawthorne effect. 
Furthermore a recent double-blind, randomized-parallel 20-week study exploring the 
mechanisms of DPP-4 i  in T1D, revealed that sitagliptin given over a 20 week period, 
showed no significant reduction in 4hour postprandial glucagon reduction with consequently 
no change in HbA1c, insulin doses or weight, despite significantly elevated GLP-1 levels at 
30minutes(Garg, Moser et al. 2013). The failure of DPP-4 i  to demonstrate an effect in T1D, 
despite an increase in GLP-1, suggest that these agents may not provide sufficient glucagon 
suppression, to impact on both post-prandial peaks as well as more chronic glycaemic factors 
such as insulin doses and HbA1c.   
A subsequent study with 141 patients with T1D given sitagliptin over 16 weeks(Garg, Moser 
et al. 2013), also showed that despite showing a post meal GLP-1 level which was much 
higher (p<0.001) and GIP levels which were lower (p=0.03), sitagliptin failed to find a 
lowering effect in glucagon AUC, A1c, insulin dose or weight despite in these patients.  A 
non-significant trend in reducing hyperglycaemia was found only in those who were C-
peptide +ve, the mechanism of which is unknown.  
A recent open label study in 20 T1D patients, looked at the effect of combination therapy 
with sitagliptin/metformin (50/1000mg).  Once again, although there was a reduction in 
HbA1c after a mean of 21 weeks, there was a return to baseline HbA1c after a mean of 49 
weeks. However there was a persistent significant reduction in weight and insulin doses even 
at a mean of 49 weeks.   It is possible that there was greater self-monitoring and self-
adaptation during this study period or it may be purely the effect of the metformin as an 
insulin sensitizer rather than the sitagliptin(Vella, Buetow et al. 2010), which could also have 
explained these results. 
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Table 6 Summary of trial data of DPP-4 i  use in T1D cohorts  
Trials Agents used Glycaemic effects Non glycaemic 
effects 
Open label ;  
CP -ve 
BH 8.7±1.3.  
(Giampietro, 
Giampietro et al. 
2013) 
 
Sitagliptin 
and 
metformin 
(46±19wks) 
After 21wks; HbA1c 8.7±1.4 to 
8.0 ±0.9% p<0.001 
After 49 wks; HbA1c 8.7±1.3 
p=ns 
Sig dec in 
weight (mean 
weight loss 
1.9±2.6kg 
p<0.001), 
fructosomine, 
LDL chol, 
insulin dose 
(0.73 to 
0.60u/kg/d 
p<0.001) 
Double blind, RCT, 
PC, CO 
CP -ve 
BH 
7.5±0.55(Farngren, 
Persson et al. 2012) 
 
Vildagliptin 
(4 weeks) 
120 min AUC of meal 
stimulated glucagon was sig 
lower (2.4 vs 2.6 p=0.022) 
No change in glucagon, 
adrenaline and cortisol during 
HHC.  
Sig drop in HbA1c from 58.1 to 
54.7mmol/mol (P<0.001) 
No change in insulin doses 
 
Double blind, RCT, 
CO  
 
20 subjects 
Sitagliptin (4 
weeks no 
washout 
period) 
Sig drop in 2 hr PPG assessed on 
CGM worn over whole trial 
period. 
Sig drop in 24hr AUC glucose.  
Sig drop in HbA1c over 4 
weeks. (-0.27% estimated diff 
p=0.03) 
Measures of overall GV (mean 
glucose, M100, J-index) 
significant drop 
Measures of within day and 
between day GV (SD, CV and 
MAGE) showed no sig change 
No difference in 
weight. 
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Trend for spending more time 
hypo (<3.1) p=0.08 
Sig drop in insulin doses LSM (-
0.051 p=0.012) 
 
 
 
 
Open label, 
randomised study 
C-peptide +ve 
N=6 
(Hari Kumar, Shaikh 
et al. 2013) 
Sitagliptin 
(1 year) 
Sig drop in HbA1c 9.6 to 7.5% 
(p=0.0017).   
Sig drop in insulin doses 0.84 to 
0.4 (p=0.012) 
No change in C peptide 
 
BH; Baseline HbA1c RCT: Randomized controlled trial.  PC; Placebo controlled. CO. Cross over. CP; C 
peptide HHC; Hyperinsulinemic hypoglycaemic clamp. LSM; Least square means   Mean±SD 
A more potent drug; GLP-1R agonists 
 
GLP-1R agonists however are a group of drugs, which are resistant to DPP-4 inhibition, and 
have a more direct (cf DPP-4 inhibitors) effect on both the beta and alpha cells to both 
increase insulin secretion and suppress glucagon secretion respectively.  The results of GLP-1 
agonists in T1D have been more positive, possibly as a result of a more powerful effect on 
the pancreas, but it has also been shown to have several extra-pancreatic effects (delay in 
gastric emptying, increase in brain satiety)  
A study looking at 10 type 1 diabetic patients with residual β-cell function (C-peptide 
positive- all given liraglutide and insulin) and 19 without (C-peptide negative-randomly 
assigned to liraglutide plus insulin or insulin monotherapy) over a 4-week intervention period 
showed that total insulin dose decreased from 0.50+/-0.06 to 0.31+/-0.08 units/kg per day 
(P<0.001) in C-peptide-positive patients and from 0.72+/-0.08 to 0.59+/-0.06 units/kg per day 
(P<0.01) in C-peptide-negative patients treated with liraglutide but did not change with 
insulin monotherapy. HbA1c also decreased in both liraglutide-treated groups, but this did 
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not reach significance. At the same time, weight loss with liraglutide was common during 
treatment (mean [range] -2.3+/-0.3 kg [-0.5 to -5.1]; P<0.001).  
In a longer-duration open label, proof of concept, study conducted by Varanasi et al 
(Varanasi, Bellini et al. 2011), 24-weeks liraglutide and insulin therapy in type 1 diabetes in 
addition to beneficial effects on weight and mean HbA1c, resulted in significant reductions in 
mean fasting and mean weekly glucose concentrations, as well as reduction in glycaemic 
variability measured by coefficient of variation (cv).  Conversely, blocking endogenous GLP-
1 receptors has been shown to increase post-prandial glucagon levels (Kielgast, Holst et al. 
2011) 
A recent oral presentation(Kuhadiya 2014) at the American Academy of Clinical 
Endocrinologists presented findings on the first RCT on the effects of adjunct liraglutide 
therapy in those with T1D.  In 72 patients with T1D (mean HbA1c 7.57±0.09%) of at least 1 
year,   54 patients received either 0.6mg, 1.2mg and 1.8mg of liraglutide daily for 12 weeks; 
18 patients were randomized to placebo.  The 0.6mg and placebo showed no benefit, apart 
from weight loss of 6lbs in the 0.6mg group.  In the 1.2mg and 1.8mg, benefits were seen as 
compared to placebo, in mean change in average blood glucose (-10±2 and -10.0±1 mg/dL 
p<0.0001 vs placebo), in HbA1c respectively (-0.78% (p<0.01 vs placebo) and -0.42% 
(p=0.39 vs placebo).  There was also a significant reduction in insulin doses (12.4±3.9 units, 
10.0±2.3 units) and a significant improvement in diabetes specific quality of life in both the 
higher doses.  In addition, those on the 1.8mg dose, showed a significant improvement in 
systolic blood pressure.   
A further study(Sarkar, Alattar et al. 2014) showed that 24 weeks of exenatide also resulted 
in a significantly lower post-prandial glycaemia, despite a reduction in meal time insulin 
doses in patients with long duration T1D. This is particularly significant as post-prandial 
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glycaemia is thought to be a strong risk factor for cardiovascular disease(Ceriello 2005). 
Furthermore this study(Sarkar, Alattar et al. 2014) showed 85% of participants  having a 
marked improvement in their insulin sensitivity, as assessed through a euglycaemic clamp.  
Although this has been shown in animal models, the mechanism in improvement of whole 
body insulin mediated glucose utilization has not been fully understood (Gedulin, Nikoulina 
et al. 2005).  
Although the evidence points to a more powerful glucagon suppressive effect with GLP-1R 
agonists, STUDY 2 utilised the less potent DPP4-I because of the difficulties in producing a 
placebo-controlled product for the injectable former therapy and also the ease for the patient 
of an oral medication.  DPP4-I were therefore used for its ability to reduce both fasting and 
post-prandial glycaemic load, and consequently GV.  The association between GV and 
hypoglycaemia, meant that this therapy could in turn improve the CRR and therefore 
hypoglycaemia awareness. (See figure 15) 
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Figure 15 ; Proposed mechanism for STUDY 2.  
 
Non-glucose effects of incretins ; effect on vasculature 
 
The endothelium is an effective transducer of signals between the circulation and the vessel 
wall, and responds through production of a wide range of factors which regulate vessel tone, 
adhesiveness, growth and coagulation (Luscher 1990).  A change in the function has been 
shown in several studies to predate the development and progression of atherosclerosis 
(Juonala, Viikari et al. 2004, Halcox, Donald et al. 2009).  Hyperglycaemia has shown to 
reduce the migratory capacity of endothelial cells to areas of need in order to restore good 
endothelial integrity. A recent study also showed that endothelial progenitor cells (EPC) 
when cultured in high glucose had a mitochondrial impairment and autophagy.   
The bone marrow is key in producing endothelial progenitor cells (EPCs) (Fadini, Agostini et 
al. 2007).  Maintaining a good level and function of EPCs is crucial for good cardiovascular 
health.  Levels are considered a good biomarker for coronary and peripheral artery disease, 
with a low EPC level predicting future cardiovascular outcomes (Fadini, Losordo et al. 2012).  
There is now a body of evidence that there is both an impairment of function and reduction of 
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EPCs in both T1D and T2D (Menegazzo, Albiero et al. 2012).  This is in part due to diabetes 
affecting the structure and function of the bone marrow (Fadini, Boscaro et al. 2010).   
The DPP4 enzyme cleaves a dipeptide from the N terminus of several proteins, and therefore 
not only is GLP-1 one of the main substrates for DPP4 inhibition, but it has come to light 
recently that SDF-1α (CXCL12) is also another important substrate (Ou, O'Leary et al. 2013).  
SDF-1α binding to its receptor (CXCR4) stimulates the bone marrow to produce endothelial 
progenitor cells (EPCs). The complex then undergoes homodimerization and then interacts 
with inhibitory Gαi, which is then phosphorylated by JAK2/3 kinase and STAT factors.  
When DPP4 binds to SDF-1α, it has been shown to impair its capability to trigger CXCR4, 
inhibiting its chemotactic function (Proost, Struyf et al. 1998).  So theoretically if DPP4-
inhibitors can block SDF1-α breakdown, then they could exert a positive effect on vascular 
progenitor cells.  Indeed this was shown in a recent study where sitagliptin was given for 4 
weeks, and showed a significant increase in SDF1-α and also in endothelial progenitor cells 
(EPC)(Fadini, Boscaro et al. 2010).  There has been much debate as to how an EPC is 
defined.  CD34+ is expressed on most EPC.  However a recent study looking at the effect of 
sitagliptin on EPC in patients with T2D, showed a 2 fold increase in CD34+KDR+, but no 
change in CD34+.  This was explained because SDF-1α receptor CXCR4 was only expressed 
on 17% of CD34+ and on 63% of CD34+KDR+ cells.  
Furthermore a recent study, showed that during both acute hyperglycaemia and acute 
hypoglycaemia, there is a significant increase in MMP-9 (possibly through generation of 
oxidative stress (also increase in 8-iso-PGF2α), however simultaneous infusion of GLP-1was 
able to counter-act this effect in both scenarios(Ceriello, La Sala et al. 2015).  Therefore an 
agent such as DPP-4 i may have a further therapeutic benefit, through increasing endogenous 
GLP-1 on reduction of oxidative stress, and potentially on cardiovascular disease.   
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DPP-4inhibitors (DPP-4 i ) (des-fluor-sitagliptin, (Matsubara, Sugiyama et al. 2012) 
sitagliptin(Shah, Kampfrath et al. 2011) vildagliptin(Maeda, Matsui et al. 2012)) has also 
shown to inhibit inflammatory cytokines such as TNF-α, interleukin (IL-6), IL-1β and MCP-
1, and cause up regulation of endothelial NO production and also to suppress the NF-ĸβ in 
experimental animal models.    
Therefore, focusing on therapies such as DPP-4 i to both improve function and number of 
EPCs, with its additional possible anti-inflammatory role, as well as increasing GLP-1 may 
potentially offer additional benefits  and aid in reducing macrovascular burden of T1D.   
Methods 
 
We designed an investigator-funded 12-week double-blind, randomized, cross-over study in 
individuals with established c-peptide negative T1D to determine whether DPP-4 inhibition, 
through primarily its glucagon suppressive effect was able to reduce insulin requirements and 
improve overall glucose variability, and would subsequently reduce frequency and exposure 
to hypoglycaemia, therefore improving the magnitude of the counterregulatory symptom and 
hormone responses during subsequent insulin-induced hypoglycaemia. 
This was a single center, randomized, double-blind, placebo-controlled randomized trial.  
Ethical approval was obtained from an independent research ethics committee and the 
Medicines Healthcare Products Regulatory Agency (MHRA)).  The study was carried out in 
accordance with the Declaration of Helsinki, and written informed consent obtained from all 
participants before inclusion in the study. All participants were identified using the Scottish 
Diabetes Research Network (SDRN), and the study took place at the Clinical Research 
Centre, Ninewells Hospital, Dundee. (Ethics REC No; 12/SS/0125 and Clinical Trials.gov; 
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NCT 01922817.  Adult subjects (n=14) with well-controlled c-peptide negative T1D >5 years 
duration were recruited and underwent medical screening.   
 
Criteria are detailed below 
Table 7 Inclusion and exclusion criteria for the DPP-4 i study 
Inclusion criteria 
 Type 1 diabetes with greater than 5 years disease duration 
 HbA1C<10%  
 Age 18 and over 
 Current use of intensive insulin therapy (injections or pump) 
 BMI 19-35 kg/m2 
 Ability to give written informed consent to participate in the study 
Exclusion criteria 
 Previous history of pancreatic disease/cancer 
 Significant renal disease eGFR <50 ml/min 
 Significant microvascular disease  
 Personal/family history of Medullary thyroid cancer 
 Personal/family history of MEN Type 2 
 Moderate/Severe hepatic impairment (Child Pugh B,C) 
 Pregnancy/Breast feeding 
 History of epilepsy/hypoglycaemia induced seizure 
 Those on any other hypoglycaemic drug apart from insulin for their diabetes.  
 Currently on CYP3A4 inducers like carbamazepine, dexamethasone, 
phenobarbital, phenytoin and rifampicin 
 Currently on CYP3A4 inhibitors like ketoconazole, diltiazem 
 Less than 30 days since participation in another drug trial or longer depending on 
the drug half-life.   
 
Baseline demographic and information on current diabetes management was collated.   
Screening bloods (renal and liver enzymes) and thorough review of medical notes was 
conducted to ensure that the participant could be included. Consenting participants had an 
initial 3-4 week baseline period where they underwent two blinded continuous glucose 
monitoring (CGM) periods for at least 5 days (one at the start and one at the end).   
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The first blinded CGM (iPRO) was used for education purposes – following this each 
participant had their insulin, dietary and exercise regimes completely reviewed by myself for 
consistency and carbohydrate ratios reviewed by a single dietician.  Treatment of 
hypoglycaemia was re-iterated with an emphasis on quick recognition and treatment of all 
hypoglycaemia episodes. These were all done in a one-to-one manner.  The participant would 
then have an opportunity to optimize their diabetes management.  A second blinded CGM 
was performed after a minimum of 3-4 weeks and the data from this was used as a baseline 
for calculation of glycaemic variability (GV) indices prior to entry into the drug treatment 
phase. During each CGM, participants were required to fill in the iPRO blood glucose-
recording diary for calibration purposes during the 5-7 day monitoring period.  This involved 
checking blood sugars at least 3 times a day prior to meals and an additional reading prior to 
bed. In addition, participants were also encouraged to check blood sugars during all 
symptomatic hypoglycaemia episodes, and to record all blood sugars below 3.5mmol/L 
(frequency of hypoglycaemia measures).  The data sheet from the iPRO web based software 
was exported to EasyGV (Hill, Oliver et al. 2011), an excel-enabled workbook.  This 
program uses macros to calculate 10 different measures of glycaemic variability from 
continuous glucose monitoring data using a simple interface.  For the purposes of this study, 
we focused on Low Blood Glucose Index (LBGI) and Average Daily Risk Range (ADRR).  
The former was chosen as an index reflecting hypoglycemic stress during the monitoring 
period (Kovatchev, Cox et al. 1998) and the latter, because it is equally sensitive to both 
hypoglycaemia as well as hyperglycaemia (due to log transformation of original values) and 
is a good marker of both extremes of GV(Kovatchev, Otto et al. 2006).  HbA1c, insulin doses 
and weight were also recorded prior to the first treatment phase.   
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Subsequently, subjects were enrolled into Group 1 (Gp 1) or Group 2 (Gp2) using a 
randomized block design. Subjects were randomized in blocks of 4 using a computer 
generated randomization sequence generator.  Seven subjects were in each treatment 
sequence.  Sequence A received placebo for the first 12 weeks, before receiving the DPP-4 i  
for the second arm.  Sequence B was in reverse order to Sequence A.  All subjects were 
advised to continue their usual diabetes, dietary and exercise regime during the entire trial.  
Subjects were contacted on a weekly basis for the first month, and then monthly thereafter.  
During each contact, adverse events were recorded and advice provided as required on insulin 
dose adjustment.  
Subjects were provided with a single daily oral 5mg dose of the DPP-4 inhibitor saxagliptin 
(Onglyza ®, Bristol Myers Squibb) or placebo for 12 weeks. Both placebo and Saxaglitpin 
were encapsulated to ensure they were identical in appearance. At the end of each 12-week 
period the subjects underwent a further period of blinded CGM (at least 5 days), blood 
samples were taken and each subject underwent a hyperinsulinemic hypoglycemic clamp 
study to assess the magnitude of their counter-regulatory responses.    Participants had at least 
a 2-week washout period before entering the second arm of the trial.  
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Figure 16;  Diagrammatic representation of DPP-4 i study design  
 
Single step hyperinsulinemic hypoglycaemic clamp  
 
Overnight-fasted subjects reported to the Clinical Research Centre, Dundee at 8.00am.  All 
subjects were asked to avoid hypoglycaemia (<3.5mmol/L) in the last 24 hours prior to the 
clamp study and to reduce their long acting insulin by 10-20% and this was subsequently 
confirmed by CGM (this period was excluded from final analysis of GV).   A cannula was 
inserted into the non-dominant hand, and placed in a heated box (50-55ᴼC) to obtain 
arterialized venous blood.  A further cannula was inserted into the dominant antecubital vein 
of the contralateral arm.  Insulin was started at a priming dose of 15u/hr until a blood glucose 
of 7.0 mmol/L was reached, and then insulin was maintained at a dose of 1.5mu/kg/min.  
Glycaemic plateaus were achieved through bedside measurement of blood glucose (Analox 
GM9D, Analox instruments, London, UK) every 5-10 minutes, and using a variable 20% 
dextrose infusion. Subjects were initially maintained in the euglycaemic range (between 4-
6mmol/L) for 40 minutes, prior to hypoglycaemia (2.5mmol/l) being induced and 
subsequently maintained for 85mins. Blood samples for determination of insulin, adrenaline, 
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noradrenaline, and glucagon were drawn in triplicate during the baseline period, and then 
every 20 minutes during the hypoglycemic phase. Blood pressure and pulse rate were 
measured every 10 minutes (Accutorr Plus Monitor, Datascope Corp., New Jersey, USA).   
Blood sampling and analyses 
 
Samples were centrifuged to separate the plasma within 2 hours, and then stored at -80⁰ c 
prior to assay.   Hormones (Insulin-RIA-Diasorin; CV inter -6.7%, intra -5.8%), (Glucagon-
RIA-MilliporeUK; CV inter 4.9%, intra 8.8%), (Adrenaline-EIA-Alpco; CV inter 22%, intra 
16%), (Noradrenaline-EIA-Alpco; CV inter 16%, intra 22%) were measured by ELISA, and 
samples were analyzed in duplicate according to the manufacturer’s instructions. 
Symptoms and cognitive function tests 
 
Subjects rated hypoglycaemia symptoms three times over the 40 minute euglycaemic period 
and every 20mins during the hypoglycemic plateaus.  Symptoms were scored on a validated 
questionnaire, the Edinburgh Hypoglycaemia Scale, scoring from 1 (not at all) to 7(very 
severe) on a visual analogue scale.  Symptoms included autonomic (hunger, palpitations, 
sweating, shaking), neuroglycopenic (drowsy, confused, odd behavior, speech difficulty, 
inco-ordination) and non-specific symptoms (nausea, headache) (Deary, Hepburn et al. 
1993). 
Cognitive function was assessed along with symptoms using Trail Making B(TMB)(Kortte, 
Horner et al. 2002) and Digit symbol substitution test (DSS) tasks, which are known to be 
sensitive to hypoglycaemia (Wechsler 1981).   To minimize learning effects, all subjects had 
practiced both tasks. (5-7 days prior to the clamp study and also twice at the start of the 
clamp study) 
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Statistical analysis 
 
Data are reported as mean ± SEM. The pre-specified primary outcome was the adrenaline 
counter-regulatory response during insulin-induced hypoglycaemia following 12 weeks of 
saxagliptin treatment vs. placebo. Prior power calculations indicated that 12 subjects were 
needed for a matched analysis, with 80% power to detect a difference in change of 
450pmol/L (Amiel, Sherwin et al. 1988) with SD of 500 and an alpha of 0.05, two sided. 
Additional subjects were recruited to account for a potential 25% dropout rate. Secondary 
outcomes included insulin requirements, HbA1c, glucose variability indices, frequency of 
hypoglycaemia, hypoglycaemic awareness, and glucagon response during hypoglycaemia. 
Statistical analyses were conducted using Graphpad Prism 6 and p<0.05 was considered 
statistically significant. Normally distributed data were compared using paired samples t 
tests, while non-normally distributed data were compared using the Wilcoxon signed rank 
test. Repeated measures ANOVA was used to determine differences in other parameters 
measured over time, with t-testing used to localize effects where indicated. No order effects 
were noted in any of the subsequent analyses.  
Visits structure 
 
V1; Informed consent was taken on the first visit (V1). Screening was performed. (See 
Inclusion and Exclusion Criteria in Table 3).  History of frequency of hypoglycaemia 
alongside questionnaires to assess hypoglycaemia awareness (Gold) will be assessed.  A 
comprehensive history of their diabetes will be taken including current insulin doses. I will 
also document their past medical history and general demographics (BMI, Sex, Ethnicity).  
Baseline bloods will be taken (FBC, UE, LFT, Amylase, Lipids, and HbA1c). A continuous 
glucose monitor (CGM) will be fitted and participant encouraged to fill simultaneously a 
food and insulin diary.  
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V2; 2-7 days after V1, the CGM will be reviewed. General dietary and insulin advice will be 
given.  A dietician will also be present. Participant will be encouraged to make appropriate 
changes over the following 4 weeks. The 4-week baseline period is designed to familiarize 
the participants with CGM and to optimize diabetes management prior to entry into the trial. 
The first CGM will be predominantly used for educational purposes.  
V3; 3-8weeks after V2, a 2nd CGM would be fitted.   
V4; 2-7 days after V3, CGM will be reviewed. A review of hypoglycaemia frequency will be 
recorded. This CGM will be used for assessment of glucose variability prior to entry into the 
treatment phase.  The investigational medicinal product (IMP) will be issued to the 
participant.   
Follow up; I made telephone contact with the participant on a weekly basis for the first 
month, and then monthly contact after that.  This will be used both as an opportunity to 
reduce insulin if the participants are having increasing hypoglycaemia episodes and also to 
document any adverse events.   
V5; 12-14weeks after V4; Frequency of hypoglycaemia and insulin doses would be 
documented.  Baseline bloods would be repeated.  A repeat CGM would be performed.  The 
participant will be familiarised with the cognitive tests to be performed during the 
hyperinsulinemic hypoglycaemic clamp study a few days later.    
V6; 2-7 days after V5; CGM will be used to assess glucose variability post treatment 1.   
Pt will undergo the single step hyperinsulinemic clamp study.  At the end of the study, 
participants will then be given a meal, and asked to take their short acting insulin.  After their 
meal, we will make sure their parameters such as BP, pulse, blood sugars are in an acceptable 
range, and that the participant feels back to normal before considering discharge.   
There will then be at least a 2 week washout period.  
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V7; Subjects will be given the IMP (placebo/drug), and compliance will be reinforced. 
Telephone contact with the participant will be made on a weekly basis for the first month, 
and then monthly contact after that.  This will be used both as an opportunity to reduce 
insulin if the participants are having increasing hypoglycaemia episodes and also to document 
any adverse events.   
V8 and V9; will be similar to V5 and V6.   
 
Results 
 
Eighteen subjects with T1D were screened, with fourteen (8 male, 6 female) Caucasian 
subjects completing the two arms of the trial. The consort diagram is shown in Figure 9.  
Mean age of participants was 42.9 (3.3) years. Mean weight was 74.1(3) kg. All participants 
had C-peptide –ve (<0.10nmol/L) T1D, with a mean duration of disease of 20.5 (2.7) years 
with relatively well controlled disease (mean HbA1c 64 (2) mmol/mol.  Mean insulin doses 
were long acting insulin 27 (4) and short acting insulin 28 (4) units. Median (IQR) baseline 
Gold score was 3.0 (2-4).  (See table 8)  Compliance with study drug was high in both arms 
of the trial (placebo and saxagliptin arms, 94.4 and 91.8% respectively). 
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Figure 17 Consort diagram for the DPP-4 i study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Final analysis (n=14) 
Excluded (n=4) 
Screen –ve (n=2) 
Withdrew consent (n=2) 
 
Screened for suitability n=18 
Randomized (n=14) 
Allocated to treatment (n=14) 
Received 2 allocated treatments (n=14) 
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Table 8; Baseline clinical and biochemical characteristics for STUDY 2 
 
Median (IQR) age (yrs.) 44.5 (14) 
Median (IQR) weight (kg) 72.3 (13.4) 
Median (IQR) duration of diabetes (yrs.) 17.5 (15.5) 
Median (IQR) Gold Score 3 (1.8)  
Median (IQR) HbA1c (mmol/mol/%) 63mmol/mol/7.9% (7.5) 
Median (IQR) insulin doses  
-long acting (u) 28 (18) 
-short acting (u) 25 (18) 
 
Glycaemic control, hypoglycaemia frequency, hypoglycaemia awareness and body 
weight 
 
There was no overall effect of saxagliptin on glycaemic control [HbA1c F (1, 11) =2.49 
p=0.14], 
Or daily insulin dose [F (1, 11) =0.069 p=0.80]. 
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Table 9 Measures of glycaemic control and glucose variability following 12-weeks adjunct therapy 
with DPP-4 i  (Saxagliptin) or placebo in subjects with type 1 diabetes. Glucose variability measures 
recorded using continuous glucose monitoring assessments in the final week of the trial. Values 
shown as mean (SEM). 
 Variable Placebo Saxagliptin 
Glycaemic control HbA1c (mmol/mol) 66 (2) 65 (2) 
 Total insulin dose (iu) 60 (8) 56 (7) 
Glycaemic 
variability 
LBGI 6.1 (1.6) 6.1 (1.8) 
 HBGI 12.8 (1.6) 13.5 (1.9) 
 ADRR 12.3 (1.9) 12.3 (1.7) 
 Mean glucose  9.7 (0.6) 10.2 (0.6) 
 SD 3.6 (0.2) 3.7 (0.3) 
 
During each treatment phase the change in HbA1c was small (0.3mmol/L with saxagliptin 
and 1.6mmol/L with placebo) and did not differ significantly between groups (p=0.61). In 
addition, no overall effect of saxagliptin on self-reported hypoglycaemia frequency [F (1, 11) 
=0.393 p=0.54] or hypoglycaemia awareness [F (1, 11) =3.43 p=0.09] was seen. There was 
no effect of saxagliptin on weight [mean increase of 0.24kg with saxagliptin and 0.07kg with 
placebo; F (1, 11) =0.40 p=0.54]. 
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Glucose variability 
No significant effect of saxagliptin adjunct therapy was seen on CGM measures of mean or 
Standard deviation of glucose or on the principal measures of LBGI [F (1, 9) =0.418 
p=0.534] or ADRR [F (1, 9) =0.365 p=0.365] (see Table 4) (see Figure 9) 
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Figure 18. Effect of saxagliptin on Hypoglycaemia Awareness, Low Blood Glucose Index and Average Daily Risk Range.  
Non-insulin adjunct therapy with Saxagliptin in c-peptide negative type 1 diabetes had no effect on (A) 
Hypoglycaemia Awareness, (B) Low Blood Glucose Index (LBGI), (C)Average Daily Risk Range (ADRR). 
Saxagliptin shown by black bars, Placebo by white bars. Values shown as Mean ±SEM. 
 
S a x a g lip t in P la c e b o  
-2 .0
-1 .5
-1 .0
-0 .5
0 .0
C
h
a
n
g
e
 i
n
 G
o
ld
 S
c
o
re
S a x a g lip t in P la c e b o  
-2
0
2
4
C
h
a
n
g
e
 i
n
 L
B
G
I 
s
c
o
re
 f
ro
m
 b
a
s
e
li
n
e
S a x a g lip t in P la c e b o  
-3
-2
-1
0
C
h
a
n
g
e
 i
n
 A
D
R
R
 s
c
o
re
 f
ro
m
 b
a
s
e
li
n
e
205 
 
Hyperinsulinemic hypoglycaemic studies 
 
Glucose profiles during the hyperinsulinemic clamps studies were also well matched with no 
Effect of treatment [F (1, 26) =0.00 p=0.96]. (Fig 11a/b) 
 
Figure 19;  Blood glucose and Glucose Infusion Rate during STUDY 2 clamp studies 
Blood glucose (a) and GIR (b) was comparable in both hyperinsulinemic hypoglycaemic clamp with placebo 
and with saxagliptin 
 
Glucose infusion rates (GIR) required to maintain the hypoglycaemia plateau were also 
comparable in the two treatment groups [F (1, 26) =0.23 p=0.64] (Figure 10b). 
Plasma adrenaline increased with time over the clamp period [main effect of time, F (6, 
156) =40.36 p<0.0001]. However there was no effect of treatment [F (1, 26) =0.02 p=0.89] 
and 
There was no time X treatment interaction [F (6,156) =0.17 p=0.98]. The AUC of the 
Adrenaline responses were also similar between groups [25,775 vs. 24,454, Placebo vs. 
Saxagliptin, respectively, p=0.76] (Figure 11a). No significant effect of either hypoglycaemia 
or treatment was seen on the glucagon response to hypoglycaemia (p=ns; Figure 11b) 
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Figure 20; Comparison of Epinephrine and Glucagon responses in placebo/saxagliptin clamp studies.  
During the hyperinsulinemic hypoglycaemic clamp studies, there was no significant differences in adrenaline 
and glucagon secretion with saxagliptin  
 
Consistent with the hormonal responses, subjects did not report any differences in their 
total symptom scores during hypoglycaemia between the two treatment arms [26 (4) vs. 28 
(3), Placebo vs. Saxagliptin; p=0.38], or between autonomic symptoms [12 (1) vs. 13 (1), 
Placebo vs. Saxagliptin; p=0.36) (see Figure 12a). The two groups also performed similarly 
on cognitive tasks during hypoglycaemia: TMB [37 (6) vs. 37 (8) s; p=0.96] or DSS [67 (4) 
vs. 62 (4); p=0.16] both Placebo vs. Saxagliptin, respectively (see Figure 13 b and c). 
Adverse events 
No serious adverse events were reported during the trial. Other adverse events reported were 
infrequent (<10%), mild and did not differ with placebo or Saxagliptin therapy.  
 
 
E u g ly c e a m ia 2 .5  m m o l/L
0
2 0 0
4 0 0
6 0 0
8 0 0
E
p
in
e
p
h
r
in
e
 n
g
/m
l
P la c e b o
S a x a g lip tin
E u g ly c e a m ia 2 .5  m m o l/L
0
5 0
1 0 0
1 5 0
G
lu
c
a
g
o
n
 c
o
n
c
 (
p
g
/m
l) P la c e b o
S a x a g lip tin
207 
 
 
Figure 21;  Effect of saxagliptin/placebo on symptoms and cognitive function tests.  
 
Non-insulin adjunct therapy with Saxagliptin in c-peptide negative type 1 diabetes 
had no effect on symptom and cognitive responses to acute hypoglycaemia. (a.)Total Hypoglycaemia Symptom 
Score during euglycemic and hypoglycaemic plateaus. (b) Trail making B score (c) Digit symbol substitution 
score.  Saxagliptin group shown by black bars, Placebo by white bars. Values shown as Mean ±SEM. 
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Discussion 
 
It has recently come to light that there is dysregulation of glucagon release in patients with 
T1D alongside destruction of pancreatic βcells.  This leads to a paradoxical increase in 
glucagon in the post-prandial state, and a failure to secrete glucagon during hypoglycaemia 
(Gerich, Langlois et al. 1973, Dupre 2005).  
The importance of glucagon’s contribution to the hyperglycemic state in diabetes was elegantly 
demonstrated in a recent study of transgenic mice lacking functional glucagon receptors. When 
these mice were injected with streptozotocin to chemically destroy the majority of β-cells, overt 
diabetes did not develop despite marked insulinopenia (Lee, Wang et al. 2011). Studies such 
as these have led to the hypothesis that non-insulin adjunct therapy aimed at restoring, at least 
in part, physiological glucagon secretion would improve glycemic control in T1D. However, 
before such therapy can be advocated more widely, properly controlled, randomized clinical 
trials need to be performed in individuals with T1D to show improvement in acceptable 
outcome measures.  
We sought to determine whether adjunct therapy with oral DPP-4 i, agents known to suppress 
glucagon secretion during hyper- and not hypoglycaemia, would improve glycemic control and 
or act as insulin sparing agents in T1D. In addition, we reasoned that some restoration of 
physiological glucagon secretion would reduce daily insulin requirements and therefore lead 
to improved (reduced) glucose variability and less frequent hypoglycaemia, potentially 
improving hypoglycaemia awareness and the counter-regulatory responses to hypoglycaemia. 
In this context, even if DPP-4 i  did not improve overall glycemic control they might provide 
a safer means of achieving glycemic targets.  
However, we report that 12-weeks of adjunct saxagliptin therapy in subjects with established 
T1D failed to show any significant benefit on glycemic (frequency of biochemical 
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hypoglycaemia, insulin doses, GV and HbA1c) or metabolic parameters (weight), and did not 
significantly improve either subjective awareness of hypoglycaemia (Gold score) or formal 
testing of counterregulatory responses by the hyperinsulinemic clamp.  
The main limitations of the study include the size of the study cohort; while our study was 
adequately powered to detect a significant effect of DPP-4 i on adrenaline responses to 
hypoglycaemia using the hyperinsulinemic clamp, we are more limited in the conclusions we 
can reliably draw from our secondary analysis.  In addition, assessment of glucose variability 
and hypoglycaemia frequency was made during periods of CGM over the 6 days of 
measurement and longer periods of assessment may have been more representative. However 
the robust methodology involved in the clamp studies is very suggestive that hypoglycaemia 
frequency was not reduced. Finally, we were not able to measure GLP-1, glucagon and c-
peptide responses to a standard meal in the current trial so we cannot say for certain that 
saxagliptin therapy in T1D was effective at improving post-prandial glucose and glucagon 
responses. However, other DPP-4 i  drugs in T1D have been shown to act in this way (Farngren, 
Persson et al. 2012), while in T2D saxagliptin significantly increases insulin secretion and 
improves glucagon area under the curve in the postprandial state (Henry, Smith et al. 2011, 
Sjostrand, Iqbal et al. 2014).  
Our findings are consistent with a recent double-blind, randomized, parallel group study of 
DPP-4 i in T1D, which revealed that sitagliptin had no independent effect on HbA1c, insulin 
dose, weight, or C-peptide after 16 weeks of treatment. It was however noted that C-peptide 
positive patients randomized to sitagliptin had a non-significant trend toward decrease in 
HbA1c, mean glucose, and time spent in hyperglycaemia (Garg, Moser et al. 2013). It has been 
noted in trials so far, with both DPP-4 i  and GLP-1 receptor agonists, that subjects who are c-
peptide positive have a greater effect on post prandial glucose excursion and glucagon than 
those who are c-peptide negative (Creutzfeldt, Kleine et al. 1996, Dupre 2005)(as in our study), 
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and it has been suggested that not only is α cell suppression important in these patients but also 
the effect of delayed gastric emptying with these agents.    
However, our results contrast with those of Ellis et al. (Ellis, Moser et al. 2011) who compared 
the DPP-4 i  sitagliptin with placebo in a 4-week double-blind cross-over trial in 20 subjects 
with T1D. They reported that sitagliptin adjunct therapy significantly improved HbA1c (-
2.91± 1.16 mmol/l) and glucose variability as assessed by M100, Glycemic Risk Assessment 
Diabetes Equation and J-index. However, this was a trial with a short duration of treatment and 
no wash-out period. There were apparent differences in baseline HbA1c between treatment 
arms and a marked Hawthorne effect suggesting that increased contact with health care 
personal and more frequent monitoring played a large part in the improvements seen. In 
addition, there were no significant changes in measures of GV (LBGI, MAGE, CV, SD) and 
even a trend to more time spent in the hypoglycaemia range (<3.5 mmol/l) in the sitagliptin 
group (Ellis, Moser et al. 2011).  
The lack of effect of saxagliptin in the current study on HbA1c, daily insulin dose, and 
measures of GV suggests that oral DPP-4 i may have limited impact on basal or post-prandial 
glucagon in T1D. Although not specifically addressed in the current study through 
measurement of GLP-1, glucagon and c-peptide responses to a standard meal, in T2D 
saxagliptin has been shown to significantly increase insulin secretion and reduce glucagon area 
under the curve in the postprandial state (Henry, Smith et al. 2011, Sjostrand, Iqbal et al. 2014). 
In a study of 28 subjects with c-peptide negative and positive T1D, Farngren et al. (Farngren, 
Persson et al. 2012) reported that 28 days prior therapy with the DPP-4 i  Vildagliptin 
significantly suppressed blood glucose and glucagon (approx. 9% reduction in AUC glucagon) 
responses to a standard breakfast meal test and increased basal and meal-stimulated GLP-1. 
This group also reported a small benefit of DPP-4 i  in terms of HbA1c (Farngren, Persson et 
al. 2012). It is possible however that the effect of Vildagliptin in this study was indirect, 
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occurring via an enhancement of residual endogenous insulin secretion in those subjects who 
were c-peptide positive. This would be consistent with the findings of Garg et al. (Garg, Moser 
et al. 2013) who also found that the DPP-4 i  sitagliptin in T1D increased post-meal GLP-1 and 
suppressed glucagon, and suggested the benefits of DPP-4 i  tended to be in C-peptide positive 
patients. 
DPP-4 i have the advantage of oral administration but the injectable therapies such as GLP-1 
receptor agonists (Kielgast, Holst et al. 2011) or amylin analogues (Chase, Lutz et al. 2009), 
may have a more potent effect on the α cell, and hence be a more suitable adjunct therapy.  
Overall, more convincing trials need to be reported before the case of α cell directed therapies 
can be implemented.   
In summary, the present study demonstrates that in subjects with moderately well-controlled C 
peptide –ve long-standing T1D, non-insulin adjunct therapy with the DPP-4 i  saxagliptin has 
no measureable effect on HbA1c, glucose-variability or symptomatic awareness and 
counterregulatory responses to acute hypoglycaemia. These findings do not support the use of 
DPP-4 i  in the management of T1D. 
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CHAPTER 6;  
STUDY 3; THE GV COHORT; Glycaemic variability and the cortisol 
curve 
Introduction 
 
The impact of GV in T1D is highly debated. Clearly, there is a strong relationship between 
GV and hypoglycaemia.  Glucose variability has been shown to independently predict severe 
hypoglycaemia risk in the DCCT (1995) (Kovatchev, Cox et al. 2000). In this context, 
hypoglycaemia recently emerged as a significant risk factor for CVD mortality in 3 multi-
center intervention trials in Type 2 diabetes (Gerstein, Miller et al. 2008, Patel, MacMahon et 
al. 2008, Duckworth, Abraira et al. 2009)  
The association between GV and hypoglycaemia is the basis of STUDY 2, but we now 
wanted to explore additional potential effects of GV and in particular recurrent 
hypoglycaemia (RH) on whole body physiology.  It has recently been proposed that GV, a 
measure of the fluctuation of glucose reading around the mean daily value, may be involved 
in the pathogenesis of macrovascular disease.  The Verona Diabetes Study showed glycaemic 
variation was a significant and independent predictor of mortality. (Muggeo, Zoppini et al. 
2000). The mechanisms through which glycaemic variability might accelerate progression of 
macrovascular disease are unclear although increased glucose variability has a negative 
impact on cell apoptosis and oxidative stress (Li, Liu et al. 1996, Quagliaro, Piconi et al. 
2003).  Monnier et al demonstrated induced glycaemic variability caused a dramatic fall in 
prostacyclin synthetase, a major anti-atherogenic endothelial cell enzyme.  Glucose 
fluctuations have also been shown to have harmful effects on retinal and kidney vasculature. 
(Li, Liu et al. 1996, Jones, Saunders et al. 1999) 
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While hyperglycaemia is clearly implicated in the development and progression of 
microvascular complications in T1D, the association between hyperglycaemia and 
macrovascular complications is not clear, and therapeutic interventions targeting glucose 
control have so far failed to show a marked reduction in adverse cardiovascular outcomes.  
Certainly, T1D is associated with an increase in all-cause and cardiovascular (CVD) 
mortality.  Data from the UK General Practice Research Database revealed the hazard ratio 
for major CVD was 3.6 (95%CI 2.9-4.5) in Type 1 diabetic men and 7.6 (5.5 – 10.7) in 
women (Soedamah-Muthu, Fuller et al. 2006). A recent prospective cohort study from the 
Scottish Diabetes Research Network epidemiology group reported that the estimated loss in 
life expectancy is still related to ischemic heart disease (36% in men, 31% in women 
(Livingstone, Levin et al. 2015).   
Hypoglycaemia however presents a profound stimulation to the HPA axis and stimulates a 
rise in peripheral glucocorticoid, while repeated hypoglycaemia may eventually lead to a 
down-regulation of this response. This represents a form of ‘stress habituation’, which has 
been shown to lead to blunting of cortisol diurnal variation (Heim, Ehlert et al. 2000). In the 
Whitehall II study, blunting of the diurnal cortisol curve was linked to increased risk of all-
cause mortality (Kumari, Shipley et al. 2011).   Diurnal cortisol decline has also been related 
to increased coronary calcification in the CARDIA study. (Matthews, Schwartz et al. 2006).  
Thus, increased glucose variability and repeated hypoglycaemia may, independently from 
chronic hyperglycaemia, contribute to CVD mortality in TIDM.    In STUDY 3, we explored 
whether glucose variability and/or repeated hypoglycaemia adversely affects the daily diurnal 
cortisol profile.  If this is the case, we hypothesize could this play a contributing factor to the 
excess cardiovascular events seen in T1D?  
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Methods 
 
This study was designed to focus on the effects of both recurrent hypoglycaemia and 
glycaemic variability on the HPA axis.   
Following informed consent, a structured interview enabled collection of demographic 
details, diabetes and hypoglycaemia history.  Following this the subject was fitted with a 
blinded professional CGM device (iPRO) and given a calibration diary (to record blood 
glucose readings at least 4 times a day as detailed by Medtronic).  Subjects were encouraged 
to wear the monitor for 7 days, but shorter periods (min 4 days) due to other commitments 
would be possible.  Subjects were given 8 pre-labelled sample bottles to collect the saliva (for 
measurement of cortisol) at pre-determined times –see Appendix 1.  Subjects were advised to 
collect the sample, not more than 3 days prior to returning it back to myself.  Samples were 
stored at room temperature until it was returned back.  On receipt of the samples, the samples 
were stored at -20⁰C until analysis.  
During the 2nd visit, the subject’s iPRO device was downloaded with the aid of the calibration 
readings.  The raw glucose values were exported to the EasyGV version 8.7 program (an 
excel sheet with pre-determined formulae, which enables calculation of several GV 
parameters from the raw glucose data).   
During the analysis phase, subjects with T1D were divided into those with low exposure to 
hypoglycaemia (LBGI<5) and those with high exposure to hypoglycaemia (LBGI>5).   
Age, sex and BMI matched non-diabetic control subjects were also recruited to match these 2 
groups with diabetes.  
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Assessment of GV - Continuous glucose monitoring 
 
Most of the studies to date have examined the impact of GV on diabetes-related 
complications by further analysing the DCCT/EDIC database and have primarily used SMBG 
as a means of assessing glucose variability.  SMBG (usually 7 point) has many limitations 
including patient reliability in taking adequate readings, and the absence of data from the 
nocturnal period.  Current continuous glucose monitoring (CGM) systems overcome both 
these problems, and are capable of capturing data at 5 minute intervals for a duration of 5-7 
days.  They are able to therefore provide a much more robust means of measuring short term 
glucose variability. It is particularly valuable during times when SHBG cannot be performed 
(i.e. during sleeping).   
In our study, the sterile disposable continuous glucose monitoring (CGM) sensor iPro CGM 
system (Medtronic, Northridge, CA) was inserted subcutaneously.  Subjects were instructed 
to record at least 4 glucometer readings (preferably pre-meal and bedtime) for calibration 
purposes. CGM was worn for an average of 5-7 days.  Data was recorded every 5 minutes. At 
the end of the monitoring period, the sensor and meter data were downloaded on the Carelink 
iPRO Therapy Management Software for diabetes.  The data was then transferred to the Easy 
GV software, where, various metrics of glucose variability were calculated.  We considered 
Low Blood Glucose Index (LBGI)/High Blood Glucose Index (HBGI) as an indicator of 
hypo and hyperglycaemic stress.  Average Daily Risk Ratio (ADRR) was also calculated to 
take into account both extremes.  Other measures indicative of short lived glucose variability 
were assessed by measuring SD, MAGE and CONGA.   
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Accuracy 
 
CGM systems are often assessed for accuracy through evaluation of MARD (Mean Absolute 
Relative Difference).  This is calculated by comparing the mean of the duplicate capillary BG 
readings which are then paired to interpolate CGM readings. The difference in the 2 readings 
is divided by the mean of the duplicate capillary BG measurement results.  The Enlite sensor 
(using the Veo calibration algorithm) produced a MARD of 13.9% with 97.3% of points 
within A+B zones of the Clarke error grid (Keenan, Mastrototaro et al. 2012).   
The SG:BG (sensor glucose: blood glucose), which is % of readings within 1.1mmol/L of 
capillary readings has been reported as 88.7% (2.2-4.4mmol/L), 83.3% (4.4-6.6), 
94.9%(13.3-22.2) for the sof-sensor(Welsh, Kaufman et al. 2012) which was used in this 
study.   
Time lag 
 
There have been many criticisms regarding the time lag in continuous glucose monitoring 
systems.  However a recent study using isotope tracer technology and micro dialysis 
techniques sampling from the interstium, has shown that in the fasting state, the physiological 
delay from the vascular compartment to the interstitium is actually only 5-6 minutes.(Basu, 
Dube et al. 2013)  
Problems at hypoglycaemia range 
 
Based on corresponding SMBG and CGMS, an abstract presented at the ADA(choudhary 
2006) suggested a cut off value for detection of hypoglycaemia of 3.3mmol/mol. based on the 
optimal sensitivity and specificity (0.73 and 0.73 respectively) at this level, and showed that 
at lower levels, although there is an increase in sensitivity, this is at the expense of lower 
specificity (0.92 and 0.38).   
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Assessment of HPA axis 
 
95% of secreted cortisol is bound to large proteins such as Cortisol Binding Globulin and 
albumin. Due to its low molecular weight and lipophilic nature, cortisol moves into cells by 
passive diffusion, and therefore it is possible to measure cortisol in all bodily fluids.   Most of 
the cortisol eventually binds to either the cytosolic mineralocorticoid or glucocorticoid 
receptors, and it is only the unbound fraction which is thought to be biologically active.   
Saliva 
 
It has been 30 years since steroids were first looked at in the saliva.  Saliva is mostly 
produced by three pairs of glands (parotid, submandibular and sublingual), with variable 
amounts of crevicular fluid from the tooth-gum margin, as well as exudates from plasma or 
blood from abrasions or other lesions. Neutral hormones generally enter by rapid diffusion 
through acinar cells and more importantly is independent of rate of saliva flow. (Vining, 
McGinley et al. 1983).  There is poor correlation between total cortisol levels in plasma and 
saliva, because of variable amounts of CBG. Several studies have shown a good correlation 
between paired saliva samples and plasma cortisol, however correlation has been found to be 
best when cortisol levels are less than 500nmol/L (Putignano, Dubini et al. 2001) which is 
approximate saturation point of CBG binding affinity.   
However a number of studies have shown that unbound cortisol (which is not affected by 
CBG) either in serum or plasma samples correlates very well to salivary samples (r>0.90).  
However due to the high concentration of 11β hydroxysteroid dehydrogenase in the saliva, 
part of the cortisol is converted to cortisone, therefore the salivary cortisol represents only 
about 60-100% of the free fraction in the circulation, and is about 4-6% of the total plasma 
concentration.   
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Single basal cortisol (unstimulated) has been used in many studies but is a poor indicator of 
the HPA axis, due to the low intra-individual stability (Coste, Strauch et al. 1994) and large 
inter-individual variation.  However day time cortisol profile have been shown to be a much 
better indicator of HPA activity.  In contrast, urinary measurement of cortisol shows an 
inability to assess rapid changes in cortisol levels.   
All subjects were provided with verbal and written instructions for collecting saliva samples 
using the simple tongue and cheek sucking, following which they would spit out into a wide 
topped universal container.  Subjects were asked to collect 7 saliva samples throughout a 
chosen day (at wakening, +30mins, +45mins after wakening, +3, 6, 9 and 12 hours after 
wakening).  They were advised to wake up promptly, to get an accurate time of wakening, to 
avoid food consumption and brushing teeth for at least 30 minutes before collection and to 
refrain from exercise and alcohol both on the day of collection and 24 hours prior. They were 
advised to rinse their mouth just prior to collection and to avoid contamination with debris. 
All blood stained samples were discarded, and subjects were advised to repeat the sample. 
Subjects were advised to collect the sample, not more than 3 days prior to returning it back to 
the research team.  Samples were stored at room temperature until it was returned back.  On 
receipt of the samples, the samples were stored at -20°C until analysis. 
Advantages 
 
The main advantages are that salivary assessment is non-invasive, stress free and real time, 
and is possible done during a subjects’ normal day, rather than serum samples which would 
require extended stay at the healthcare setting or multiple repeated blood sampling.  Salivary 
sampling also measures free unbound hormone (biologically active) and is therefore not 
confounded by high affinity binding proteins  (Vining and McGinley 1987).  Salivary cortisol 
from the earliest reports have shown to be  a good reflection of overall unbound levels in the 
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plasma, and particularly it has been shown to reflect the diurnal variation seen in plasma 
cortisol.  (James, Walker et al. 2004) Salivary cortisol has also been found to be stable across 
widely varying temperatures and movement,  as was demonstrated in a study which 
compared levels of cortisol between saliva which had been frozen within 1 hour and saliva 
which had been exposed to different temperatures over 5 days( R2=0.92, p<0.001) (Clements 
and Parker 1998). It has been further confirmed that the enzyme immunoassay method can be 
used reliably when measuring cortisol levels when the samples have been exposed to multiple 
different temperatures (-18 to room temperature for up to 72 hours) and therefore home 
sampling has been shown to be a reliable way of collecting real life samples(Nalla, Thomsen 
et al. 2015) 
Disadvantages 
 
Measurement of cortisol can be challenging as it can be affected by several external factors. 
Amongst others acute stress cannot be controlled during these collection periods.  Other 
factors which could influence levels would be differences during working days and 
weekends, variations in waking time and sleep duration prior to collection.   
Measurement of cortisol requires dealing with the difficult matrix of saliva, and this is often 
through multiple freeze-thaw cycles and centrifugation.  Steroids are also present at a much 
lower concentration in the saliva, which again can lead to problems with analysis.  Blood 
contamination has been shown to be associated with presence of both sex hormone binding 
globulin and corticosteroid binding globulin (CBG), which may interfere with measurement 
of unbound hormone.  (Hammond and Langley 1986)  Saliva cortisol is not a good marker of 
total plasma cortisol because of the presence of CBG which is saturated up to a level of 500-
600nmol/L of cortisol, however it  correlates better with free cortisol.   The salivary  gland 
has abundant 11-Beta hydroxysteroid dehydrogenase type 2 activity and therefore saliva has 
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up to 3 times cortisone level as opposed to plasma (10% of cortisol level), therefore the 
assay- cortisol antibodies has to be found not to interfere with cortisone, otherwise there 
could be quite variable levels.  (Lewis 2006) 
Various pitfalls in collection of saliva has been seen with stimulated saliva(Gordon, Peloso et 
al. 2005) (that is through chewing), with both increased variability and alteration of true 
levels.(Vialard-Miguel, Belaidi et al. 2005), and therefore experts (Lewis 2006) have 
suggested unstimulated saliva is often best.  
Methodological issues 
a. It relies heavily on proper adherence to the sampling protocol, particularly the early 
morning rise is heavily reliant on the first sample being done on waking, and subsequent 
samples done within the first 45 minutes of waking.  A study (n=47) using an electronic 
monitoring advice showed that only 74% were found to be compliant with the salivary 
collection schedule.  The diurnal rhythm was significantly different for the compliant and 
non-compliant groups.  Most importantly, increased compliance was associated with a 
good rise of cortisol on wakening and the steepness of the cortisol decline during the latter 
part of the day.  49% of the group were also informed of the nature of the electronic 
device, and had greater adherence to the protocol, compared to the non-informed 
group(Kudielka, Broderick et al. 2003).   
b. It is important that food or drink intake is avoided for 1-2 hours prior to sampling, due 
to variations in salivary secretion which in turn will negatively affect the result. 
Particularly foods that lower the mouth pH, can compromise antibody-antigen binding and 
enzyme activity thus leading to invalid immunoassay results(Papacosta and Nassis 2011).   
This may not always be possible in subjects experiencing recurrent hypoglycaemia, where 
prompt treatment is essential.   
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c. Alcohol consumption 24 hour prior to sampling is known to increase saliva secretion 
and may also influence the results(Martin and Pangborn 1971).  Alcohol consumed the 
night before salivary sampling has also been shown to decrease CAR the following 
day(Stalder, Hucklebridge et al. 2009).  For this reason, we instructed all participants to 
avoid alcohol for at least 24 hours prior to salivary sampling. Chronic consumption of 
alcohol has also been shown to increase CAR particularly in women(Badrick, Bobak et al. 
2008) and also blunt the cortisol decline over the day, suggesting alcohol consumption 
activates the  HPA axis.   
d. A further confounder was smoking.  Smoking acutely increases cortisol levels in a 
dose dependent manner (Rohleder and Kirschbaum 2006).  Chronic exposure to smoking 
has also shown to cause higher basal cortisol levels and greater morning rises and a lesser 
decline in cortisol over the day(Kumari, Badrick et al. 2010, Direk, Newson et al. 2011).  
Therefore smokers were excluded.   
e. Women who were on oestrogen therapy were excluded.  This was done as rodent 
studies have shown that oestrogen treatment was able to normalise any alteration of the HPA 
axis such as altered response to stress and an ineffective steroid negative feedback 
mechanism.   
f. Blood contamination of saliva through abrasions in the oral cavity  can also 
significantly affect the results, as plasma cortisol is typically 200-800nmol/L but in saliva is 
only 3-30nmol/L, and so if there is blood leakage, it can increase the concentration of 
salivary cortisol levels.  This can be determined indirectly, by ensuring that albumin levels in 
the saliva do not exceed the threshold levels(Papacosta and Nassis 2011).   
g. Multiple days of sampling may be better to assess the HPA axis, however this is not 
feasible in many studies. (Hellhammer, Fries et al. 2007).  One off assessment of HPA using 
cortisol samples spread out over a day, only gives us a cross sectional view of the data. 
222 
 
Recruitment 
 
Currently there is no literature looking at levels of salivary cortisol and diurnal patterns in a 
population with T1D. Therefore, we have calculated our sample size using a population study 
looking at salivary cortisol in a middle aged healthy community in Germany (Lederbogen, 
Kuhner et al. 2010) (Chen, Couto et al. 2006).  Using this, the AUC of the salivary cortisol 
diurnal curve was roughly 100 in a healthy population.   To determine a 25% change in the 
AUC of the cortisol curve, between the low and high glucose variability, with a power of 
80%, we needed 49 patients in each group.  We aim to recruit 75 participants in each group to 
complete 49 in each group to account for incorrect sampling or patients not returning salivary 
cortisol samples.   
Approvals were sought from our local sponsorship committee (Ref; 2012DM05) (Joint 
sponsorship from University of Dundee/NHS Tayside), local ethics committee (East of 
Scotland Research Ethics Service (EoSRES) REC 2)  REC ref; 12/ES/0048  and also from 
the local Research and Development (R&D) office at Tayside.   
Subjects were identified through one of the recruitment strategies outlined below.   
 
1. Participants were initially approached either by PI (PG) or Research Nurse.  This was 
usually a visit organized through the NHS, whereby patients are given the opportunity 
to have a period of continuous glucose monitoring.  Patients will be given a patient 
information sheet at this point to consider the research information.  Patients will 
return their CGM a few days later, and at this point, they will be asked whether they 
would be willing to take part in the trial.  Following informed consent, screening of 
the patient will take place.  If the patient is screen +ve, then they will be asked all the 
other questions pertinent to the study and will be given the salivary cortisol containers 
223 
 
with instructions, and a pre-paid envelope to return the containers.  An agreement is in 
place with the clinic consultants with regard to this search strategy.   
2. Participants were identified through the SDRN (Scottish Diabetes Research Network), 
who fit the inclusion and exclusion criteria.  The research team have an agreement 
with SDRN to perform these searches.  These patients have agreed to be contacted.  
Patients would be contacted by phone to see if they would like to be involved in this 
research.  A study letter and patient information sheet (PIS) will be sent by the PI to 
the participants.  Participants will be contacted by phone by member of the research 
team (>24 hours) to arrange an appointment to discuss the study, give consent and 
undergo screening.   
3. Suitable participants attending for routine diabetic clinic appointments within NHS 
Tayside will be approached by a member of the research team (PI, research nurse) and 
asked if they would consider taking part.  If they agree, a PIS was provided.  
Participants will then be contacted at least 24 hours later, to ask if they would like to 
be involved in the study.  If so they will be invited for screening visit and fitted with a 
continuous glucose monitor, and given the salivary cortisol containers and 
instructions.   A verbal agreement is in place with clinic physicians to approach 
patients in this way.   
4. Participants were identified through the SCI-DC Diabetes Clinical Database who fit 
the inclusion/exclusion criteria.  Caldicott approval has been sought to enable the 
research team to screen this database for potential participants.  We will write to the 
patients on behalf of the NHS Consultant, to see if they would like to take part. The 
PIS that the patients are sent will have a tear off slip/email to enable participants to 
agree to be contacted.  The research team will then contact them.   
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Control –Healthy, non-diabetics 
5. Partners of participants if agreeable will be contacted after consent from the 
Participant.  The participant will be given a participant information sheet to be given 
to their partner, with a tear off slip/email which if there is a reply, then the partner will 
be contacted.   
6. Participants will be recruited from advertising on the University Website. 
7. Participants will be recruited from posters that will be placed around Ninewells 
Hospital and Medical School.   
Inclusion criteria  
1. Group 1  
a. T1D 
b. Age 18-60 
c. Low glucose variability (LBGI<5) 
d. Ability to give written consent to participate in the study 
 
2. Group 2 
a. T1D 
b. Age 18-60 
c. High glucose variability (LBGI≥5) 
d. Ability to give written consent to participate in the study 
3. Group 3 
a. Non-diabetic 
b. Age 18-60 years 
c. Ability to give written consent to participate in the study 
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Exclusion criteria 
 
1. Acute physical or mental illness 
2. Those on steroid treatment 
3. Those who would not follow salivary protocol (due to inability to stop smoking on the 
day of sampling, or unable not to have alcohol on the day of sampling)  
4. Those who have Cushing’s syndrome 
5. Those who had primary or secondary adrenocortical failure 
6. Pregnancy or on greater than 36 mcg oestrogen treatment (alters circulating levels of 
Cortisol Binding Globulin) 
7. Breastfeeding mothers 
8. If incompliance with sampling procedure of salivary cortisol or if it exceeded 7 days 
before salivary collection and sample arrival.  (At least 4 out of the 7 timed samples 
need to done at the time windows for valid analysis) 
 
Study visits 
 
1st visit; Screening visit 
Informed consent obtained 
History 
Eligibility criteria checked 
Demographics obtained (BMI, Gender, Ethnicity, Marital status, Education, Occupational 
status, Physical activity) 
Diabetes history (Duration, HbA1c, insulin doses, frequency of hypos, evidence of 
microvascular and macrovascular complications) 
General medical history (Past medical and psychiatric history, SF-12 and PHQ-9)  
Smoking and alcohol history 
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Diabetes Specific Questionnaires (Gold questionnaire, Composite score, Hypoglycaemia Fear 
survey –II, High Blood Sugar survey) 
Continuous Glucose Monitor (CGM) insertion 
Medtronic I-PRO device will be inserted in an appropriate place (usual site will be in the 
abdomen).  Subjects will be advised to keep a detailed food and exercise diary.  They will 
also be asked to enter blood sugar readings at least twice a day, usually before each meal for 
calibration purposes.   They will be advised to enter insulin doses and carb content in the 
monitoring sheets provided.   
Sample collection 
Subjects will be given the salivary log sheets (see appendix) and 7 labelled containers to 
collect saliva as per the collection instructions (see appendix). This will be done whilst the 
subject is wearing the CGM, so that glycaemic variability can be correlated with the cortisol 
diurnal patterns.  
2nd visit 
Subjects will be seen 4-7 days after insertion of the CGM.  The PI will go through the CGM 
in detail and provide advice (insulin doses, carb counting, if not carb counting advice and 
basic information will also be provided, tailoring therapy for exercise, advice regarding 
hypoglycaemia treatment and prevention).  This part of the exercise is not directly related to 
this PhD but will be provided as a service to the participants.   
Subjects will also return the salivary samples with the log.  This will be stored in -20 Deg C 
freezer, until analysis.   
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Visit 2/3 
The last 30 subjects of this cohort of participants will also have a CRH (Corticotrophin 
Releasing Hormone) stimulation study. Participants will have 1 cannulae inserted in the ante-
takes place.   Participants will have the CRH (1mcg/kg) injected intravenously over 1 minute. 
All studies will be performed after 5pm to allow the basal cortisol levels to be at its lowest.  
Two baseline blood tests will be done (-15 and -5 minutes before the CRH injection).  
Following CRH injection, blood samples will be taken every 15 minutes for the first hour and 
then every 30 minutes for the second hour. (8 samples in total). These will be analysed for 
ACTH, cortisol and adrenaline.  
Results 
 
In total, 178 subjects were screened for suitability.  28 subjects were excluded.  12 were 
excluded because of smoking status, 4 were excluded because of oestrogen therapy,1 had an 
ongoing physical illness,  1 had significant psychiatric problems, 8 withdrew consent, 2 were 
on steroid therapy. Finally we had 50 subjects with low LBGI (less than 5), and 50 subjects 
with high LBGI (≥5) and 50 non-diabetic controls. 
Table 10; Baseline characteristics of the original cortisol cohort.  N=50 in each group.   
 Low LBGI High LBGI Control 
Age (years) 42.1 (1.7) 40.7 (1.8) 39.6 (1.5) 
% male 52 38 40 
BMI (% of total group)kg/m2 
18-24.9 
44 36 36 
25-29.9 38 52 42 
>30 18 12 22 
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Duration of diabetes (years) 20.9 (11.5) 23.7 (10.8)  
HbA1c (%) 8.9 (1.4) 9.1 (1.7)  
Basal/bolus split (units) 47.4/52.6 51.5/48.5  
Insulin units/kg 0.7 (0.2) 0.7 (0.4)  
Complications    
Retinopathy (% of total 
group) 
30 20  
Nephropathy (% with 
micro/macroalbuminuria) 
10 14  
Neuropathy (% with any 
evidence)  
20 26  
Marital status (% 
married/living with someone) 
72 86 62 
Alcohol (units/week) 6.7 (1.3) 4 (1) 4.6 (0.7) 
Years in education 14.6 (0.5) 14.8 (0.4) 17 (0.5) 
In employment/student (% of 
whole group) 
82 80 96 
High job strain (% of whole 
group) 
54 48 44 
Good Social support (% of 
whole group) 
96 90 90 
Physical activity (% of whole 
group)  
26 42 58 
 
Reliability of this data set 
 
1.  Frequency of reported SH was shown to  predict computed LBGI using 4-7 days 
of CGM data 
Subjects were asked to report frequency of severe hypoglycaemia (SH) over the last 2 years.  
Before the subject volunteered this information, the definition of SH was explained to them.  
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SH was defined for the purpose of this study, to be all episodes which required third party 
assistance because of incapability of the subject.  The frequency of SH significantly predicted 
the LBGI computed from the CGM data set. (R2 =0.06; F=4.74; df=1; p=0.03)   It is therefore 
suggested from this data set, that previous SH, resulted in higher LBGI during this period of 
CGM monitoring.  I feel this gives this dataset (captured over 5-7 days), some backing that it 
is reflective of a subjects usual hypoglycaemic exposure 
 
2. HbA1c was found to significantly predict HBGI 
 
HbA1c measures were found to significantly predict the HBGI computed from the 4-7 days 
of CGM.  (R2 =0.39; F=59.6; df=1; p<0.05).  This again is in keeping with published data.  
In summary, both these validity checks suggest that the period of CGM monitoring was 
reflective of both their previous exposure to hypo and hyperglycaemia.   
When the data points were examined for normality using the D'Agostino & Pearson omnibus 
normality test and also the Shapiro-Wilk normality test, it was ascertained that the data was 
not normally distributed with each time point measured.  Therefore all data underwent 
square-root transformation, which normalised the data set.  All summary measures were 
calculated using the transformed data.   
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Cleaning data 
 
Due to the nature of salivary sampling, in obtaining repeated measures over the course of one 
day, there were subjects who had not given us saliva for all 7 time points during the course of 
one day.  Other reasons for missing data, was poor repeatability during analysis of the 
cortisol levels, and very low levels detected.  Means and standard deviations were calculated 
for each time point for each group (Low, High, and Control).  If a result was out with of 2 
SD, then that result was removed and thought to be spurious.  A reason for this includes, if 
the subject had gum pathology that can spuriously, elevate the salivary cortisol levels.  This 
would particularly be suspected if there were numerous high readings for one day on a 
particular individual.   
Table 11; Individual data points which were excluded from the main data set.  
**very low levels were often seen at the end of the day, and therefore due to technical reasons, could not be measured 
accurately.  
Missing data Low LBGI High LBGI Control 
Poor repeatability 
during analysis 
11 4 6 
Very low levels* 6 3 3 
Forgotten sample 7 8 13 
Result out with 
mean +2SD 
(outliers) 
7 18 12 
Total % of data 
points- missing 
 
33/350= 9% 
 
33/350=9% 34/350=9% 
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Area under the curve (AUC) 
 
The AUC was calculated using Graphpad Prism.  Prism computes the AUC by connecting 
points by straight lines and then utilising the trapezoidal method.  It calculates the area of 
each trapezoid by calculating the area of the equivalent rectangle.  The sum of all the 
rectangles would then give the AUC.  It computes the figure from the first x value (first 
salivary sample of the day), till the last x value (this maybe 9 or 12 hours, depending on the 
last sample).  If first value is not the wakening sample, prism will use the first x value (first 
time sample of the day), and calculate AUC from there.  It is more likely, there will be bigger 
impact on AUC calculations, if first value is missing rather than last value.  The numbers of 
first missing values, are equivocal in the 3 groups, and therefore should not make a major 
impact on the calculations.   
Table 12 No of missing first values in each group  
Group  No of missing 1st values  
Low LBGI 3 
High LBGI 4 
Control 3  
I carried out an AUC analysis using all my data, and left the missing points as “blank” in the 
data sets.  The graphs below show the impact of missing points on AUC calculations.  It is 
clear that 3 and 4 time points missing in an individual clearly shift the AUC downwards, and 
therefore these subjects were removed from further analysis.  
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Table 13; No of subjects in each group with either 3 or 4 missing points  
Low LBGI 2 
High LBGI 3 
Control 2 
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Figure 22;  Graphs showing impact of missing points on a. low LBGI b. high LBGI c. control 
 
 
 
As LBGI (Low Blood glucose index) has been shown to be predictive of severe 
hypoglycaemia, these 2 variables were compared in the raw data set, for any discrepancies 
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Table 14; Table correlating the no of subjects with severe hypoglycaemia and their LBGI scores. 
No of subjects Low LBGI High LBGI 
Frequency of SH 
1 or 2 episodes 
5 8 
>5 1 4 
 
One patient in the Low LBGI had more than 5 SH in the last 2 years.  This was a patient, who 
was referred to the diabetes clinic from a peripheral centre, due to IAH and recurrent severe 
hypoglycaemia.   On examination she had significant lipohypertrophy on the abdomen due to 
her insulin injections, and she was on a total of 120 units of insulin/day.  Her insulin doses 
were reduced by 40% initially.  This led to a dramatic reduction in her frequency of 
hypoglycaemia.  Therefore her CGM which she had a few days later (after considering the 
PIS), did not reveal her prior exposure to hypoglycaemia.  This subject was also removed 
from the analysis.  Therefore the total number of subjects after removing the subjects with 3 
or 4 missing values, and also removing the above subject was 
Table 15;  Total number of subjects (excluding single pt with discrepancy between CGM and hypo frequency) analysed after 
removing those with 3 or 4 points  
 Low LBGI High LBGI Control 
No of subjects 
removed 
2 + 1 (above) = 3 3 2 
Total number of 
subjects analysed 
47 47 48 
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AUC was then calculated on these remaining subjects 
The graph below shows the AUC for each of the 3 groups 
Figure 23; Graphical representation of AUC of mean and confidence intervals for each of the groups 
 
 
There was no significant difference for the total AUC for each of the 3 groups.  (F 
2,139)=0.518 p=0.5969.  Since both early morning cortisol levels (CAR) and the diurnal 
decline are under different regulatory control (as they have shown not to correlate), it has 
been suggested that AUC of these different periods need to be looked at separately.  There 
was no significant difference in the wakening AUC cortisol (0-45mins) between the 3 groups 
(KW 0.8714).  AUC was also calculated for the curve between (3 and 12 hours).  However, 2 
or more readings missing in these calculations, significantly impacted the AUC on visual 
inspection. Therefore these subjects were removed to avoid distortion of the data.   
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Table 16; Total number of subjects analysed after removing subjects with 2 or more individual readings missing 
 Low LBGI High LBGI Control 
No of subjects 
removed 
1 3 0 
Total number of 
subjects analysed 
46 44 48 
 
There was a significant difference between the AUC (3-12) groups  F(2,135)=3.081 
p=0.0492. This was driven by a significant increase in AUC between the High LBGI group 
and Control groups. (31.8 (0.9) vs 28.5 (1.1) p=0.0239.   
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Figure 24; Graph charting the salivary cortisol levels throughout the day.   
Time 0 is time of awakening.  
 
 
Mean levels 
 
Mean levels were calculated for both the first 45 minutes and also for the 3-12 hour period, to 
determine if there was any evidence of hypercortisolaemia evident in either of these time 
periods. There was a significant increase in the mean levels of cortisol between the 3 groups, 
and this was only seen in the 3-12 hour period.  This was primarily driven by a significant 
increase between both groups with diabetes and the control group, with no difference 
between the Low and High LBGI groups.  
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Table 17; Mean cortisol levels (standard error of the mean) of the 2 main periods of the day.  
 Low LBGI High LBGI Control  
Mean (SEM) levels over 
the first 45 mins 
5.7(0.14) 5.2(0.13) 5.1(0.14) F (2, 139) = 0.5 P = 
0.5939 
Mean (SEM) levels over 
the 3-12 hour period 
3.7(0.11) 3.7(0.10) 3.4(0.11) F (2, 139) = 3.2 P = 
0.0456 
A. First 45 minutes B. 3-12 hours after wakening. This shows the mean (standard error of the mean) cortisol levels divided 
in the 2 periods of the day (firstly the first 45 minutes of the  day, then the mean levels over the next 3 to 12 hours after 
wakening.   
Slope 
 
Looking at the graph of the trend of cortisol levels through the day, it appears that the greatest 
decline occurs from the 45 min sample to the 3 hour sample, so this part of the curve was 
analysed first, particularly in relation to the downward slope. 
This was calculated by subtracting the 3 hour cortisol value from the 45 min value, and then 
dividing it by the number of hours.  
= (C45-C3)/2.25 
If a subject had a missing value in either the 45 min or the 3 hour samples, then they were 
excluded from this analysis 
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Table 18;  Total number of subjects analysed after removing those subjects with Missing F45 (45 minutes after wakening) 
or F3 (3 hours after wakening) and also removing those subjects with 3 or 4 data points missing and also the one subject 
with the CGM which was not reflective of previous hypo exposure due to treatment regime change.  
 Low LBGI High LBGI Control 
Missing F45 or F3 6 6 10 
Total number of 
subjects analysed out 
of the 50 
41 41 38 
 
Analysis of the slope from 45mins (peak period) to 3 hours after wakening showed a mean 
(SD) slope of 0.48 (0.11) in the low LBGI group vs 0.28 (0.09) in the high LBGI group and 
0.72 (0.09) units of cortisol decrease over time in the control group.  There was a significant 
difference in the 3 groups for the slope.  F(2,117)=4.837 p=0.0096.   Univariate analysis 
showed that neither age F(1,117) p=0.188 nor gender F(1,117) p=0.259 did not have a 
significant influence on the slope.   
I also looked at the slope for the whole day (from 45 mins to 12 hours after wakening).  If 
either of these values were missing, the next value (either later- for early samples or earlier-
for last samples) was taken to calculate the slope. 
Analysis of this slope which took into account the later samples revealed a similar pattern and 
showed a mean slope of 0.21 (0.02) in the lower LBGI vs 0.14 (0.02) in the higher LBGI vs 
0.24 (0.02).  There was a significant difference in the 3 groups for the daily slope ( F(2, 139) 
=6.042 p=0.003.   
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CAR 
 
This looks at the dynamic of the initial rise in cortisol on wakening.  Several methods for 
calculating CAR have been described in the literature. These include mean increase (MnInc), 
area under the curve with respect to increase and ground. (AUCi and AUCg respectively) and 
mean cortisol levels.  As both AUCg and mean levels do not provide any information on the 
dynamics of the increase, investigators often use both a measure of the dynamics of increase 
(Mean increase or AUCi) and a measurement of the value of the first sample.       
Prior to running the analysis, those subjects with any missing values in the first 3 samples 
(F0, F30 and F45), were removed from the analysis, as there is currently no agreed method 
for imputation. 
Table 19; Total number of subjects analysed after removal of subjects with missing points in F0, F30 and F45 (on wakening, 
30 minutes and 45 minutes after wakening) and after removing those with 3 or 4 points missing + removing the 1 subject 
where CGM did not reflect previous hypo frequency, as insulin doses was reduced quite dramatically prior to insertion of 
CGM due to safety reasons. 
 Low LBGI High LBGI Control 
No of subjects with 
missing points 
9 5 9 
Total number of 
subjects analysed 
38 42 39 
 
Thereafter, mean increase of cortisol rise was calculated as below 
= (F45 + F30)/2 – F0 
Mean increase for the 3 groups respectively (low LBGI, high LBGI, and Control) were 
0.32(0.20) vs 0.16(0.17) vs 0.42(0.19).  There was no significant difference between the CAR 
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in the 3 groups using this method. (F 2,139) =0.4128 p=0.5984.   Moreover, the distribution 
of the mean increase in CAR shows a large variation.   
Figure 25; Box plot of mean increase in cortisol for each of the 3 groups.   
Box extends from 25th to 75th percentile.  Middle line is median.  The whiskers are at 2.5 and 97.5 percentiles.   
 
Box extends from 25th to 75th percentile.  Middle line is median.  The whiskers are at 2.5 and 97.5 percentiles.   
 
This showed that 2 subjects were out with of 2.5 to 97.5 percentile.  CAR was once again 
calculated with these outliers removed. Mean increase of CAR for the 3 groups were 
0.31(0.20) vs 0.21(0.17) vs 0.42(0.19).  Once again, there was no significant difference 
between the CAR between the 3 groups. F(2,114) p=0.74. 
A number of subjects did not show any rise in cortisol levels in the morning.   
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Table 20; Number of subjects analysed after removal of subjects with missing points within F0, F30 or F45 and removal of 
those where no CAR could be detected ( no increase in cortisol levels from wakening)  
 Low LBGI High LBGI Control 
No of subjects with Missing 
points within F0, F30 and F45 
9 6 8 
No CAR detected 8 13 5 
Total number now analysed 30 29 34 
 
The analysis was then carried out again by taking these subjects out of the analysis as well, to 
determine whether exclusion would have a significant impact on the analysis.  This was done 
to exclude participants with a potential of incorrect sampling.   
Mean CAR (using mean increase) for the 3 groups now was 0.81 (0.13) vs 0.63(0.18) vs 
0.65(0.18).  Once again, there was no significant difference between the 3 groups. (F (2, 90) 
p=0.3368.    I also calculated AUC using the first 3 data points (F0, F30 and F45).  If any of 
these values were missing, then the subjects were not included in this analysis. 
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Table 21; Total number of subjects used to analyse AUCg by removing those subjects who had any missing values in the 
first 3 data points (F0, F30 and F45) and after removing those with 3 or 4 points missing totally + 1 subject where CGM did 
not reflect previous hypo frequency, as insulin doses were reduced quite dramatically prior to insertion of CGM due to 
safety reasons.  
 
 Low LBGI High LBGI Control 
No of subjects with 
missing values in the 
wakening period 
9 6 8 
Total number of 
subjects analysed 
38 41 40 
 
Mean AUCg for the 3 groups (Low LBGI, High LBGI and Control) showed no significant 
difference (238.1 (5.8) vs 233 (6.6) vs 241 (5.9)  F (2,116)  p=0.41.   
Mean AUCi (AUC with respect to increase which takes into account dynamic increase of 
cortisol was calculated according to published calculations (F30 +((F45-F0)/2))-2*F0.  AUCi 
showed no significant difference between groups F (2,115) p=0.95.  
A two way ANOVA was conducted to examine the effect of gender and age on the CAR 
(mean increase).  There was no statistical significant interaction between the effects of gender 
and age on the CAR.  F(3,84)=0.156 p=0.93.  Univariate analysis showed that age did not 
have a significant influence on the CAR.  F(28,25) p=0.58.  I also performed linear 
regression, and this once again showed that age and gender did not statistically predict CAR 
(MnInc), F(2,90)=0.45 p=0.639.  
 
 
244 
 
Correlation analysis 
 
Correlation coefficients between each of the glycaemic variability indices and the summary 
measures of the diurnal cortisol patterns are presented (see table 22) 
The correlation between LBGI and slope was inverse and statistically significant (rs =-0.23; 
p=0.0393) ie. so the greater the exposure to hypoglycaemia, the more blunted the slope.  This 
was particularly the case in the early slope (calculated from 45 mins to 3 hours after 
wakening.  (+ve slope indicates a downward slope, and a –ve slope indicates an upward 
slope) 
Measures which are more indicative of higher glucose readings throughout the day (such as 
HBGI and mean) both show that there is a correlation between these measures and both Mean 
cortisol values of 3-12 hours and Total AUC.  This correlation was inverse and statistically 
significant.  So this data suggests that as mean glucose values and HBGI (which has been 
shown to be related to mean glucose) increase, the total AUC decreases. 
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Table 22; Correlation coefficients of the glycaemic variability indices to each of the main parameters of the cortisol curve. *denotes p<0.05 and was statistically significant. 
 
 
Mean (0-
45) 
Mean (3-
12) 
CAR CAR-
AUC 
Early 
slope (45-
3 hours) 
Late slope 
 (3-12) 
Total 
AUC  
LBGI -0.040 0.083 -0.027 -0.036 -0.23* -0.15 0.12 
HBGI 0.030 -0.22* -0.18 0.079 0.025 -0.053 -0.23* 
ADRR 0.043 -0.15 -0.16 0.073 0.086 -0.0034 -0.17 
Mean 0.024 -0.22* -0.20 0.086 0.083 -0.055 -0.23* 
SD 0.0053 -0.15 -0.21 0.030 -0.063 -0.084 -0.17 
LI 0.026 -0.077 -0.29* 0.0037 -0.051 -0.061 -0.097 
CONGA 0.015 -0.23 -0.19 0.083 0.058 -0.066 -0.24 
J index 0.025 -0.22* -0.18 0.080 0.057 -0.058 -0.23* 
MODD -0.0093 -0.17 -0.13 -0.00089 0.026 0.0080 -0.17 
MAGE 0.18 -0.044 -0.083 0.19 0.081 -0.0075 -0.10 
M-value 0.045 -0.22* -0.18 0.083 0.037 -0.050 -0.21* 
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Discussion 
 
The main finding of this ambulatory study was a significantly blunted slope of the cortisol 
curve in those with a high LBGI (greater duration and depth of hypoglycaemia) compared to 
those with low LBGI and the control (non-diabetic group). The blunting was significant 
between 45minutes to 3 hour time interval (p=0.01, when typically in a healthy cohort, you 
would expect the fastest decline of cortisol. The blunting of the slope was also seen in the 2nd 
part of the slope (3-12 hours), with most significant blunting seen in those with high LBGI. 
(p=0.003)   Many studies have showed that a blunted cortisol decline is associated with poor 
physical and psychosocial outcomes (Adam, Hawkley et al. 2006, Cohen, Schwartz et al. 
2006) 
This blunting of the cortisol decline was combined with a significantly increased AUC 
between 3-12 hours after wakening in those with a high LBGI.  This elevated cortisol in those 
with T1D, could be as a result of a number of mechanisms.  This may be as a result of 
chronic hypersecretion of CRH due to recurrent exposure to hypoglycaemia.  CRH may then 
cause a possible cortical adrenal hypertrophy.   It appears that this effect of elevated cortisol 
in those in the high LBGI group is over and above the effects of diabetes particularly when 
associated with poor glycaemic control. It has been shown in animal studies that poorly 
controlled diabetes also leads to an activated basal HPA axis, which consequently leads to 
increased baseline CRH and ACTH and total cortisol levels(Chan, Chan et al. 2001). In 
animals with STZ-induced diabetes, the HPA axis hyper activation appears to start at the 
level of CRH gene expression in the PVN, resulting in a strong feed forward cascade, with 
increased CRH, ACTH and corticosterone. However, some animal studies also report that 
insulin replacement results in partial resolution of this hyper-secretion state particularly of 
ACTH and glucocorticoid (Chan, Chan et al. 2002). Other effects are a decreased 
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hypothalamic pituitary feedback sensitivity and increased adrenal sensitivity to ACTH, with 
an associated adrenal hypertrophy (Revsin, van Wijk et al. 2008).     
The elevated CRH has also been shown to stimulate the sympathoadrenal pathways, 
promoting release of adrenaline and noradrenaline, which actively promote glycogenolysis 
and gluconeogenesis further compounding to the glycaemic load(Clore and Thurby-Hay 
2009).  However, in contrast, Davis and colleagues showed that a cortisol infusion resulted in 
a markedly reduced adrenaline response to IIH the following day, suggesting that it was the 
cortisol increase that was responsible for the defective counter-regulation(Davis, Shavers et 
al. 1996).  This would fit with this data as those with high LBGI (and more likely to have 
defective counter-regulation), showed the highest AUC (cortisol) with a blunted decline.   
The adrenal gland has two distinct endocrine tissues; the steroid producing adrenocortical 
cells and the catecholamine producing chromaffin cells.  The interaction between 
glucocorticosteroids and catecholamines is relatively poorly studied.  Glucocorticosteroids 
induce the enzyme phenyl-N-methyl-transferase, a crucial enzyme involved with 
catecholamine synthesis (Cole, Blendy et al. 1995).  Those with Addison’s disease have been 
shown to have a low plasma adrenaline levels compared to age/sex matched controls and a 
degree of adrenomedullary dysplasia(Bornstein, Breidert et al. 1995).  However, prior 
increase in cortisol has also shown to contribute to the defective counter-regulatory 
adrenaline responses.  It has been suggested that the increase in cortisol by negative feedback, 
activates the type 2 glucocorticoid receptor, with a resulting downregulation of CRH and 
ACTH and decreased sympathoadrenal activation(Davis, Shavers et al. 1996).   
Therefore, it can be speculated that the rise in cortisol in those with recurrent hypoglycaemia 
further contributes to the defective counter-regulation also likely to be seen in this group  
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In addition, there is some data suggesting that there is diminished cortisol feedback at the 
level of hippocampal/hypothalamic glucocorticoid receptors in streptozotocin (STZ) induced 
diabetes in rats. There is also often a lack of glucocorticoid inhibition with dexamethasone 
seen in this cohort(Roy, Collier et al. 1990). 
There was however, no significant difference in CAR between the three groups.  It is 
reassuring to know that although we calculated CAR based on one day of measurement, that 
studies have shown CAR to have a high intra-individual stability over 2 consecutive 
days(Hucklebridge, Hussain et al. 2005). (r=0.63 for the AUCi).  Accurate measurement of 
the CAR is highly dependent on subject compliance to the salivary protocol.  Notably the first 
sample must be done immediately on wakening.  Any delay in this sampling may 
underestimate the rise in cortisol that is seen in CAR or even result in capturing the 
downward trend of cortisol after the initial burst of cortisol release.  A study using 
polysomnography to determine wakening have shown, the majority of individuals who do not 
display a CAR, are due to incorrect sampling. This showed that a delay of >15 minutes 
between wake time and first cortisol sample collection resulted in smaller CAR values (Okun, 
Krafty et al. 2010).  However, even when sampling is done correctly, up to 10% of healthy 
cohorts have shown not to demonstrate a CAR.  Two measures of dynamic increase were 
calculated- mean increase and AUCi. The  AUCi makes the assumption that F45 is the peak 
sample.  This is particularly a problem in a study involving mixed gender as in this study, as 
it is known that men’s cortisol peaks at ≈30 mins post awakening, whereas women often peak 
later at ≈45minutes (Pruessner, Wolf et al. 1997).  It is known that both the increasing age 
and sex can affect the CAR.  However in this dataset, neither of these factors was found to be 
interact with the CAR.  Factors such as alcohol and smoking are known also to affect the 
CAR.  To minimise this, subjects were advised to restrain alcohol intake for at least 24 hours 
prior to salivary sampling and current smokers were excluded.    
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Understanding the modulation of the HPA axis in T1D is currently limited, with most data 
derived from animal models.  A study comparing Type 1 patients with and without 
retinopathy, suggested that the dysregulation (higher post-dexamethasone plasma levels of 
ACTH) was present in patients with moderate to severe retinopathy, and not in those with 
minimal to no retinopathy.  It has previously been speculated that this may be as a result of 
microvascular damage in the limbic-HPA pathways which may have led to this 
dysregulation.  However this difference was no longer significant, when duration of diabetes 
was incorporated (Roy, Collier et al. 1991).  
However limited clinical studies show conflicting results.  Overnight dexamethasone 
suppression tests in those with diabetes, are often non suppressed, particularly at 4pm rather 
than 8am, suggesting a prolonged hypercortisolaemic state in these individuals(Hudson, 
Hudson et al. 1984). However insulin has also been shown to promote several steps in the 
steroid synthetic pathway,  with increased lipoprotein uptake and metabolism, increased 
levels of P450 side chain cleavage enzymes, as well as increased enzymatic activity of 3β 
hydroxysteroid dehydrogenase, 21 and 11β hydroxylase(Ghizzoni, Vanelli et al. 1993) and  
may also contribute to this hypercortisolaemic state. However, glucocorticosteroids are also 
known for their anti-insulin action on peripheral tissues.  We find in our study that increased 
exposure to hypoglycaemia can further contribute to this hypercortisolaemic state.  This state 
could have the potential to contribute or worse the vascular complications of diabetes.   
Limitations 
 
One of the main limitations of this study is the cross-sectional nature of data collection, and 
therefore no conclusion can be made on the long term impact of a potential dysregulated 
HPA axis.    Studies have suggested asking the subjects to collect saliva over multiple days.  
However, they have often asked subjects to collect less samples if collecting on multiple days 
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(e.g. wakening, 30min and before bed) to ensure sampling compliance.  Our approach was a 
more detailed look at the slope, and hence we chose the multiple samples-single day 
approach.  Reassuringly, a previous study(Edwards, Clow et al. 2001) utilising sampling over 
2 consecutive days showed both the AUC of the wakening period (0-45mins) and the slope of 
the decline showed reasonable stability over the 2 days of sampling, suggesting that a single 
day of sampling as in our study, may be adequate and representative.   
Even with a day of salivary cortisol sampling, it is nevertheless a cross sectional analysis and 
reveals more acute changes.  Recently analysis of scalp hair cortisol (with a growth rate of 
approximately 1cm/month  with the most proximal part growing in the last month) has been 
shown to be a promising technique for the retrospective assessment of average cortisol 
exposure over a few months(Lee, Kim et al. 2015).  
Other exploratory studies on this dataset 
Correlation between HbA1c and GV parameters 
 
Over the last 40 years, HbA1c has been understood as reflecting mean blood glucose over the 
previous 2-3 months.  However indicators of GV could provide information about other 
aspects, revealing patterns of high and low excursions and indicators of lability.  Studies have 
looked at comparing HbA1c with self-monitoring of blood glucose (SMBG) over a 3 month 
period.  As expected a close correlation was shown between HbA1c and mean blood glucose 
from SMBG (r=0.62), and within subject SD was also shown to be correlated with HbA1c 
(r=0.375)(Derr, Garrett et al. 2003).  A recent study also examined the relationship between 
HbA1c and various GV parameters in a study which utilised CGM for at least 48 hours, 
which included 35 patients with T1D.  Although T2D were included, HbA1c correlated with 
mean glucose (r=0.74) and AUC PP (postprandial index) only in those with T1D.  HbA1c 
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was shown not to correlate with LBGI, further demonstrating the inability of HbA1c of 
identifying those with recurrent hypoglycaemia or indeed predicting those at risk of future 
hypoglycaemia (Sartore, Chilelli et al. 2012).  In our GV cohort, we used linear regression to 
determine if there was a relationship between HbA1c and CGM-derived GV indices.  
Table 23 Correlation coefficients between HbA1c and Glycaemic variability indices.  
Index of GV R2 P value 
Mean 0.390 <0.0001 
SD 0.163 <0.001 
CONGA 0.411 <0.001 
LI 0.012 0.275 
J-index 0.396 <0.001 
LBGI 0.00032 0.860 
HBGI 0.371 <0.001 
GRADE 0.382 <0.001 
MODD 0.106 0.0009 
MAGE 0.005 0.467 
ADRR 0.202 <0.001 
M value 0.345 <0.001 
MAG 0.017 0.191 
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Univariate analysis showed that there was a close association between HbA1c and indices of 
average BG (Mean, SD, CONGA, J-index, GRADE, and MODD).  It was a poor indicator of 
the burden of hypoglycaemia as assessed by LBGI.  HbA1c was also a good reflection of 
chronic hyperglycaemia (HBGI), there was also a good correlation to ADRR (a measure of 
total variability accounting for highs and lows), but it is likely that this is because of the 
strong correlation between HBGI and ADRR.   
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Correlation between GV and insulin doses 
 
Table 24; Correlation coefficients between total insulin doses and measures of Glycaemic variability. 
Index of GV R2 P value 
Mean 0.05 0.028 
SD 0.006 0.454 
CONGA 0.052 0.025 
LI 0.002 0.685 
J-index 0.033 0.076 
LBGI 0.0003 0.85 
HBGI 0.028 0.101 
GRADE 0.062 0.01 
MODD 0.008 0.384 
MAGE 0.0001 0.912 
ADRR 0.189 0.190 
M value 0.018 0.194 
MAG 0.003 0.588 
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Univariate analysis showed that insulin doses are associated with GV indexes reflecting mean 
glucose (mean, CONGA, GRADE), suggesting that a greater dose of insulin is associated 
with a poorer glycaemic control.  This is suggestive that this greater dose of insulin is taken 
inappropriately by those with poor glycaemic control, for example, possibly through taking 
large corrective doses to overcome hyperglycaemia.   
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CHAPTER 7: 
STUDY 4; CRH testing in Type 1 Diabetes  
Background 
 
Baseline tests (such as the cortisol curve) are often simpler to perform than dynamic tests, 
however they have appeared to lack reliability in pharmacological terms.  Dynamic testing 
with either stimulation or inhibition have been shown to be far more reliable, with greater 
between person variability, and a higher reliability (Coste, Strauch et al. 1994).  We therefore 
in this follow on study, investigated the effect of Corticotrophin-releasing hormone (CRH) on 
the HPA axis in those with T1D to determine if there is a dysregulation of the axis due to 
recurrent hypoglycaemia.  It is well established that insulin induced hypoglycaemia (IIH) is a 
powerful stimulant of CRH, however, what is yet to be reported, is whether, RH and 
therefore  recurrent stimulation of CRH causes blunting or dysregulation of the whole axis.  
CRH, a 41 amino acid peptide is a principal regulator of the HPA axis (Axelrod and Reisine 
1984) and is also involved with regulating the autonomic, immunological and behavioural 
response to stress(Owens and Nemeroff 1991). CRH neurons are localised through the cortex, 
limbic system and brainstem, which are all associated with autonomic functioning. High 
concentrations are found in the paraventricular nucleus of the hypothalamus and the 
hypophyseal portal system.   CRH interacts with its receptor on the pituitary corticotrophs, 
which leads to increased formation of cAMP, leading to a cascade of events which ultimately 
results in secretion of POMC derived peptides into the peripheral circulation.(Owens and 
Nemeroff 1991).  CRH interacts with two G protein coupled receptors, CRH1 and CRH2.  
CRH1 appears to be the major receptor mediating the activation of the HPA axis in rodents.  
Mice deficient in CRH1 show adrenal atrophy and a reduced corticosterone stress 
responsiveness, whereas CRH2 null mice present with normal corticosterone responses but an 
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altered recovery phase(Yoshida-Hiroi, Bradbury et al. 2002). CRH1 appears also to be crucial 
in normal chromaffin cell development, and CRH1 null mice have also been shown to have 
an impairment in adrenal catecholamine production (Yoshida-Hiroi, Bradbury et al. 2002).   
Early studies have showed that synthetic intravenous CRH produced vasodilation and 
hypotension and central administration showed an increase in mean arterial pressure (MAP) 
and heart rate which is well known to be separate from activation of the HPA. Increases in 
MAP usually cause reduction in heart rate, however under stressful conditions, the baroreflex 
function can be altered enabling simultaneous rise in both parameters.  Central administration 
of CRH does not affect baroreflex sensitivity, but has been shown to increase sympathetic 
and decrease central parasympathetic outflow. (Overton, Davis-Gorman et al. 1990). CRH 
selectively stimulates pituitary corticotropin (ACTH) secretion in man.  Other neuro-
regulators such as oxytocin  and adrenaline have also been found to have ACTH releasing 
properties as demonstrated during immune-neutralisation of CRF(Carnes, Lent et al. 1990).   
Vasopressin was also found to stimulate ACTH secretion but also potentiates the action of 
CRH on the anterior pituitary. Insulin induced hypoglycaemia has not only been shown to 
activate CRH but has been shown to increase plasma vasopressin concentrations.  It has been 
shown there is a strong correlation between the depth of hypoglycaemia and the rise in 
plasma vasopressin. (r=0.57 p<0.001).  A study in humans showed that the release of 
vasopressin in this context was independent of blood pressure and volume changes, and as 
yet, the mechanism is unknown(Baylis, Zerbe et al. 1981).   
Although the effect of acute CRH stimulation is well established, what is less well known is 
whether recurrent stimulation of CRH can produce the same response.  A rodent study 
showed that continuous infusion of CRH caused a 40% decrease in the anterior pituitary CRH 
receptor concentration.  However when there was a concomitant infusion of vasopressin (at a 
dose resembling the concentration of vasopressin in the pituitary portal circulation), the 
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effects of CRH on the anterior pituitary was exaggerated.  (I.e. greater reduction of CRH 
receptor concentration.).  Vasopressin is both a neuroendocrine hormone (located in the 
magnocellular neurons of the hypothalamus) but also a neurotransmitter (located in the 
parvocellular suprachiasmatic nucleus), and the study showed that it is the activation of the 
parvocellular component rather than the magnocellular component, which was crucial in 
potentiating the down-regulatory effects of CRH on the anterior pituitary CRH 
receptors(Hauger and Aguilera 1993).     
The impact of chronic or excessive exposure to CRH has been debated in the literature for a 
number of years.  Both in-vivo and in-vitro studies have shown that prolonged CRH receptor 
occupancy increases the POMC peptide synthesis, with trophic actions of the pituitary 
(Westlund, Aguilera et al. 1985, McNicol, Kubba et al. 1988). However, in contrast other 
studies shown that continuous or excessive exposure to CRH cause a desensitisation.  These 
studies show reduced ACTH secretion in continuous exposure, however CRH still stimulated 
ACTH above baseline (Rivier and Vale 1983, Evans, Brett et al. 1985).  
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CRH stimulation tests 
 
CRH has been established as providing a prominent role in orchestrating the response to 
stress.  Intravenous CRH has been shown to have an apparent volume of distribution equal to 
that of plasma volume and a final eliminating half-life ranging from 45 to 180 
minutes.(Schulte, Chrousos et al. 1985). The threshold dose has been shown to be 
0.03mcg/kg, with the maximal effective doses between 3-10mcg/kg.   Doses over 0.3mcg/kg 
of CRH show a peak ACTH after 10-15 minutes, with plasma cortisol levels reaching a peak 
at 30-60 minutes.  The responses to ovine CRH (1mcg/kg) have also been found to vary 
depending on the time of administration.  Later (8pm vs 9am) administration of CRH resulted 
in ACTH responses being slightly higher, however the cortisol response was significantly 
greater in the evening. (P<0.005).   
Haemodynamic parameters were unaltered in this study, however 10% of patients reported an 
upper body and facial flush.  (Schulte, Chrousos et al. 1985).  This flush often begins almost 
immediately and lasts between 3 to 5 minutes.  A large study showed 6% also reported an 
urge to take a deep breath.  Doses often over 3mcg/kg were associated with more severe 
symptoms such as tachycardia, hypotension, dyspnoea and a chest tightness(Nink, Krause et 
al. 1991).       
Studies so far in those with Type 1 Diabetes 
 
Roy et al, (Roy, Roy et al. 1993) examined the CRH response in 22 subjects who had T1D 
with no history of depression,  and showed total plasma integrated (p<0.004) and peak 
cortisol levels(p<0.002) were significantly higher in those with T1D compared to 
age/sex/BMI matched controls, however plasma ACTH was not significantly different 
between the groups.  Roy et al, also found there was a trend (p<0.1), of patients with any 
complications (retinopathy, neuropathy or both) having a higher peak plasma cortisol to CRH 
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than subjects without complications.   These differences were not attributed to changes in 
cortisol binding globulin (CBG).  Specifically looking at neuropathy in those with Type 1 
Diabetes, Cairo et al(Coiro, Volpi et al. 1995), examined 3 groups (controls, Type 1 with 
neuropathy and Type1 without neuropathy) and found that when CRH (0.03µg/kg)  (a dose 
which would give an accurate evaluation of the HPA and a plasma level of CRH equivalent 
to that in the hypophyseal portal circulation), the ACTH response was significantly higher 
(F=6.73. p<0.02) in non-diabetic control subjects, and within the groups with diabetes, 
ACTH response was greater in those without neuropathy, compared to those with neuropathy.  
(F=5.43, p<0.05).  The cortisol response was found to be significantly lower in non-diabetic 
controls as opposed to the 2 diabetes groups and within the diabetes groups, higher levels of 
cortisol were found within the group with neuropathy.  This would suggest that neuropathy 
exacerbates an already abnormal HPA axis.  
Hypothesis for dysregulation of the HPA axis 
 
HPA hyperactivity 
 
This has been recognised as an elevated circulating level of cortisol and/or ACTH 
(corticotrophin) and a resistance to dexamethasone suppression. (Cameron, Kronfol et al. 
1984, Roy, Collier et al. 1990)  Several hypothesis have been reported in the literature as to 
the reason for this, and detailed below. 
Increased hypothalamic drive 
 
Rodent models have shown a reduction in ACTH response to CRH, and this was shown to be 
as a result of a decreased number of CRH receptors in the anterior pituitary, which then led to 
greater CRH hypersecretion and therefore an increased hypothalamic drive. (Scribner, 
Walker et al. 1991) 
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Downregulation of CRH receptors in the anterior pituitary-  
Decreased sensitivity of pituitary 
 
Studies using a higher dose of CRH 1µg/kg are thought to be useful to ascertain pituitary 
ACTH storage, however lower doses of CRH are needed to assess pituitary sensitivity.(Coiro, 
Volpi et al. 1995)  Studies using the low dose of CRH, have shown there is a reduced(Coiro, 
Volpi et al. 1995) (Schulte, Chrousos et al. 1985)or unaltered(Roy, Roy et al. 1993) ACTH 
release with CRH stimulation suggesting pituitary insensitivity.  This tolerance appears to be 
at the level of CRH receptor and its coupling to adenylate cyclase.  Chronic CRH infusion for 
48 hours has shown a 46% decrease in CRH receptor binding (Wynn, Harwood et al. 1988).   
Decreased glucocorticoid negative feedback sensitivity 
 
It has been postulated that in those with diabetes, the HPA axis has decreased sensitivity to 
the negative feedback of glucocorticoids.  This has been seen in the poor suppression of 
glucocorticoids with dexamethasone (25mcg/kg) suppression tests seen in diabetic animals 
(Chan, Inouye et al. 2002) and in patients with diabetes.  (Hudson, Hudson et al. 1984) 
Lack of blunting of ACTH. 
 
Roy et al(Roy, Roy et al. 1993), showed that ACTH levels in the context of high cortisol 
levels were either normal or just slightly increased, and therefore there is a lack of blunting of 
ACTH suggesting dysregulation of the HPA axis.   This is a similar pattern to those who are 
severely ill intensive care patients and those who are under chronic physical stress, also show 
normal or exaggerated response of the corticotroph to CRH, nevertheless with high levels of 
endogenous glucocorticoids(Reincke, Allolio et al. 1993).   
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Direct stimulatory effect of CRH on the adrenals 
 
Roy et al also proposed that CRH and/or ACTH had an exaggerated effect on the adrenals, 
with CRH having a potential direct action on the adrenals.  It has been proposed this may be 
due to adrenal hypertrophy, which is seen after a few days of excessive stimulation with 
ACTH(Symington, Duguid et al. 1956).  This is also seen in diabetic mice, showing an 
increase in the size of the adrenal glands(Carson, Hanker et al. 1982).  However CRH has 
also been shown in rodent models to have a direct trophic response to the chromaffin cells in 
the absence of pituitary ACTH, suggesting a close link between the HPA axis and the 
neuroendocrine system.(Hoheisel, Schauer et al. 1998) 
Hyperinsulinaemia 
 
Hyperinsulinaemia is commonly seen in those with T1D, and it has been suggested that these 
high insulin levels may stimulate the adrenal medulla via binding of insulin to its own adrenal 
receptors.  Euglycaemic clamp studies using high dose (15 mU/min/kg) and low dose (1.5 
mU/min/kg) insulin infusions showed that CRH stimulation during euglycaemia resulted in 
an ACTH response only in the high dose insulin subgroup (p<0.01) and serum cortisol levels 
were also found to be significantly greater only in the high dose insulin group 
(p<0.02)(Fruehwald-Schultes, Kern et al. 1999) Roy et al also found that greater insulin 
doses were associated with greater perturbation of the HPA axis. (Roy, Roy et al. 1993) 
Poor glycaemia control 
 
Poor diabetic control is associated with hyper activation of the hypothalamo-pituitary-adrenal 
(HPA) axis.  (Cameron, Kronfol et al. 1984)  Wurzburger et al found that better glycaemia 
control was related to significantly lower 24 hour cortisol secretion profile in those with 
T1D(Wurzburger, Prelevic et al. 1990).   
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Hypoglycaemia and the HPA axis 
 
Early reports have confirmed that insulin induced hypoglycaemia (IIH) is a powerful 
stimulant of ACTH production with CRF (permissive role)(Plotsky, Bruhn et al. 1985) and 
vasopressin (modulatory role) accompanying this response(Plotsky, Bruhn et al. 1985).  In a 
pilot study of non-diabetic healthy men, IIH produced peaks in CRH, ACTH and AVP at 45 
minutes after insulin injection, and maximal cortisol responses were seen at 90 minutes(Ellis, 
Schmidli et al. 1990).  Studies have shown that IIH can also stimulate production of adrenal 
E, this was shown to stimulate production of hypothalamic E, found also to be a stimulator of 
ACTH via β adrenergic receptors found on the pituitary, thereby suggesting both central and 
peripheral pathways involved in activation of HPA activity(Tilders, Berkenbosch et al. 1982).  
It may be that the magnitude of hypoglycaemia impacts the pathway activated with more 
profound hypoglycaemia activating peripheral mechanisms and vice versa (Aizawa, Yasuda 
et al. 1981). There is very little literature about the specific impact of recurrent 
hypoglycaemia on the HPA axis.  We know that a 2 hour episode of acute hypoglycaemia to 
3.0mmol/L is usually required to diminish the cortisol response to further hypoglycaemia. 
(Davis and Shamoon 1991, Veneman, Mitrakou et al. 1993, Fruehwald-Schultes, Kern et al. 
1999).  However it appears that the diminished response of cortisol to further hypoglycaemia 
are stimulus specific as illustrated by a study (Welt, Kinsley et al. 1998), which assessed the 
HPA axis in those with recurrent hypoglycaemia by using a non-hypoglycaemic stimulus 
(ACTH) and found that there is an exaggerated cortisol response to ACTH.  This was 
proposed to be as a result of some adrenal gland priming due to endogenous ACTH release 
during prior hypoglycaemia and the exogenous ACTH.   This was confirmed in a study that 
gave repeated doses of ACTH, which resulted in a significantly increased cortisol response 
during the second exposure to ACTH. (Kolanowski, Pizarro et al. 1975)  
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Methods 
 
The last 30 subjects in the (GV and cortisol study-Study 3) were recruited to perform an 
exploratory study to examine whether RH (through recurrent stimulation of CRH) in subjects 
with T1D affected the response to further exogenous CRH.   The pituitary and adrenal 
responses to CRH were examined by measuring ACTH and cortisol responses after 
intravenous administration of CRH.   
10 subjects each with high LBGI, low LBGI and normal individuals with no endocrine 
disorders were studied. All subjects were informed of the purpose of the study, and gave their 
written informed consent. Following discussion, strategies were also implemented so that 
those with T1D, would not have a hypoglycaemic episode from the afternoon (12pm till after 
the conclusion of the CRH stimulation test).  This was done so that there would be no other 
stimulus for cortisol release in the afternoon/evening on the day of the test.   
Subjects were asked to attend the clinical research centre (CRC), Ninewells, at a time 
between 4 and 6pm.  On arrival, an intravenous cannula was inserted into the ante-cubital 
vein of the non-dominant arm.  Baseline bloods were only done at least 30-60mins after the 
insertion of the cannula. (to overcome effects of cannulation (a potential stressor) on 
cortisol).  Bloods were taken for ACTH and cortisol. Plasma ACTH (ELISA, ALPCO) and 
cortisol (radioimmunoassay, DIASORIN) concentrations were measured in all samples.  
Cortisol samples had an inter-assay CV -7.4% and intra-assay CV -7.2% with a sensitivity of 
5.88nmol/L.  ACTH had an inter-assay CV -6.2% and intra-assay CV-2.6% with a sensitivity 
of 0.22pg/ml.  Blood glucose and blood pressure were also checked every 10minutes for the 
cohort with diabetes.  Blood glucose was only checked at the beginning and end of the study 
in the non-diabetic cohort.   Baseline bloods were taken 15 (TP1) and 5 (TP2) minutes before 
CRH administration.  Synthetic ovine CRH was administered as a slow intravenous bolus at a 
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dose of 1mcg/kg.  Blood samples were then taken at 15 minute intervals for the first hour 
(TP3-6), and then at 90 (TP7) and 120 (TP8) minutes.  Subjects were given a meal at the end 
of the study and then discharged.   
Based on a similar study looking at patients with Type 1 Diabetes and neuropathy (Coiro, Volpi 
et al. 1995)  and assessing the cortisol and ACTH responses to intravenous CRH in patients 
with T1D, we found we would need to  recruit 10 subjects in each group  accounting for a 20% 
drop out rate, to give us 90% power, to detect α of 0.05.   
Results 
 
Outliers 
 
Any results (ACTH or cortisol) which were out with of 2 SD were removed from the dataset. 
If a subject had 3 or more outliers, then that subject was also removed from the final analysis. 
One subject was removed from the high group because of 5 ACTH outliers.  Examining the 
demographics of this subject, age, duration of diabetes and glycaemic control, there were no 
differences in these parameters compared to the rest of the group.  However this was the only 
subject in this group, who had laser photocoagulation for proliferative diabetic retinopathy.  
Therefore, this result requires further exploration.  Could it be hyper-functioning of the HPA 
axis contributed to the development of this chronic complication or is presence of diabetic 
retinopathy a required condition for increased HPA activity?   
Two subjects were removed from the low group, the first subject was removed because 
therapy had changed prior to fitting the CGM, such that CGM did not reflect prior exposure 
to hypoglycaemia, so LBGI calculation could not be used.  2nd subject was removed because 
of 4 ACTH readings which were out with 2 SD.  No explanation could be found in this 
subject, for these abnormal results.   
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1 subject was removed from the control group because there were 5 ACTH readings out with 
2SDs.   
Table 25 The final numbers of subjects out of 10 who were studied as part of the CRH stimulation study.  
Reasons for exclusion are detailed above.  
 High  Low Control 
Final number 
analysed 
9 8 9 
 
 
None of the T1D had any major microvascular complications (>mild BDR, 
>microalbuminuria, >subclinical neuropathy) or macrovascular complications.   
 
Table 26; Demographics of each group examined during the CRH stimulation tests. 
 High Low  Control  
Age 39.6 (4.6) 46.5 (4.6) 43.8 (3.6) F (2, 23) = 0.6647 P = 0.52 
 
Duration of 
diabetes 
27.2 (3.5) 16.2 (2.9) n/a P=0.03 
Glycaemic 
control 
8.4 (0.3) 8.8 (0.4) n/a P=0.37 
LBGI 
(mean(SEM)  
8.6(0.6) 2.8(0.4) n/a P<0.0001 
 
ACTH parameters 
 
Does hypo frequency affect ACTH response in T1D? 
After CRH (1mcg/kg), the rise in ACTH is shown in the graph below 
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Figure 26; This shows the ACTH response from baseline to after stimulation with CRH.   
Intravenous CRH is given at time 0.   
 
 
The mean (SEM) baseline ACTH (taken from TP2), was (H v L v C) (14.7 (2.4) vs 12.5 (1.3) 
vs 18.6 (2.9). (Kruskall Wallis statistic 3.77, p=0.15).  This showed that baseline ACTH was 
not statistically different in the 3 groups. 
The rise in ACTH following CRH administration was calculated by subtracting the baseline 
ACTH from peak ACTH.  Firstly, there was no effect of grouping on the change in ACTH.  
F(2,23) =2.17 p=0.137.  Two way ANOVA showed there was no statistical significant 
interaction between the effects of group and duration of diabetes on change in ACTH F(1,12) 
=0.028 p=0.869.  There was also no effect of group and glycaemia on change in ACTH 
F(2,10)=0.469 p=0.639.   
Table 27 This shows basal and maximal response (peak) and the maximal rise (Δ) in ACTH responses between the 3 groups 
 
ACTH  High Low  Control 
Basal (mean 
(SEM) 
14.7 (2.3) 12.5 (1.1) 18.5 (2.8) 
Peak  53.1 (5.9) 41.8 (3.0) 59.0 (4.4) 
∆ 38.4 (3.6) 29.3 (1.9) 40.5 (1.7) 
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A two-way ANOVA was conducted to examine the effect of group and duration of diabetes 
on the peak ACTH. There was no statistically significant interaction between the effects of 
group and duration of diabetes on peak ACTH. F(1, 12) = 0.019 p=0.893.  A further two way 
ANOVA looked at the effect of group and glycaemia on the peak ACTH.  Again there was no 
statistically significant interaction between the effects of group and glycaemia on the peak 
ACTH F(2,10) =0.256 p=0.779.   
The mean (SEM) area under the curve (AUC) of the ACTH curve was (H v L v C) (4441 
(476) vs 3583(326) vs 4907 (369)). Although the AUC of the high group was higher than the 
low group, this was not statistically significant.  (p=0.09).  One way ANOVA, showed no 
significant difference between the 3 groups F(2,23)=1.37 p=0.27.   Two way ANOVA, 
showed no statistically significant interaction between group and glycaemia on the AUC 
(ACTH). F(2,10) =0.693 p=0.523.  There was also no significant interaction between group 
and duration of diabetes on the AUC (ACTH) F(1,12)=0.472 p=0.505.   
Does having T1D affect ACTH response to CRH stimulation? 
Figure 27; ACTH response following CRH stimulation.  
CRH administered at time 0  in the combined group with Type 1 Diabetes (low LBGI + high LBGI) T1D (n=17) and in the 
control cohort (n=9) 
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There was a trend towards reduction in peak ACTH response in those with T1D compared to 
the control subjects however it did not reach significance.  (D vs C) (47.7 (3.8) vs 59.0 (4.7). 
(unpaired t test p=0.08) There was also no significant change in AUC (T1D-68809, Controls-
75951 p=0.63) 
 
Cortisol parameters  
 
Peak cortisol was highest in the control group compared to the diabetic groups, however this 
did not reach statistical significance F (2,23)= 1.883 (p=0.17).  Two way ANOVA showed 
that there was no statistically significant interaction of group or diabetes duration on the peak 
cortisol F(1,12)=0.955 p=0.348.  There was also no significant interaction between group and 
glycaemia on the peak cortisol F(2,10)=0.654 p=-.541.   
 
 
Figure 28; This shows the cortisol response from baseline to after stimulation with CRH. 
Intravenous CRH is given at time 0.   
 
 
The rise in cortisol from baseline was highest in the control group however this was not 
statistically significant F= 0.5253 p=0.60. Two way ANOVA showed that there was no 
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statistically significant interaction of group or glycaemia on the rise in cortisol F(2,10)=0.125 
p=0.884.  There was also no statistically significant interaction of either group or diabetes 
duration on the rise in cortisol F(1,12)=1.416 p=0.257.    
Table 28; This shows basal and maximal response (peak) and the maximal rise (Δ) in cortisol responses between the 3 
groups 
Cortisol (nmol/L) High Low  Control 
Basal 325.0 (47.3) 266.3 (20.9) 334.0 (52.8) 
Peak  694.1 (51.2) 590.6 (48.6) 736.6 (50.1) 
∆ 369.2 (4.0) 324.3 (60.0) 402.6 (59.7) 
There was no significant difference between the AUC (cortisol) between the 3 groups (H vs L 
vs C)  (73386 (5932) vs 63661 (4072) vs 75951 (6476).  F(2,23)=1.243 p=0.307.  Two way 
ANOVA showed no statistically significant interaction between group and glycaemia on the 
AUC (cortisol) F(2,10)=1.039 p=0.389.  There was also no statistically significant interaction 
between group and duration of diabetes on the AUC (cortisol) F (1,12)=1.3 p=0.277.   
Baseline cortisol (TP2) did not differ between the 3 groups (325 (49.8) vs 266.3 (23.4) vs 334 
(55.6).  F=0.6(p=0.56).  However two subjects in the control group had basal cortisol levels 
outside of 2 SDs, were thought to be stressed, based on their basal cortisol levels.   
Figure 29; Box and whiskers plot showing the scatter of the baseline cortisol levels in the 3 groups.  
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The profile of ACTH and Cortisol release are shown with these 2 subjects removed.  
Figure 30;  Cortisol and ACTH responses following CRH stimulation.  
a. Cortisol and b. ACTH responses following CRH stimulation at time 0, with the 2 outliers in the control group removed.  
   
    
 
All the analysis, were carried out with these 2 subjects removed to determine if removing 
these outliers had an impact on the results.  There was still no difference in peak cortisol F 
(2,21)=1.176 p=0.3281,  AUC of cortisol  F(2,21)=1.066 p=0.3623 or rise in cortisol 
F(2,21)=1.652 p=0.2156.   
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Does T1D affect cortisol response to CRH? 
Figure 31; Cortisol responses following CRH stimulation in those with Type 1 Diabetes (T1D) compared to non-diabetic 
control subjects.  
This illustrates the cortisol response following CRH administration at time 0.  
 
There was a non-significant decrease in peak cortisol responses to CRH stimulation in those 
with T1D.  (D v C) (645.4 (39.3) vs 736.6 (52.8).  p=0.1818.   
Discussion 
 
These results show a trend (however non sig at p=0.08) towards a lower ACTH response in 
T1D compared to controls (it is thought that plasma ACTH is a more sensitive marker of the 
central regulation of the HPA axis, rather than plasma cortisol, which is partly dependant on 
the adrenal sensitivity to steroids), with no difference in the cortisol response between the 3 
groups.  Subdividing the T1D group further by exposure to hypoglycaemia did not reveal any 
further trends. These results do not suggest major dysregulation of the HPA axis in subjects 
with T1D.  
If the trend towards a lower ACTH, were likely to increase to significance, with increased 
numbers of subjects, then this is consistent with other studies in T1D showing a lower ACTH 
-5 0 0 5 0 1 0 0 1 5 0
2 0 0
4 0 0
6 0 0
8 0 0
T im e  (m in )
C
o
r
ti
s
o
l 
n
m
o
l/
L
T 1D
C o n tro ls
 
272 
 
response to CRH stimulation. Lower ACTH responses to CRH may indicate a pituitary 
insensitivity.   
We may have missed a true result of pituitary insensitivity in this circumstance, by giving too 
high a dose of CRH. A similar (normal ACTH responses to CRH) was seen in another study 
using a similar dose (1mcg/kg) (Roy, Roy et al. 1993), but a study using a threshold dose of 
CRH (0.03mcg/kg)(Coiro, Volpi et al. 1995) did show poor ACTH responses in those with 
T1D.   It has been shown that in order to truly study pituitary sensitivity, a minimal effective 
dose (0.03mcg/kg) of CRH should be used.  This has been shown to be the threshold dose 
which produced a plasma CRH in the reported range in the hypophyseal portal circulation.  
This threshold dose was shown to stimulate with reproducibility POMC peptide secretion 
from the anterior pituitary(Watson, Lopez et al. 1988).  The maximal dose (such as 
100mcg/or 1mcg/kg such as in this study), may just cause release of pre-stored ACTH from 
the pituitary corticotrophs rather than truly test pituitary sensitivity.  However dose-response 
studies have shown that 1mcg/kg is the lowest dose at which maximal cortisol stimulation 
occurs.  We may have been able to differentiate further by conducting two studies using 
0.03mcg/kg to look at pituitary sensitivity, and possibly a higher dose i.e. 1mcg/kg to look at 
adrenal responsiveness.  
A number of explanations could be given for a possible reduction in ACTH responses in 
those with T1D.  STUDY 3 investigated diurnal cortisol rhythms in those with T1D.  I 
showed that there was a blunted cortisol decline as well as a greater mean AUC of cortisol 
from 3-12 hours post wakening, through the day in patients with T1D, and therefore greater 
exposure to cortisol, may result in enhanced feedback control over corticotropin (ACTH) 
peptide release.  
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An alternative explanation, patients with T1D may also be exposed to chronic 
overstimulation of CRH release due to a number of factors such as hypoglycaemia, poor 
glycaemic control and even exogenous insulin’s action on the hypothalamus.  Rodent studies 
have shown chronic overstimulation of CRH in diabetic animals leads to a significant 
downregulation of CRH receptors in the anterior pituitary, resulting in a reduced ACTH 
response (Scribner, Walker et al. 1991).  
The latter explanation is more likely in this scenario, as the basal levels of cortisol for the 
subjects with diabetes did not differ between the three groups.  F(2,23)=0.5983 p=0.5581. 
Removing the 2 possible control subjects who were stressed, showed there was still no 
difference in the basal cortisol in the T1D group compared to the controls (297.4 (28.7) vs 
259.9 (31.9), p=0.4571.  A previous similar study(Roy, Roy et al. 1993) showed that there 
was no difference between T1D and controls in the evening, when basal cortisol levels are 
low, but during the morning, the cortisol was significantly higher in diabetic group.  Rather it 
maybe the raised cortisol during the day (as suggested by STUDY 3), that has more impact 
on the suppression of corticotrope response to CRH in those with T1D.  We chose to study 
our subjects in the evening, because a series of experiments in human subjects have shown 
that amplitude of cortisol pulses are greatest in the early hours after wakening, with the 
amplitude decreasing over the course of the day, with the lowest in the evening.  It was 
suggested (by Lightman, SL) that in order to assess the response to exogenous oCRH with 
minimal variability, the experiment should be carried out in the evening after 5pm. The 
response to CRH could show much variability in the morning/afternoon, when the amplitude 
of endogenous cortisol release is greatest as the responses may be affected by whether the 
cortisol was in the upward or downward phase of the secretory response.  Therefore in order 
to minimise variability in ACTH and cortisol responses following intravenous injection of 
CRH, all studies were carried out in the evening hours (after 5pm), when theoretically the 
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levels of endogenous cortisol and amplitude would be at its lowest.    This would be a time 
period where the amplitude of cortisol secretion would be low, and therefore, there would be 
minimal variability in the cortisol and ACTH responses.  However by doing the study in the 
evening, we may be able to avoid variability, but may not pick up the maximal cortisol 
response compared to a morning study.   
In this study, there was no difference in the cortisol response to CRH between the three 
groups.   This is in contrast to a study in adolescents(Ghizzoni, Vanelli et al. 1993) whereby a 
1mg/kg CRH stimulation study led to a significant increase in plasma cortisol.  The authors 
suggest that this may be due to the metabolic status of diabetes, with consequently a stress 
related change in the overall physiology leading to a preferential production of steroids and 
cortisol.  This study also did not show any change in ACTH, suggesting an absence of a 
centrally mediated mechanism.  It was suggested that the increased cortisol production was 
rather a peripherally driven mechanism.  Mechanisms proposed include a direct action of 
insulin on specific adrenal receptors (Penhoat, Chatelain et al. 1988) and a paracrine 
activation of an intraadrenal CRH/corticotropin mechanism. It appears that this intra-adrenal 
system (in rodent studies)  is particularly active during a central alteration of the CRH/ACTH 
branch (during hypophysectomy), possibly through a negative feedback 
mechanism(Mazzocchi, Malendowicz et al. 1994). This system does not appear to provide 
adequate replacement, as demonstrated by the essential need of hydrocortisone replacement 
in those patients with hypopituitarism.  The adrenal zona medullaris of several species has 
been shown to co-release CRH with catecholamines(Suda, Tomori et al. 1986).  Rodent 
studies have shown that high dose CRH can stimulate secretion of corticosterone which is 
independent of ACTH release by the pituitary(Andreis, Neri et al. 1991).   It may therefore be 
that there is a chronic activation of CRH in patients with diabetes either as a result of the 
metabolic state or through intermittent activation of CRH during times of particular stress 
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(extreme glucose variability) leading to high peripheral cortisol levels. Presence of 
neuropathy in the threshold CRH study (0.03mcg/kg) was shown to further suppress the 
ACTH responses to stimulation.   
Abnormal responses to CRH have been shown in a number of pathological states. For 
example in Cushing’s syndrome, those with a pituitary Cushing’s had an exaggerated 
response of ACTH and cortisol to CRH, whereas those with adrenal or ectopic disease had a 
blunted response of ACTH and cortisol release following CRH administration.  (Chrousos, 
Schulte et al. 1984).  This may be due to an enhanced and appropriate negative feedback on 
the corticotropes.  Several psychiatric disorders such as depression(Gold, Loriaux et al. 1986) 
and anorexia nervosa(Gold, Gwirtsman et al. 1986) and those with panic disorder(Roy-Byrne, 
Uhde et al. 1986) have shown a basal hypercortisolaemia associated with a blunting of ACTH 
response to CRH stimulation, which suggests an appropriate negative feedback on the 
corticotropes, which is in contrast to the response in patients with pituitary Cushing’s.   
A major limitation of this study is the low numbers of subjects.  However this was a pilot 
study to determine if there was initially a signal before conducting a larger scale study. 
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CHAPTER 7; Conclusions and opportunities for further research 
 
90 years have passed since the discovery of insulin and despite all the advances in insulin 
therapy, delivery devices and education, there still remains a “dark side to this potent 
preparation” which is hypoglycaemia. The frequency of hypoglycaemia has not really 
changed in the past few decades, and continues to contribute to the significant morbidity and 
mortality associated with T1D.   
Chapter 1 looked at the problem and epidemiology of “hypoglycaemia” in those with Type 1 
Diabetes (T1D) commenting on the particular risk factors related to recurrent hypoglycaemia.  
The likely mechanisms responsible for the development of defective counter-regulation 
during hypoglycaemia in those with T1D were reviewed.  On average, a person with T1D 
experiences 2 or 3 mild symptomatic hypoglycaemia every week, and the consequences of 
recurrent hypoglycaemia on various physiological states were reviewed.  
In chapter 2, both non-drug and drug strategies when used as adjunct therapies to insulin was 
reviewed.  In general, education strategies were very effective in teaching patients the 
importance of recognition and quick treatment of hypoglycaemia and more recently newer 
technologies with regard to continuous glucose monitoring systems have been used to 
supplement this.  However the main limitations of these methods are that they require 
significant input from health care professionals.  Reviewing adjunct drug strategies currently 
reported so far, shows that there seems to be a dissociation between symptomatic 
improvement during hypoglycaemia and improvements in the counter-regulatory hormonal 
responses, with none of the studies showing an improvement in both of these parameters. 
Therefore, one of our main aims in this thesis was to explore adjunct therapies to insulin to 
determine whether we could reduce frequency of hypoglycaemia and hence improve the 
magnitude of the counter-regulatory responses during insulin-induced hypoglycaemia (IIH). 
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We also explored whether there would be any improvements in the symptomatic and 
cognitive responses to IIH.   
We aimed to look at existing licensed drugs to determine whether they would complement 
intensive insulin therapies.  Prior to this, I went onto review aspects of glucose sensing, 
concentrating on the mechanisms present in the hypothalamus and in particular how this 
generates the counter-regulatory responses during hypoglycaemia.  Various components of 
this complex cascade were reviewed in particular focusing on the ATP-sensitive potassium 
channels due to its relevance in STUDY 1.  Research in cell culture and animal models has 
revealed that ATP-sensitive potassium (KATP) channels are integral to hypoglycaemia 
detection and initiation of CRRs, however, to date this has not been confirmed in human 
subjects. In STUDY 1, we examined whether KATP-channel openers (KC0) were able to 
amplify the CRR to hypoglycaemia in T1D subjects with IAH.   A randomized double-blind 
placebo-controlled cross-over trial using a stepped hyperinsulinemic (1.5mu/kg/min) 
hypoglycaemia clamp (4.0, 3.5, 3.0, 2.5mmol/L) was performed in 12 T1D with prior 
ingestion of Diazoxide (D) (7mg/kg) (non-selective KCO) or placebo (P). Following 
Diazoxide T1D subjects showed a significant increase in adrenaline (ng/ml) responses at 2.5 
mM glucose (0.40(SE) 0.06 vs.  0.290.05  , D vs. P: p<0.05) as well as a significant 
increase in noradrenaline(ng/ml) ( 0.850.07  vs. 0.59  0.06 , D vs. P: p<0.05.  Total 
symptoms of hypoglycaemia score were higher in the diazoxide group at 2.5mmol/L, (D; 
21.5 and P; 19.3),p=NS. (Aut scores D;10.25±1.5 P; 8.9±1.4).     Although battery of 
cognitive tests showed shorter timings and possible cognitive preservation with diazoxide, 
none reached statistical significance.   No adverse effects including significant hypotension 
were noted.   
Therefore, diazoxide amplified the CRR hormonal but not symptomatic response to 
hypoglycaemia in subjects with long-duration T1D and IAH.  This study shows for the first 
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time that KATP channels may play an important role in the detection of hypoglycaemia and 
that a therapeutic strategy using KCOs may offer a viable approach to restoring 
hypoglycaemia awareness in T1D.  In addition, a subgroup analysis revealed that participants 
with E23K polymorphism in the KATP channel had a blunted response to oral diazoxide.  This 
study has therefore shown for the first time the potential utility of KATP channel activators to 
improve counterregulatory responses to hypoglycaemia in individuals with T1D, and 
moreover that it may be possible to stratify therapeutic approaches by genotype. 
The ability to choose patients by genotype and tailor drug therapies and/or dose is a very 
exciting prospect.  We plan to conduct further studies whereby, for example we use a higher 
dose of KATP channel openers in patients who have the E23K polymorphism to determine if 
we can improve response.  The risk of side effects  with diazoxide at higher doses will need 
to be explored by further dose finding studies, to utilize the maximum safe dose.  The other 
possibility is the development of a specific Kir6.2/SUR1 opener, which would theoretically 
eliminate the side effects seen by a compound such as diazoxide with more general systemic 
effects.  
Therapies targeted at secondary physiological abnormalities in type 1 diabetes such as 
dysregulated glucagon secretion may also offer an effective and safe means of improving 
glycemic control.  STUDY 2, examined the hypothesis that Dipeptidyl DiPeptidase 4 
inhibition (DPP-4 i ) in type 1 diabetes would result in improved glycemic control, reduced 
glucose variability and enhanced counterregulatory responses to hypoglycaemia. 
Following informed consent, we recruited 14 subjects with moderately well controlled 
(HbA1c 64±2 mmol/mol) type 1 diabetes of long-standing (20.5±2.7 years). Subjects 
received 12-weeks therapy with oral saxagliptin (5mg) or placebo.  HbA1c, weight, total 
daily insulin dose, glucose-variability assessed via continuous glucose monitoring, 
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hypoglycaemia awareness, and symptomatic, cognitive and counterregulatory hormone 
responses to hypoglycaemia 
We found no significant improvement in HbA1c (placebo vs. saxagliptin: 66 ± 2 vs 65± 2 
mmol/mol, p=0.5), weight (74.6± 3.6 vs. 74.2± 3.3 kg, p=0.64), Low Blood Glucose Index, 
Average Daily Risk Range, and counterregulatory hormonal responses (AUC adrenaline, 
25,775 vs. 24,454, placebo vs. saxagliptin, respectively, p=0.76) was seen following 
saxagliptin therapy in addition to usual insulin for 12-weeks.  Our findings do not support the 
use of DPP-4 i in the management of type 1 diabetes.   
The importance of dysregulated pancreatic α cell function particularly in the post-prandial 
state is increasing appreciated.  Although STUDY 2 did not show a significant benefit on the 
parameters measured, agents that have a more potent effects on the α-cell such as Amylin 
analogues or GLP-1 receptor agonists may prove more effective forms of adjunct therapy. 
There are currently on-going studies designed to address this question. It is notable that, as 
with DPP-4 i, GLP-1 infusion in subjects with c-peptide positive T1D has a far more 
profound effect on post-prandial glucose excursions and glucagon than is seen in c-peptide 
negative T1D and it has also been suggested that a major contribution to reduced post-
prandial glucose excursions with GLP-1 in T1D reflect delayed gastric emptying as much as 
it does α-cell suppression.  Overall, the case for α-cell targeted non-insulin adjunct therapy in 
T1D remains to be convincingly demonstrated. I would be keen to explore the current GLP-1 
therapies, of which there are an increasing number of new compounds through physiological 
studies (such as mixed meal studies), to determine the best drug to lower post-prandial 
glucagon and therefore glucose excursion, and then potentially through reduction of 
hypoglycaemia, improve the counter-regulatory responses to further hypoglycaemia.  I would 
then anticipate testing this agent as an adjunct therapy to IIT in further long term trials 
looking at similar parameters to STUDY 2.  
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Following STUDY 2, the direction of the thesis becomes broader with an exploration of the 
impact of glucose variability (GV) in patients with T1D.  Several indices of GV have been 
measured over the last few decades, however to date, there is little consensus on which index 
to use, which may give some standardization of reporting particularly in clinical trials aiming 
at impacting GV.  
 There is also much debate and little evidence that GV in patients’ with T1D has any 
significant long term effect.  We however sought to explore the impact of GV and recurrent 
hypoglycaemia on the hypothalamo-pituitary adrenal axis (HPA), an area which is currently 
poor in evidence.  Our main index of assessing this axis was a thorough analysis of the 
diurnal cortisol curve and its various components.   
STUDY 3 particularly examined the relationship of recurrent hypoglycaemia through 
measurement of LBGI (Low Blood Glucose Index), an index of hypoglycaemia stress 
(through utilization of CGM) and the cortisol diurnal curve (salivary sampling).   In this cross 
sectional study of subjects with T1D, there was a significant blunting (both in early and late 
decline) of the cortisol slope in those with a heavy burden of hypoglycaemia (as determined 
by a high LBGI).   This was associated with a significantly increased AUC between 3-12 
hours after wakening in this cohort.  Therefore there appears to be prolonged exposure of 
endogenous steroids to the individual who is exposed to recurrent hypoglycaemia. Clues to 
the potential impact of this supraphysiological exposure to steroids can be derived from those 
with hypercortisolaemic conditions such as Cushing’s syndrome.  What is interesting is the 
similarities in the end effects of Cushing’s and patients with T1D, in the propensity to 
develop cardiovascular risk factors such as hyperlipidemia and hypertension and 
development of mood disorders such as depression.   
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I would value the opportunity to explore this in greater detail.  The challenge would be to 
disentangle the multiple risk factors in the development of these complications to determine 
the contribution of this mild hypercortisolaemic state on the physiological systems.  Studies 
looking at different cohorts of patients who have similar abnormalities in their HPA system, 
such that they have exposure to supra-physiological but not pathological amounts of cortisol 
could be illuminating.  Furthermore, recently, analysis of hair cortisol has been shown to be 
reflective of cortisol exposure over the last 3 months, and therefore, may provide a more 
robust measure which is unaffected by transient stresses of everyday life and therefore, could 
be used during further studies assessing the HPA axis.   
With regard to GV assessment, there has been much debate as to the optimal time of CGM, in 
order for a thorough evaluation of GV.  Naturally as CGM duration increases, there is a 
reduction in %error from the 90 day value (gold standard), but reached a median value of 
<10% error at 12 days, suggesting that this might be an optimal time period.  Recently, 
Abbott has launched a Freestyle Libre Flash Glucose monitoring System which has the 
ability to monitor for 14 days with one sensor, and has the ability to record and store 90 days 
of CGM data. This new technology with its longer monitoring period, may therefore provide 
a more robust measurement of GV, than the technology used during my studies.   
Further study using a biochemical marker such as 1,5 anhydroglucitol (structurally similar to 
glucose, and has been shown to be inversely correlated with hyperglycaemia) has been shown 
to be well correlated with several markers of GV (SD, MAGE and LI), however, this 
correlation only seemed to exist in patients with moderate glycaemic control (mean CGMS 
glucose < 10mmol/L(Seok, Huh et al. 2015) as opposed to those with poor glycaemic control.  
The other added benefit, is that it is thought to relate very well to GV over the preceding few 
weeks, avoiding the need to attach a patient to a needle for several days.  Therefore this 
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technique may have been less influenced by patient’s behavior (with a change often seen 
when patients are attached to a device).   
With the disturbances in cortisol patterns seen in those with T1D, we also went on to study 
whether we could ascertain the exact location of the underlying problem within the HPA 
system in STUDY 4, by conducting CRH testing in a cohort of subjects from STUDY 3.   
This showed that there was a trend (p=0.08) towards a lower ACTH response in T1D 
compared to controls, with no difference in cortisol responses to CRH stimulation.  This 
suggests that there may be a pituitary insensitivity as a result of continuous negative feedback 
from increased levels of endogenous steroids in those with recurrent hypoglycaemia. If there 
is indeed a confirmed, real dysregulation of the HPA system, in the future, I would anticipate 
using smaller doses of CRH to determine the true sensitivity of the pituitary gland and 
potentially, a larger dose may be required to determine the sensitivity of the adrenal glands, 
but currently based on the current study, we don’t have any evidence that the adrenal glands 
are not sensitive to the effects of ACTH.   
Ultimately, we would want to determine whether improvement of glycaemic parameters, 
particularly reduction in frequency of hypoglycaemia, would be able to reverse the 
dysregulation of the HPA system, if one indeed is present, and reduce the burden of 
endogenous steroids on the physiological systems, and therefore improve long term outcomes 
for patients particularly with regard to macrovascular complications of T1D.   
This thesis has really enabled me to understand some of the key problems faced by patients 
with T1D such as recurrent hypoglycaemia (RH) and glycaemic variability (GV) and its 
wider impact on other physiological systems.  Many trials have focused on HbA1c, which is 
clearly related to long term micro and macrovascular complications, however both RH and 
GV have significant short term morbidity and has a significant impact on patient’s immediate 
 
283 
 
quality of life, and therefore needs to be addressed and hopefully I have shown in this body of 
work, different therapeutic strategies that should be considered in addressing the latter. The 
impact of GV has always been debated in patients’ with T1D, but we show that GV and 
recurrent hypoglycaemia can potentially cause a disturbance in the HPA axis and ultimately 
affect long term outcomes such as macrovascular disease.  
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